
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital‐Based Towards Home‐Sampling - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="616CF3B180951BA300F3B1002C744DE9.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11907759/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Biomedical Chromatography">
<meta name="citation_title" content="Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital‐Based Towards Home‐Sampling">
<meta name="citation_author" content="Marinda Meertens">
<meta name="citation_author_institution" content="Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands">
<meta name="citation_author" content="Hilde Rosing">
<meta name="citation_author_institution" content="Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands">
<meta name="citation_author" content="Neeltje Steeghs">
<meta name="citation_author_institution" content="Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands">
<meta name="citation_author_institution" content="Department of Medical Oncology, Utrecht University Medical Centre, Utrecht University, Utrecht, The Netherlands">
<meta name="citation_author" content="Jos H Beijnen">
<meta name="citation_author_institution" content="Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands">
<meta name="citation_author_institution" content="Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands">
<meta name="citation_author" content="Alwin D R Huitema">
<meta name="citation_author_institution" content="Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands">
<meta name="citation_author_institution" content="Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands">
<meta name="citation_author_institution" content="Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands">
<meta name="citation_publication_date" content="2025 Mar 14">
<meta name="citation_volume" content="39">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="e70056">
<meta name="citation_doi" content="10.1002/bmc.70056">
<meta name="citation_pmid" content="40084678">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11907759/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11907759/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11907759/pdf/BMC-39-e70056.pdf">
<meta name="description" content="Home‐sampling for therapeutic drug monitoring (TDM) for oral targeted anticancer drugs offers a promising alternative to traditional hospital‐based sampling methods, though it presents challenges. This review aims to summarize the state‐of‐the‐art ...">
<meta name="og:title" content="Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital‐Based Towards Home‐Sampling">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Home‐sampling for therapeutic drug monitoring (TDM) for oral targeted anticancer drugs offers a promising alternative to traditional hospital‐based sampling methods, though it presents challenges. This review aims to summarize the state‐of‐the‐art ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11907759/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11907759">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/bmc.70056"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/BMC-39-e70056.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11907759%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11907759/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11907759/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11907759/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1002/bmc.70056" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Biomed Chromatogr</button></div>. 2025 Mar 14;39(5):e70056. doi: <a href="https://doi.org/10.1002/bmc.70056" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/bmc.70056</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Biomed%20Chromatogr%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Biomed%20Chromatogr%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Biomed%20Chromatogr%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Biomed%20Chromatogr%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital‐Based Towards Home‐Sampling</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Meertens%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Marinda Meertens</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Marinda Meertens</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Meertens%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marinda Meertens</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rosing%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Hilde Rosing</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Hilde Rosing</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rosing%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Hilde Rosing</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Steeghs%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Neeltje Steeghs</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Neeltje Steeghs</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Medical Oncology, Utrecht University Medical Centre, Utrecht University, Utrecht, The Netherlands</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Steeghs%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Neeltje Steeghs</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Beijnen%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Jos H Beijnen</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Jos H Beijnen</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands</div>
<div class="p">
<sup>
<sup>4</sup>
</sup>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Beijnen%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jos H Beijnen</span></a>
</div>
</div>
<sup>1,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huitema%20A%C2%A0R%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Alwin D R Huitema</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Alwin D R Huitema</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands</div>
<div class="p">
<sup>
<sup>5</sup>
</sup>Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands</div>
<div class="p">
<sup>
<sup>6</sup>
</sup>Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huitema%20A%C2%A0R%22%5BAuthor%5D" class="usa-link"><span class="name western">Alwin D R Huitema</span></a>
</div>
</div>
<sup>1,</sup><sup>5,</sup><sup>6,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="bmc70056-aff-0001">
<sup>
<sup>1</sup>
</sup>Department of Pharmacy &amp; Pharmacology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands</div>
<div id="bmc70056-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands</div>
<div id="bmc70056-aff-0003">
<sup>
<sup>3</sup>
</sup>Department of Medical Oncology, Utrecht University Medical Centre, Utrecht University, Utrecht, The Netherlands</div>
<div id="bmc70056-aff-0004">
<sup>
<sup>4</sup>
</sup>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands</div>
<div id="bmc70056-aff-0005">
<sup>
<sup>5</sup>
</sup>Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands</div>
<div id="bmc70056-aff-0006">
<sup>
<sup>6</sup>
</sup>Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong>
 
Alwin D. R. Huitema (<span>a.huitema@nki.nl</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Feb 20; Received 2024 Dec 11; Accepted 2025 Mar 1; Issue date 2025 May.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Biomedical Chromatography</em> published by John Wiley &amp; Sons Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11907759  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40084678/" class="usa-link">40084678</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>Home‐sampling for therapeutic drug monitoring (TDM) for oral targeted anticancer drugs offers a promising alternative to traditional hospital‐based sampling methods, though it presents challenges. This review aims to summarize the state‐of‐the‐art of home‐sampling methods for TDM and evaluates the analytical and clinical validation challenges. A comprehensive search was conducted across Embase, Medline, and Scopus. Eligible articles described analytical and/or clinical validation of home‐sampling methods for oral targeted anticancer drugs. ASReview was used to process unique references and to identify relevant studies. Of the 39 included articles, 32 detailed on analytical validation experiments, while 27 covered clinical validation experiments. Dried blood spot and volumetric absorptive microsampling were the primary sampling methods. Key challenges were ensuring robust sample collection, sample pretreatment, hematocrit effects, and sample stability, which were generally thoroughly investigated. Clinical validation yielded promising results for most analytes, although external validation remains crucial for confirming reliability. Home‐sampling methods for TDM of oral targeted anticancer drugs show promising results for clinical implementation. Methods for well‐studied drugs may be clinically implemented immediately, while others require further external validation. Future research should address device‐specific challenges and assess patient feasibility to facilitate the routine use of home‐sampling in clinical practice.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> dried blood spots, home‐sampling, LC‐MS/MS, oral targeted anticancer therapies, therapeutic drug monitoring, volumetric absorptive microsampling</p></section></section><section id="bmc70056-sec-0001"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Therapeutic drug monitoring (TDM) is a practical tool for personalizing oral targeted anticancer therapy. For several agents, TDM has the potential to enhance efficacy and to reduce toxicity, leading to recommendations for its routine use (van der Kleij et al. <a href="#bmc70056-bib-0061" class="usa-link" aria-describedby="bmc70056-bib-0061"><sup>2023</sup></a>). In specific scenarios such as bariatric surgery or drug–drug interactions, TDM may provide benefits irrespective of whether it is routinely recommended (Lau et al. <a href="#bmc70056-bib-0040" class="usa-link" aria-describedby="bmc70056-bib-0040">2024</a>; Le Louedec et al. <a href="#bmc70056-bib-0041" class="usa-link" aria-describedby="bmc70056-bib-0041"><sup>2023</sup></a>).</p>
<p>Home‐sampling for TDM presents a promising alternative to traditional hospital‐based methods, offering several advantages. A hospital‐based procedure necessitates presence of the patient at a medical facility for venepuncture. The home‐sampling approach is already common in fields like organ transplant patients, and its application in the field of oncology could potentially lead to significant advancements (Brunet et al. <a href="#bmc70056-bib-0009" class="usa-link" aria-describedby="bmc70056-bib-0009">2019</a>). For patients, it is less invasive as it requires smaller blood volumes and enables rapid dose adjustments without the need for (expensive) hospital visits. The reliability could also be enhanced through the possibility of drawing trough levels at home, which is not always feasible in the hospital setting due to the random timing of hospital visits. Analytically, home‐sampling methods offer benefits like improved stability due to the dried form, room temperature storage avoiding freeze/thaw cycles, and relatively simple sample preparation. This could potentially reduce costs by decreasing the need for trained staff for venepuncture, eliminating the need for dry ice transport and avoiding necessity of plasma storage at −70 °C (Verougstraete et al. <a href="#bmc70056-bib-0073" class="usa-link" aria-describedby="bmc70056-bib-0073">2022</a>).</p>
<p>Currently, various assays and devices are available for home‐sampling, with dried blood spots (DBS) and volumetric absorptive microsampling (VAMS) being the most commonly reported in the literature (Delahaye et al. <a href="#bmc70056-bib-0018" class="usa-link" aria-describedby="bmc70056-bib-0018">2021</a>). Some methods such as dried plasma spots, where plasma is aliquoted onto DBS filter paper, are not suitable for home use. After selection of a convenient sampling method, the following critical step is the development of a robust analytical method. This requires comprehensive validation including standard analytical validation experiments as well as specific tests for home‐sampling devices, such as extraction recovery and hematocrit (Hct) influence assessments, among additional tests (Capiau et al. <a href="#bmc70056-bib-0012" class="usa-link" aria-describedby="bmc70056-bib-0012">2019</a>; European Medicines Agency <a href="#bmc70056-bib-0024" class="usa-link" aria-describedby="bmc70056-bib-0024"><sup>2011</sup></a>).</p>
<p>Subsequently after the establishment of a validated analytical method, clinical validation must be conducted (European Medicines Agency <a href="#bmc70056-bib-0024" class="usa-link" aria-describedby="bmc70056-bib-0024"><sup>2011</sup></a>). Despite having an operational robust analytical method, successful clinical validation is not guaranteed (Zimmermann et al. <a href="#bmc70056-bib-0082" class="usa-link" aria-describedby="bmc70056-bib-0082">2023</a>). When whole blood results correlate well with plasma levels, the process is relatively straightforward. However, in cases where they do not, a conversion method must be developed for accurate clinical interpretation. Different strategies for clinical interpretation include correcting for Hct levels or employing a conversion factor (Iacuzzi et al. <a href="#bmc70056-bib-0029" class="usa-link" aria-describedby="bmc70056-bib-0029">2021</a>). Even after successful analytical and clinical validations, it remains essential that patients correctly collect samples to ensure reliable results, which requires further evaluation in daily practice (Boffel et al. <a href="#bmc70056-bib-0004" class="usa-link" aria-describedby="bmc70056-bib-0004">2024</a>).</p>
<p>While the use of home‐sampling offers numerous benefits, it also presents several challenges. The aim of this review is to summarize the current state‐of‐the‐art of home‐sampling methods for TDM of oral targeted anticancer drugs, to evaluate the entire process from analytical and clinical validation to practical implementation in clinical practice.</p></section><section id="bmc70056-sec-0002"><h2 class="pmc_sec_title">2. Methods</h2>
<section id="bmc70056-sec-0003"><h3 class="pmc_sec_title">2.1. Search Strategy</h3>
<p>A comprehensive search was conducted across Embase, Medline, and Scopus, yielding a total of 941 references. After removing duplicates, 635 unique references remained (Figure <a href="#bmc70056-fig-0001" class="usa-link">1</a>). The search strategy employed is detailed in the Supplemental <a href="#bmc70056-supitem-0001" class="usa-link">material</a>.</p>
<figure class="fig xbox font-sm" id="bmc70056-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a42/11907759/449ad99d40ee/BMC-39-e70056-g001.jpg" loading="lazy" id="jats-graphic-1" height="207" width="709" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/bmc70056-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flowchart article filtering and inclusion.</p></figcaption></figure></section><section id="bmc70056-sec-0004"><h3 class="pmc_sec_title">2.2. Article Filtering and Inclusion and Exclusion Criteria</h3>
<p>The unique references were processed using ASReview, an AI‐assisted tool. ASReview was used in its default mode following the initial upload of five relevant and five non‐relevant articles. Criteria for completion required screening at least 25% of the articles and identifying 10% of all articles as non‐relevant in one row (i.e., respectively 159 articles and 64 non‐relevant in this case) (van de Schoot et al. <a href="#bmc70056-bib-0060" class="usa-link" aria-describedby="bmc70056-bib-0060"><sup>2021</sup></a>). The relevant records based on title and abstract screening underwent further evaluation based on full‐text analysis to assess their suitability for inclusion.</p>
<p>Articles were considered eligible if they described a home‐sampling method for analyzing one of the drugs of interests in oncology, including oral targeted therapies and oral anti‐hormone therapies (see Supplemental <a href="#bmc70056-supitem-0001" class="usa-link">material</a>). Studies focusing on either analytical validation and/or clinical validation experiments were included. Exclusions comprised articles concerning microsampling methods applied in non‐human species, reviews, insufficient detail provided for analytical and/or clinical validation, and studies specific for everolimus in transplantation populations.</p></section><section id="bmc70056-sec-0005"><h3 class="pmc_sec_title">2.3. Data Collection</h3>
<p>Data regarding analytical and clinical validation experiments were collected and summarized in tables. For the analytical validation, information was collected on the technique used, sample volumes, sample preparation procedures, analytical ranges, extraction recovery rates, stability, and critical factors. Only the circumstances outside the hospital were considered for stability, referred to as transport stability. For the clinical validation, data were collected on the number of collected samples and patients involved, comparisons between the different matrices and the tested conversion methods including their predictive performance.</p></section></section><section id="bmc70056-sec-0006"><h2 class="pmc_sec_title">3. Results and Discussion</h2>
<section id="bmc70056-sec-0007"><h3 class="pmc_sec_title">3.1. Literature Search</h3>
<p>Ultimately, 264 (42%) of the 635 articles were screened until 64 consecutive non‐relevant records were identified, marking the termination of screening after the last relevant article were found. Using this approach, 56 relevant records were selected based on title and abstract screening. These 56 articles were evaluated by full‐text analysis to assess their suitability for inclusion. These articles were then assessed for analytical and clinical validation experiments, as depicted in Figure <a href="#bmc70056-fig-0001" class="usa-link">1</a>. Out of these, five articles were excluded because they used dried plasma spots, which require centrifuging whole blood—a process unsuitable for the home‐sampling setting. Additionally, seven articles were excluded due to a lack of relevant information on analytical or clinical validation, or because only the application of a method was described without sufficient analytical details. One method appeared in duplicate across two journals—one local and one international; the local was excluded. Furthermore, two sampling methods (both from the same research group) were covered in multiple publications: one method was reported three times for DBS and one for VAMS, and another combination article described both methods together. The combination article was selected for inclusion, while the other four articles were excluded. Ultimately, 39 articles were included in this review. Of these, 32 articles detailed analytical validation experiments, while 27 reported (also) on clinical validation experiments. Specifically, 27 articles focused on DBS, 9 on VAMS, 1 on both DBS and VAMS, 1 on the Microsampling Wing and 1 on the Rhelise device. These four different sampling methods were first discussed.</p>
<section id="bmc70056-sec-0008"><h4 class="pmc_sec_title">3.1.1. Dried Blood Spots</h4>
<p>DBS sampling was the most reported home‐sampling method in our search. This technique uses paper cards, such as the widely used Whatman 903 protein saver, where a drop of whole blood is “spotted” onto the card. In case of home‐sampling, the volume of this drop of capillary whole blood is variable, therefore a fixed punch size is commonly used for quantification. The Whatman 903 protein saver cards are cellulose‐based, whereas other types of cards, such as DMPK‐A cards, include additional additives like Tris and SDS. Both Tris and SDS are surfactants that can denature proteins (Jager, Rosing, Schellens, and Beijnen <a href="#bmc70056-bib-0033" class="usa-link" aria-describedby="bmc70056-bib-0033"><sup>2014</sup></a>). In contrast, DMPK‐C cards are, similar to the Whatman 903 protein saver cards, not impregnated with additives and may be more suitable for preserving protein‐based molecules. Therefore, the choice of card type should be based on the properties of the drug. For instance, DMPK‐A cards, impregnated with Tris and SDS, provided better extraction for vemurafenib, a hydrophobic drug with poor aqueous solubility (Food and Drug Administration <a href="#bmc70056-bib-0026" class="usa-link" aria-describedby="bmc70056-bib-0026"><sup>2011</sup></a>; Nijenhuis et al. <a href="#bmc70056-bib-0052" class="usa-link" aria-describedby="bmc70056-bib-0052"><sup>2014</sup></a>). The volumetric DBS device hemaPEN was also reported. This device collects four DBS of 2.74 μL simultaneously, thus 10.96 μL in total (Deprez et al. <a href="#bmc70056-bib-0022" class="usa-link" aria-describedby="bmc70056-bib-0022">2019</a>; Neto et al. <a href="#bmc70056-bib-0050" class="usa-link" aria-describedby="bmc70056-bib-0050"><sup>2018</sup></a>; Venkatesh et al. <a href="#bmc70056-bib-0068" class="usa-link" aria-describedby="bmc70056-bib-0068"><sup>2023</sup></a>). Another DBS device, the Hemaxis DB 10, collects the drop of blood via a micro‐channel, instantly absorbing it followed by spotting 10 μL onto DBS paper card, resulting in volumetric DBS samples (Canil et al. <a href="#bmc70056-bib-0010" class="usa-link" aria-describedby="bmc70056-bib-0010">2023</a>; Leuthold et al. <a href="#bmc70056-bib-0044" class="usa-link" aria-describedby="bmc70056-bib-0044"><sup>2015</sup></a>).</p></section><section id="bmc70056-sec-0009"><h4 class="pmc_sec_title">3.1.2. Volumetric Absorptive Microsampling</h4>
<p>The VAMS device, branded as Mitra®, was the second most reported technique. VAMS uses a polymeric tip which absorbs a fixed volume of blood (10, 20, or 30 μL), which then can be removed from the stick for sample preparation. This sampling method addresses the limitations of conventional DBS, such as variable spot volume and homogeneity issues (Denniff and Spooner <a href="#bmc70056-bib-0020" class="usa-link" aria-describedby="bmc70056-bib-0020">2014</a>).</p></section><section id="bmc70056-sec-0010"><h4 class="pmc_sec_title">3.1.3. Liquid Microsampling Devices</h4>
<p>Two other identified liquid microsampling devices were the Microsampling Wing (MSW) from Shimadzu, and the Rhelise kit from Redhot diagnostics, both using volumetric capillaries. The MSW, a small capillary with K<sub>2</sub>EDTA coating for anticoagulation, fills with 23 μL of blood and can be centrifuged to yield 5.6 μL of plasma by snapping of one part of the capillary (Hotta et al. <a href="#bmc70056-bib-0028" class="usa-link" aria-describedby="bmc70056-bib-0028">2021</a>; Saito et al. <a href="#bmc70056-bib-0058" class="usa-link" aria-describedby="bmc70056-bib-0058"><sup>2022</sup></a>). The Rhelise kit, which fills with 50 μL of blood, mixes with a protein extraction liquid, precipitating the blood to maintain stability (Rehnmark et al. <a href="#bmc70056-bib-0055" class="usa-link" aria-describedby="bmc70056-bib-0055">2022</a>).</p></section><section id="bmc70056-sec-0011"><h4 class="pmc_sec_title">3.1.4. Data Collection</h4>
<p>Information from the included articles on analytical and clinical validation experiments has been summarized in Tables <a href="#bmc70056-tbl-0001" class="usa-link">1</a> and <a href="#bmc70056-tbl-0002" class="usa-link">2</a>, respectively. Both tables list the first author, technique, brand device, and drugs of interest. Table <a href="#bmc70056-tbl-0001" class="usa-link">1</a> focuses on analytical validation experiments, including sample volume, sample preparation, analytical range, overall extraction recovery, stability data, and critical factors like Hct. These critical steps will be discussed in detail in Section <a href="#bmc70056-sec-0012" class="usa-link">3.2</a>. Accuracy and precision were not included since all methods met the required criteria (European Medicines Agency <a href="#bmc70056-bib-0024" class="usa-link" aria-describedby="bmc70056-bib-0024"><sup>2011</sup></a><sup>, </sup><a href="#bmc70056-bib-0025" class="usa-link" aria-describedby="bmc70056-bib-0025"><sup>2022</sup></a>). All included analytical methods utilized liquid chromatography–tandem mass spectrometry for quantification. Accordingly, this review will focus on the analytical aspects inherent to this method. Table <a href="#bmc70056-tbl-0002" class="usa-link">2</a> summarizes the tested conversion methods and the predictive performance of those methods. Additionally, a column for remarks is included. These experiments will be discussed in Section <a href="#bmc70056-sec-0019" class="usa-link">3.3</a>.</p>
<section class="tw xbox font-sm" id="bmc70056-tbl-0001"><h5 class="obj_head">TABLE 1.</h5>
<div class="caption p"><p>Validated chromatographic mass spectrometric methods using home‐sampling devices to support TDM.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">First author (year)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Drugs</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Technique; device</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Sample volume</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Sample preparation</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Range (ng/mL)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Extraction recovery (CV%)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Transport and storage stability</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Critical factors</th>
</tr></thead>
<tbody valign="top">
<tr>
<td rowspan="3" align="left" valign="top" colspan="1">Venkatesh et al. (<a href="#bmc70056-bib-0068" class="usa-link" aria-describedby="bmc70056-bib-0068">2023</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Osimertinib</td>
<td align="center" rowspan="3" valign="top" colspan="1">DBS; HemaPEN®</td>
<td align="center" rowspan="3" valign="top" colspan="1">Volumetric 20 μL for 4 × 2.74 μL</td>
<td align="center" rowspan="3" valign="top" colspan="1">Extraction with acetonitrile and IS working solution, while mixing</td>
<td align="center" rowspan="3" valign="top" colspan="1">1–729</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>LLOQ, 92.9 (3.8)</p>
<p>Low, 97.9 (5.5)</p>
<p>Mid, 95.2 (7.3)</p>
<p>High, 98.9 (5.6)</p>
</td>
<td align="center" rowspan="3" valign="top" colspan="1">
<p>RT: 10 d; 4 °C: 72 h;</p>
<p>−80 °C: 1 mo</p>
</td>
<td align="center" rowspan="3" valign="top" colspan="1">Hct 0.30–0.60 no significant impact accuracy and precision</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">AZ5104</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>LLOQ, 91.8 (4.2)</p>
<p>Low, 100.9 (3.5)</p>
<p>Mid, 96.6 (4.3)</p>
<p>High, 101.2 (8.9)</p>
</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">AZ7550</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>LLOQ, 91.4 (8.2)</p>
<p>Low, 103.8 (6.5)</p>
<p>Mid, 95.4 (1.7)</p>
<p>High, 103.1 (9.2)</p>
</td>
</tr>
<tr>
<td rowspan="3" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Canil et al. (<a href="#bmc70056-bib-0010" class="usa-link" aria-describedby="bmc70056-bib-0010">2023</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Niraparib</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Whatman 903 (calibrators and QCs) DBS; Hemaxis DB10 (patients)</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Whatman 903: 8 mm punch–10 μL aliquotsHemaxis DB10: volumetric 10 μL</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Extraction with IS working solution (methanol) while mixing.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>60–3000</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 56 (10)</p>
<p>Mid, 56 (6)</p>
<p>High, 57 (5)</p>
</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">20 °C, &lt;35% humidity: 219 d</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Hct 0.29–0.45 no significant impact on accuracy and precision (Hct 0.25–0.55 did not meet requirements for accuracy)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Olaparib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>140–7000</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 93 (7)</p>
<p>Mid, 94 (6)</p>
<p>High, 92 (6)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Rucaparib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>100–5000</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 66 (8)</p>
<p>Mid, 68 (8)</p>
<p>High, 66 (4)</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Zanchetta et al. (<a href="#bmc70056-bib-0079" class="usa-link" aria-describedby="bmc70056-bib-0079">2023</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Lenvatinib</td>
<td align="center" valign="top" rowspan="1" colspan="1">DBS; Whatman 31ETCHR and Whatman 903</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 mm punch–10 μL aliquots</td>
<td align="center" valign="top" rowspan="1" colspan="1">Extraction with IS in methanol and 0.1% formic acid while mixing.</td>
<td align="center" valign="top" rowspan="1" colspan="1">5–2000</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Whatman 31ETCHR:</p>
<p>Low, 85.8 (5.8)</p>
<p>Mid, 77.2 (3.4)</p>
<p>High, 76.6 (4.1)</p>
<p>Whatman 903,</p>
<p>Low, 82.7 (6.7)</p>
<p>Mid, 77.3 (3.2)</p>
<p>High, 80.1 (3.3)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>All at low and high:−80 °C: 2 F/T cycles</p>
<p>50 °C: 4 d</p>
<p>RT in paper envelope inside dryer: 98 d</p>
<p>−80 °C in plastic envelope: 25 d;</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">5 μL and 10 μL spot volumes were underestimated with 3 mm punches, therefore 8 mm punch covering the whole spot.Hct 0.25–0.55 at 3 QC levels on both Whatman papers, all no significant impact on accuracy and precision.</td>
</tr>
<tr>
<td rowspan="6" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Mukai et al. (<a href="#bmc70056-bib-0049" class="usa-link" aria-describedby="bmc70056-bib-0049">2022</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Bosutinib</td>
<td align="center" rowspan="6" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Whatman 903</td>
<td align="center" rowspan="6" style="background-color:#E7E6E6" valign="top" colspan="1">Whole spot cut–40 μL aliquots</td>
<td align="center" rowspan="6" style="background-color:#E7E6E6" valign="top" colspan="1">Extraction with acetonitrile/methanole (1/3 (v/v)) containing IS, while vortex mixing.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">10–1000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 105.5 (5.0)</p>
<p>High, 81.8 (3.7)</p>
</td>
<td align="center" rowspan="6" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>40 °C and 90% RH: 72 h for all analytes</p>
<p>RT: 12 weeks for all analytes, except ibrutinib 8 weeks.</p>
</td>
<td align="center" rowspan="6" style="background-color:#E7E6E6" valign="top" colspan="1">Hct 0.20–0.50 at Low and High no significant impact on assay performance</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Dasatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–200</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 63.6 (6.5)</p>
<p>High, 71.7 (2.1)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Ibrutinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">4–400</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 89.8 (1.7)</p>
<p>High, 81.4 (0.7)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">40–4000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 110.3 (1.5)</p>
<p>High, 95.7 (2.3)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Nilotinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">40–4000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 69.4 (2.5)</p>
<p>High, 82.3 (0.6)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Ponatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–200</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 72.8 (2.2)</p>
<p>High, 76.2 (2.7)</p>
</td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Zhang et al. (<a href="#bmc70056-bib-0080" class="usa-link" aria-describedby="bmc70056-bib-0080">2022</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Anlotinib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS; Whatman 903</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">3 mm punch–15 μL aliquots</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Extraction with 100 μL methanol with IS while vortex mixing, followed by sonication.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">5–1000</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>Low, 64.27 (11.35)</p>
<p>Mid, 59.33 (13.99)</p>
<p>High, 64.68 (5.68)</p>
</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>Both at low and high: RT: 3 mo</p>
<p>−80 °C: 3 mo</p>
</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Hct 0.30–0.55, blood spot volume: 10, 20, 30 μL, and different punch sites all no significant impact on assay performance.</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Braal et al. (<a href="#bmc70056-bib-0008" class="usa-link" aria-describedby="bmc70056-bib-0008">2021</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Ribociclib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; Whatman 903</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">6 mm punch–50 μL aliquots</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Vortex mixing and sonication with IS in methanol</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">10–1000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 72.0 (7.29)</p>
<p>High, 64.8 (2.73)</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>At low and high, protected from light: controlled cabin 20 ± 5 °C RH 25%: 5 mo</p>
<p>3–7 °C: 5 mo</p>
<p>RT: 5 mo</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Hct 0.20–0.40 at High and Low no significant impact on assay performance.</p>
</td>
</tr>
<tr>
<td rowspan="3" style="background-color:#FFFFFF" align="left" valign="top" colspan="1">Poetto et al. (<a href="#bmc70056-bib-0054" class="usa-link" aria-describedby="bmc70056-bib-0054">2021</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Palbociclib</td>
<td align="center" rowspan="3" style="background-color:#FFFFFF" valign="top" colspan="1">DBS; Whatman 31ETCHR</td>
<td align="center" rowspan="3" style="background-color:#FFFFFF" valign="top" colspan="1">3 mm punch–20 μL aliquots</td>
<td align="center" rowspan="3" style="background-color:#FFFFFF" valign="top" colspan="1">Extraction by 30 μL IS in methanol while mixing.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">1–250</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>Low, 70.5 (10.4)</p>
<p>Mid, 67.6 (5.3)</p>
<p>High, 70.2 (2.6)</p>
</td>
<td align="center" rowspan="3" style="background-color:#FFFFFF" valign="top" colspan="1">RT and −80 °C (3 F/T): 2.5 mo for all analytes;50 °C: 48 h for all analytes;</td>
<td align="center" rowspan="3" style="background-color:#FFFFFF" valign="top" colspan="1">Hct 0.25–0.49 at QC low, mid and high, blood spot volume (5, 20 and 40 μL) and different punch sites, all had no significant impact on assay performance.</td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Ribociclib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">40–10,000</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>Low, 71.1 (11.3)</p>
<p>Mid, 69.8 (7.0)</p>
<p>High, 75.7 (5.2)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Letrozol</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">2–500</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>Low, 75.6 (3.8)</p>
<p>Mid, 76.6 (2.2)</p>
<p>High, 80.3 (3.8)</p>
</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Guo et al. (<a href="#bmc70056-bib-0027" class="usa-link" aria-describedby="bmc70056-bib-0027">2021</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Bortezomib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; Whatman 903</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">6 mm punch–50 μL aliquots</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Extraction with methanol containing IS</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">0.2–20</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 97.5 (NR)</p>
<p>Mid, 92.8 (NR)</p>
<p>High, 91.0 (NR)</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>At Low, Mid, and High at:RT: 7 d;</p>
<p>4 °C: 14 d;</p>
<p>−80 °C: 60 d;</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Hct 0.20–0.50 no significant impact on assay performance.</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">Dillenburg Weiss et al. (<a href="#bmc70056-bib-0023" class="usa-link" aria-describedby="bmc70056-bib-0023">2021</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Abiraterone</td>
<td align="center" rowspan="2" valign="top" colspan="1">DBS; Whatman 903</td>
<td align="center" rowspan="2" valign="top" colspan="1">2 × 8 mm punch–50 μL aliquots</td>
<td align="center" rowspan="2" valign="top" colspan="1">
<p>Two punches cut in four pieces.</p>
<p>Extraction with methanol containing IS. Incubation at 30 °C while shaking, evaporation at 60 °C.</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">1–400</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Hct 0.20 Low, 84.6</p>
<p>Hct 0.20 High, 86.7</p>
<p>Hct 0.40 Low, 79.7</p>
<p>Hct 0.40 High, 72.6</p>
<p>Hct 0.60 Low, 77.8</p>
<p>Hct 0.60 High, 75.9</p>
</td>
<td align="center" rowspan="2" valign="top" colspan="1">
<p>At Low and High:RT: 7 d;</p>
<p>2–8 °C: 7 d;</p>
<p>60 °C: 48 h;</p>
</td>
<td align="center" rowspan="2" valign="top" colspan="1">
<p>Hct 0.20–0.50 no influence on accuracy and precision, Hct 0.60 did significant impact accuracy;</p>
<p>Hct 0.20–0.60 no influence on recovery.</p>
<p>Spot volume 20–60 μL no impact on accuracy.</p>
</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Delta(4)‐abiraterone</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.2–20</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Hct 0.20 Low, 88.2</p>
<p>Hct 0.20 High, 99.7</p>
<p>Hct 0.40 Low, 89.6</p>
<p>Hct 0.40 High, 83.4</p>
<p>Hct 0.60 Low, 88.8</p>
<p>Hct 0.60 High, 89.6</p>
</td>
</tr>
<tr>
<td rowspan="2" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Iacuzzi et al. (<a href="#bmc70056-bib-0030" class="usa-link" aria-describedby="bmc70056-bib-0030">2019</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Whatman ET31CHR</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">3 mm punch–20 μL aliquots</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">Extraction with 150 μL IS in 0.1% formic acid in methanol, while gently mixing</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">50–7500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 74.8 (5.4)</p>
<p>Mid, 77.7 (4.2)</p>
<p>High, 80.5 (2.5)</p>
</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>RT: 16 mo</p>
</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>At low, mid, high:</p>
<p>Hct 0.29–0.59; punch site and spot volumes 10–40 μL; all no significant impact on assay performance</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Norimatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">10–1500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 66.5 (7.7)</p>
<p>Mid, 66.6 (4.6)</p>
<p>High, 68.5 (2.1)</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Irie et al. (<a href="#bmc70056-bib-0031" class="usa-link" aria-describedby="bmc70056-bib-0031">2018</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Gefitinib</td>
<td align="center" valign="top" rowspan="1" colspan="1">DBS; Advantec qualitative filter paper no. 2, 125 g/m<sup>2</sup>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 mm punch–10 μL aliquots</td>
<td align="center" valign="top" rowspan="1" colspan="1">Extraction wit IS in methanol, while shaking</td>
<td align="center" valign="top" rowspan="1" colspan="1">40–2400</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Low, 104.9 (2.0)</p>
<p>Mid, 96.3 (4.7)</p>
<p>High, 95.7 (3.3)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>At High, Mid, Low: RT and −20 °C: 5 mo;</p>
<p>40 °C: 24 h;</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Knapen et al. (<a href="#bmc70056-bib-0036" class="usa-link" aria-describedby="bmc70056-bib-0036">2018</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Everolimus</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; Whatman 903</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">7.5 mm punch–30 μL aliquots</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Extraction via sonication with IS in methanol/acetonitrile</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">3–75</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>74% (freshly prepared DBS);</p>
<p>81% (DBS samples stored 17 d at 2–8 °C)</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>−20 – −30 °C: 17 d</p>
<p>2–8 °C: 80 d</p>
<p>15–25 °C: 17 d</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Hct 0.20–0.50 tested at 5, 20 and 40 ng/mL, assay performance no significant impact for Hct ≥ 0.25 for all concentrations; except at Hct 0.20 and Mid and High accuracy was &gt;15% of nominal conc.</p>
<p>20–50 μL spot volumes and Hct 0.40 had minor impact. At Hct 0.20, spot volume had significant impact on accuracy.</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Boons et al. (<a href="#bmc70056-bib-0006" class="usa-link" aria-describedby="bmc70056-bib-0006">2017</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Nilotinib</td>
<td align="center" valign="top" rowspan="1" colspan="1">DBS; Whatman FTA DMPK‐C</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 mm punch–40 μL aliquots</td>
<td align="center" valign="top" rowspan="1" colspan="1">Extraction with methanol incl. IS, while shaking.</td>
<td align="center" valign="top" rowspan="1" colspan="1">17–4100</td>
<td align="center" valign="top" rowspan="1" colspan="1">87.6</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>At low and high:</p>
<p>2–8 °C: 7 mo;</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Hct 0.25–0.50 at Low and High:no significant impact on accuracy.</td>
</tr>
<tr>
<td rowspan="4" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Tré‐Hardy et al. (<a href="#bmc70056-bib-0059" class="usa-link" aria-describedby="bmc70056-bib-0059">2016</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Tamoxifen</td>
<td align="center" rowspan="4" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Whatman 903</td>
<td align="center" rowspan="4" style="background-color:#E7E6E6" valign="top" colspan="1">3/16 in. (4.7625 mm) punch–50 μL aliquots</td>
<td align="center" rowspan="4" style="background-color:#E7E6E6" valign="top" colspan="1">(Disks were cut in half) Extraction via sonication with IS in methanol, shaking and vortex mixing with small glass balls, evaporation with nitrogen at 50 °C.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">1.7–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 95.2 (5.3)</p>
<p>Mid, 96.3 (2.1)</p>
<p>High, 95.2 (2.1)</p>
</td>
<td align="center" rowspan="4" style="background-color:#E7E6E6" valign="top" colspan="1">NR</td>
<td align="center" rowspan="4" style="background-color:#E7E6E6" valign="top" colspan="1">Hct 0.25–0.50 tested, for Hct ≥ 0.40 &gt; 15% variation from the nominal value was observed, lower Hct had no impact on accuracy.</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">4‐Hydroxy‐tamoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">0.6–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 83.8 (13.5)</p>
<p>Mid, 95.6 (3.3)</p>
<p>High, 91.8 (2.9)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Z‐endoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">3–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 88.3 (12.3)</p>
<p>Mid, 88.9 (6.3)</p>
<p>High, 95.9 (1.8)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">N‐desmethyl tamoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 90.8 (8.2)</p>
<p>Mid, 87.3 (6.8)</p>
<p>High, 92.6 (6.3)</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Verheijen et al. (<a href="#bmc70056-bib-0069" class="usa-link" aria-describedby="bmc70056-bib-0069">2016</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Pazopanib</td>
<td align="center" valign="top" rowspan="1" colspan="1">DBS; Whatman 903</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 mm punch–15 μL aliquots</td>
<td align="center" valign="top" rowspan="1" colspan="1">Vortex mixing and shaking with formic acid (99%), again vortex mixing and shaking with IS in methanol</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.000–50.000</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Low, 97.6 (≤ 2.7)</p>
<p>High, 103.7(≤ 2.7)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Ambient: 398 d;</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">All at Low and High: Punch site, spot volumes 10–30 μL and Hct 0.35–50.0 all no significant impact on accuracy and precision.</td>
</tr>
<tr>
<td rowspan="4" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Antunes, Raymundo, de Oliveira, et al. (<a href="#bmc70056-bib-0001" class="usa-link" aria-describedby="bmc70056-bib-0001">2015</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Tamoxifen</td>
<td align="center" rowspan="4" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Whatman 903</td>
<td align="center" rowspan="4" style="background-color:#E7E6E6" valign="top" colspan="1">10 mm punch–60 μL aliquots</td>
<td align="center" rowspan="4" style="background-color:#E7E6E6" valign="top" colspan="1">(Two disks were used for extraction, cut in half.) Vortex mixing with IS in methanol, ultrasonication, evaporation (55 °C).</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">7.5–300</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 89.8</p>
<p>Mid, 91.3</p>
<p>High, 93.4</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>All at low and high:</p>
<p>−20 °C, 25 °C and 45 °C: 20 d;</p>
</td>
<td align="center" rowspan="4" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>Hct 0.25–0.40 no significant impact on accuracy,</p>
<p>Hct ≥ 0.45 significant impact on accuracy</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">N‐desmethyl tamoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">15–600</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 81.5</p>
<p>Mid, 88.5</p>
<p>High, 84.5</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">−20 °C, 25 °C and 45 °C: 20 d;</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">4‐Hydroxy tamoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">0.5–50</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 38.1</p>
<p>Mid, 39.4</p>
<p>High, 41.2</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">−20 °C and 25 °C: 20 d (at 45 °C increase of 38% in conc. at day 2)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Z‐endoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">1–40</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 47.9</p>
<p>Mid, 48.5</p>
<p>High, 46.1</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">20 °C and 25 °C: 20 d (at 45 °C increase of 38% in conc. at day 2)</td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">de Wit et al. (<a href="#bmc70056-bib-0017" class="usa-link" aria-describedby="bmc70056-bib-0017">2015</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Pazopanib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS; Whatman FTA</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">4 mm punch–15 μL aliquots</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Extraction with Is in formic acid and methanol while mixing</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">100–50.000</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">NR</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Ambient: 75 d;=</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Hct 0.20–0.65 no significant impact on assay performance</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Antunes, Raymundo, Wagner, et al. (<a href="#bmc70056-bib-0002" class="usa-link" aria-describedby="bmc70056-bib-0002">2015</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; Whatman 903</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">6 mm punch–60 μL aliquots</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">(Spots cut in half) Extraction with IS in methanol, incubation while shaking</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">50–4000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">91.5 (range 88.8–93.8)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>At low and high:</p>
<p>−20 °C, 25 °C, and 45 °C: 36 d</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Hct 0.25–0.50 no significant impact on assay performance.</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Nijenhuis et al. (<a href="#bmc70056-bib-0052" class="usa-link" aria-describedby="bmc70056-bib-0052">2014</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Vemurafenib</td>
<td align="center" valign="top" rowspan="1" colspan="1">DBS; Whatman FTA DMPK‐A</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 mm punch–15 μL aliquots</td>
<td align="center" valign="top" rowspan="1" colspan="1">Extraction with methanol/acetonitrile and IS, vortex mixing and shaking.</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.000–100.000</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Low, 92.2 (8.5)</p>
<p>High, 105.0 (8.6)</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Ambient: 163 d</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>All at low and high:</p>
<p>Spot volume 10–30 μL, punch sites and Hct 0.24–0.45: all no significant impact on accuracy and precision.</p>
</td>
</tr>
<tr>
<td rowspan="2" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Jager, Rosing, Schellens, and Beijnen (<a href="#bmc70056-bib-0033" class="usa-link" aria-describedby="bmc70056-bib-0033">2014</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Tamoxifen</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Whatman DMPK‐A</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">6 mm punch–30 μL aliquots</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">Extraction with IS in methanol, vortex mixing and sonication, evaporation with nitrogen (30 °C).</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2.5–250</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 102 (&lt;15)</p>
<p>High, 91.2 (&lt;15)</p>
</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>At low and high:2–8 °C and 37 °C: 24 h</p>
<p>RT: 4 mo</p>
</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>All at low and high:</p>
<p>Hct 0.29–0.48, spot volume 20–50 μL; punch sites, all no significant impact on accuracy and precision.</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Z‐endoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">0.5–50</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 96.6 (&lt;15)</p>
<p>High, 93.9 (&lt;15)</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Xu et al. (<a href="#bmc70056-bib-0077" class="usa-link" aria-describedby="bmc70056-bib-0077">2012</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Adavosertib</td>
<td align="center" valign="top" rowspan="1" colspan="1">DBS; Whatman DMPK‐A</td>
<td align="center" valign="top" rowspan="1" colspan="1">3 mm punch–40 μL aliquots</td>
<td align="center" valign="top" rowspan="1" colspan="1">(In 96‐well plate) Extraction with 10 mM ammonium acetate, pH 3.0, IS in in 85% acetonitrile, mixing</td>
<td align="center" valign="top" rowspan="1" colspan="1">2–1000</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Low, 71</p>
<p>Mid, 81</p>
<p>High, 80</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>40 °C and 75% RH: 8 d</p>
<p>−20 °C: 6 mo</p>
<p>RT: 14 mo</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">Spot volume 30 and 50 μL, punch site, Hct 0.16–0.85 no significant impact on accuracy and precision.</td>
</tr>
<tr>
<td rowspan="3" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Kralj et al. (<a href="#bmc70056-bib-0038" class="usa-link" aria-describedby="bmc70056-bib-0038">2012</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Agilent DMS cards</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">8 mm punch–10 μL aliquots</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">(96‐well filter plate) addition of IS, extraction with 0.1% formic acid in methanol, mixing</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">50–5000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 97.4</p>
<p>Mid, 94.8</p>
<p>High, 94.5</p>
</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>RT: 28 d</p>
<p>−20 °C: 3 d</p>
<p>40 °C: imatinib and nilotinib stable 3d, dasatinib not.</p>
</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Hct 0.30–0.60 no significant impact on accuracy at low, mid, high.</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Nilotinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">50–5000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 96.1</p>
<p>Mid, 93.5</p>
<p>High, 90.5</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Dasatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2.5–250</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 108.4</p>
<p>Mid, 103.5</p>
<p>High, 93.1</p>
</td>
</tr>
<tr>
<td rowspan="4" align="left" valign="top" colspan="1">Maggadani et al. (<a href="#bmc70056-bib-0046" class="usa-link" aria-describedby="bmc70056-bib-0046">2021</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Tamoxifen</td>
<td align="center" rowspan="4" valign="top" colspan="1">
<p>DBS; PerkinElmer 226</p>
<p>VAMS; Mitra®</p>
</td>
<td align="center" rowspan="4" valign="top" colspan="1">
<p>whole spot cut–20 μL aliquots</p>
<p>Volumetric 20 μL</p>
</td>
<td align="center" rowspan="4" valign="top" colspan="1">Similar for DBS and VAMS: vortex mixing and sonication with Is in methanol, evaporation with nitrogen</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.5–200</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>DBS:</p>
<p>Low, 86.84 (5.09)</p>
<p>Mid, 82.12 (0.85)</p>
<p>High, 84.30 (6.42)</p>
<p>VAMS:</p>
<p>Low, 91.13 (1.37)</p>
<p>Mid, 92.02 (0.94)</p>
<p>High, 92.54 (1.56)</p>
</td>
<td align="center" rowspan="4" valign="top" colspan="1">
<p>Both DBS and VAMS at Low and high:</p>
<p>Benchtop: 24 h</p>
<p>RT: 60 d</p>
<p>−20 °C: 24 h</p>
<p>40 °C: 24 h</p>
</td>
<td align="center" rowspan="4" valign="top" colspan="1"></td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Z‐endoxifen</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.4–40</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>DBS:</p>
<p>Low, 86.53 (3.90)</p>
<p>Mid, 89.21 (4.03)</p>
<p>High, 78.59 (3.62)</p>
<p>VAMS:</p>
<p>Low, 88.63 (0.89)</p>
<p>Mid, 87.12 (1.07)</p>
<p>High, 87.24 (1.60)</p>
</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">4‐Hydroxy tamoxifen</td>
<td align="center" valign="top" rowspan="1" colspan="1">1.5–30</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>DBS:</p>
<p>Low, 75.12 (5.27)</p>
<p>Mid, 88.32 (9.00)</p>
<p>High, 89.03 (3.48)</p>
<p>VAMS:</p>
<p>Low, 80.48 (2.12)</p>
<p>Mid, 79.70 (1.57)</p>
<p>High, 88.27 (1.64)</p>
</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">N‐desmethyl tamoxifen</td>
<td align="center" valign="top" rowspan="1" colspan="1">2–600</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>DBS:</p>
<p>Low, 80.41 (1.99)</p>
<p>Mid, 91.86 (0.70)</p>
<p>High, 87.31 (4.57)</p>
<p>VAMS:</p>
<p>Low, 91.72 (0.85)</p>
<p>Mid, 91.92 (1.17)</p>
<p>High, 91.77 (0.73)</p>
</td>
</tr>
<tr>
<td rowspan="10" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Meertens et al. (<a href="#bmc70056-bib-0048" class="usa-link" aria-describedby="bmc70056-bib-0048">2024</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Abiraterone</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">VAMS; Mitra®</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">Volumetric 10 μL</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">Extraction with IS and methanol while shaking with small steel balls, evaporation with nitrogen (40 °C).</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–40</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 85.2 (21.4)</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>RT and 25 °C: 14 d for all analytes</p>
<p>40 °C: 14 d for all analytes, except D4A and norimatinib: 24 h</p>
<p>3 F/T (−20 °C, −70 °C): 7d for all analytes</p>
<p>−20 °C: 12 mo for all analytes</p>
<p>−70 °C: 12 mo for all analytes except norimatinib and N‐desethyl sunitinib: 9 mo</p>
</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>Hct 0.29–0.54 no significant impact on accuracy and precision</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">D4A</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">0.5–10</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 69.8 (27.7)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Alectinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">100–2000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 76.2 (5.2)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Alectinib‐M4</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">50–1000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 79.9 (3.2)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Cabozantinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">100–2000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 99.7 (2.2)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">200–4000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 88.0 (1.5)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Norimatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">50–1000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 84.6 (10.0)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Olaparib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">400–8000</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 93.1 (2.5)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Sunitinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">5–100</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 64.7 (6.0)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">N‐desethyl sunitinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">5–100</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Mid, 69.6 (1.8)</td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">Krützmann et al. (<a href="#bmc70056-bib-0039" class="usa-link" aria-describedby="bmc70056-bib-0039">2023</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" rowspan="2" valign="top" colspan="1">VAMS; Mitra®</td>
<td align="center" rowspan="2" valign="top" colspan="1">Volumetric 20 μL</td>
<td align="center" rowspan="2" valign="top" colspan="1">Incubation with 0.1% formic acid in H<sub>2</sub>0, while mixing at 45 °C. Protein precipitation with ACN with 0.1% formic acid including IS. Refrigeration at −20 °C</td>
<td align="center" valign="top" rowspan="1" colspan="1">50–2500</td>
<td align="center" valign="top" rowspan="1" colspan="1">93 (NR)</td>
<td align="center" rowspan="2" valign="top" colspan="1">
<p>RT (23–25 °C): 21 d</p>
<p>45 °C: 14 d</p>
</td>
<td align="center" rowspan="2" valign="top" colspan="1">
<p>Hct 0.25–0.55 no significant impact accuracy and precision.</p>
<p>Extraction yield differed ~ 10% among the Hct values</p>
</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Norimatinib</td>
<td align="center" valign="top" rowspan="1" colspan="1">50–2500</td>
<td align="center" valign="top" rowspan="1" colspan="1">91 (NR)</td>
</tr>
<tr>
<td rowspan="8" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Verougstraete et al. (<a href="#bmc70056-bib-0073" class="usa-link" aria-describedby="bmc70056-bib-0073">2022</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Bosutinib</td>
<td align="center" rowspan="8" style="background-color:#E7E6E6" valign="top" colspan="1">VAMS; Mitra®</td>
<td align="center" rowspan="8" style="background-color:#E7E6E6" valign="top" colspan="1">Volumetric 10 μL</td>
<td align="center" rowspan="8" style="background-color:#E7E6E6" valign="top" colspan="1">Pre‐wetting with water while vortex mixing, sonication with IS in methanol, liquid–liquid extraction with MTBE, evaporation with nitrogen.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">5–675</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 115 (16.9)</p>
<p>High, 116 (8.15)</p>
</td>
<td align="center" rowspan="8" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>−20 °C, 4 °C, RT: 1 mo for all analytes, except ibrutinib only 2 w at RT;60 °C: 2 d for all analytes except ibrutinib, which is not stable at 60 °C;</p>
<p>3 F/T cycles: all analytes;</p>
</td>
<td align="center" rowspan="8" style="background-color:#E7E6E6" valign="top" colspan="1">All at low and high: Hct 0.18–0.55 no significant impact on accuracy and precision and recovery, except for bosutinib and gilteritinib high imprecision of recovery at QC low Hct 0.18</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Dasatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">0.5–450</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 125% (8.81)</p>
<p>High, 118% (4.26)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Gilteritinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">25–675</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 118% (22.8)</p>
<p>High, 104 (7.49)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Ibrutinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">5–675</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 83 (8.84)</p>
<p>High, 104 (6.38)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">10–2250</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 109 (7.23)</p>
<p>High, 114 (6.38)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Midostaurin</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">30–2250</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 106 (4.39)</p>
<p>High, 92 (5.92)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Nilotinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">10–2250</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 110 (11.6)</p>
<p>High, 115 (4.38)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Ponatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">1–450</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 114 (4.83)</p>
<p>High, 112 (6.02)</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Opitz et al. (<a href="#bmc70056-bib-0053" class="usa-link" aria-describedby="bmc70056-bib-0053">2022</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Axitinib</td>
<td align="center" valign="top" rowspan="1" colspan="1">VAMS; Mitra®</td>
<td align="center" valign="top" rowspan="1" colspan="1">Volumetric 20 μL</td>
<td align="center" valign="top" rowspan="1" colspan="1">Pre‐wetting with water, extraction with IS in acetonitrile while shaking.</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.04–10 and 0.5–124</td>
<td align="center" valign="top" rowspan="1" colspan="1">Not executed as sample preparation was similar to Zimmermann et al and Aghai et al, with recovery between 90 and 110%.</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>RT: 7 d</p>
<p>50 °C: 24 h</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">NA</td>
</tr>
<tr>
<td rowspan="10" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Zimmermann et al. (<a href="#bmc70056-bib-0081" class="usa-link" aria-describedby="bmc70056-bib-0081">2022</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Afatinib</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">VAMS; Mitra®</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">Volumetric 20 μL</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">Rehydration with water, extraction with IS in acetonitrile while vortex mixing, evaporation.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 79.9 (4.1)</p>
<p>Mid, 81.5 (5.1)</p>
<p>High, 79.6 (4.0)</p>
</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>RT (19% RH): 6w for all analytes</p>
<p>60 °C (10% RH): 48 h for all analytes, except afatinib and osimertinib</p>
</td>
<td align="center" rowspan="10" style="background-color:#E7E6E6" valign="top" colspan="1">Low, mid, high: Hct 0.30–0.50 no significant impact on accuracy and precision.</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Axitinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 99.4 (6.8)</p>
<p>Mid, 100.8 (5.0)</p>
<p>High, 101.4 (3.6)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Bosutinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 91.8 (4.1)</p>
<p>Mid, 94.2 (4.5)</p>
<p>High, 94.2 (3.7)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Cabozantinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">6–1500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 106.3 (3.2)</p>
<p>Mid, 101.7 (2.8)</p>
<p>High, 107.9 (0.2)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Dabrafenib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">6–1500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 112.7 (3.5)</p>
<p>Mid, 114.1 (2.5)</p>
<p>High, 110.0 (2.0)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Lenvatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 93.0 (3.7)</p>
<p>Mid, 93.6 (3.2)</p>
<p>High, 94.4 (2.3)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Nilotinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">6–1500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 98.2 (4.6)</p>
<p>Mid, 98.2 (3.9)</p>
<p>High, 98.2 (2.8)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Osimertinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">6–1500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 68.1 (3.2)</p>
<p>Mid, 67.7 (3.7)</p>
<p>High, 68.9 (7.9)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Ruxolitinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 99.5 (3.5)</p>
<p>Mid, 98.3 (2.8)</p>
<p>High, 99.1 2.8)</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Trametinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2–500</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 98.7 (9.4)</p>
<p>Mid, 99.6 (6.1)</p>
<p>High, 98.8 (2.7)</p>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Voggu (<a href="#bmc70056-bib-0074" class="usa-link" aria-describedby="bmc70056-bib-0074">2020</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Selumetinib</td>
<td align="center" valign="top" rowspan="1" colspan="1">VAMS: Mitra®</td>
<td align="center" valign="top" rowspan="1" colspan="1">Volumetric 10 μL</td>
<td align="center" valign="top" rowspan="1" colspan="1">(In 96‐well plate) Extraction via and vortex mixing with 0.1% ammoniumhydroxide in methanol and IS working solution. Evaporation with nitrogen at 45 °C.</td>
<td align="center" valign="top" rowspan="1" colspan="1">2.00–2000</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>Low, 104.1</p>
<p>Mid, 101.6</p>
<p>High, 103.4</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">
<p>At low and high:</p>
<p>Bench top RT: 126 d</p>
<p>Freezer (−10 to −30 °C): 378 d</p>
</td>
<td align="center" valign="top" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Verheijen et al. (<a href="#bmc70056-bib-0070" class="usa-link" aria-describedby="bmc70056-bib-0070">2019</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Everolimus</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">VAMS; Mitra®</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Volumetric 10 μL</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Extraction with IS and methanol while vortex mixing, ultrasonication and shaking, evaporation with nitrogen.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2.5–100</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Low, 23.1 (7.3)</p>
<p>High, 20.2 (9.8)</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">At low and high: ambient: 362 d</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>At low, mid, and high:</p>
<p>Hct 0.30–0.50 significant impact accuracy. Relative biases ranging from −20 to 31%</p>
</td>
</tr>
<tr>
<td rowspan="3" align="left" valign="top" colspan="1">Rehnmark et al. (<a href="#bmc70056-bib-0055" class="usa-link" aria-describedby="bmc70056-bib-0055">2022</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Tamoxifen</td>
<td align="center" rowspan="3" valign="top" colspan="1">Volumetric capillary; Rhelise™ kit</td>
<td align="center" rowspan="3" valign="top" colspan="1">Volumetric 50 μL</td>
<td align="center" rowspan="3" valign="top" colspan="1">Protein precipitation with IS and 0.1% formic acid and acetonitrile while vortex mixing, evaporation with nitrogen</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.1–200</td>
<td align="center" rowspan="3" valign="top" colspan="1">NA</td>
<td align="center" valign="top" rowspan="1" colspan="1">8 ± 2 °C: 14 dRT (20 ± 5 °C): 7 d</td>
<td align="center" rowspan="3" valign="top" colspan="1">NA</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">4‐Hydroxy tamoxifen</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.1–200</td>
<td align="center" valign="top" rowspan="1" colspan="1">6–25 °C: 14 d</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Z‐endoxifen</td>
<td align="center" valign="top" rowspan="1" colspan="1">0.1–200</td>
<td align="center" valign="top" rowspan="1" colspan="1">6–25 °C: 14 d</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Saito et al. (<a href="#bmc70056-bib-0058" class="usa-link" aria-describedby="bmc70056-bib-0058">2022</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Lenvatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Volumetric capillary; Microsampling Wing</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Volumetric 23 μL whole blood for 5.6 μL plasma</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Centrifugation of MSW in tube. Snapping of plasma zone, centrifuging, resulting in 5.6 μL plasma. Protein precipitation with IS in acetonitrile while vortex mixing.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">1–200</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">NA</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">25 °C and 4 °C: 30 d</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">NA</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/bmc70056-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="bmc70056-note-0002"><p>Abbreviations: d, days; DBS, dried blood spots; Hct, hematocrit; IS, internal standard; Low Mid High, quality control levels; mo, months; NA, not applicable; NR, not reported; RH, relative humidity; RT, room temperature; VAMS, volumetric absorptive microsampling; w, weeks.</p></div></div></section><section class="tw xbox font-sm" id="bmc70056-tbl-0002"><h5 class="obj_head">TABLE 2.</h5>
<div class="caption p"><p>Clinical validation of chromatographic mass spectrometric methods using home‐sampling devices to support TDM.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead valign="bottom"><tr style="border-bottom:solid 1px #000000">
<th align="left" valign="bottom" rowspan="1" colspan="1">Author (year)</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Drugs</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Device</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Number of samples and patients</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Conversion method</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Predictive performance conversion method</th>
<th align="center" valign="bottom" rowspan="1" colspan="1">Remarks</th>
</tr></thead>
<tbody valign="top">
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Venkatesh et al. (<a href="#bmc70056-bib-0068" class="usa-link" aria-describedby="bmc70056-bib-0068">2023</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Osimertinib, metabolites (AZ5104 and AZ7550)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS; HemaPEN</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">15 plasma and DBS samples from 15 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">No conversion needed plasma ≈ DBS</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">NA</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="3" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Canil et al. (<a href="#bmc70056-bib-0010" class="usa-link" aria-describedby="bmc70056-bib-0010">2023</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Niraparib</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Hemaxis DB10</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">43 plasma and DBS samples from 21 patients</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Empirical: conversion factor</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Conversion factor met the criteria.</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Limitation: Hct must be known in time frame close to home‐sampling because must be within (0.29–0.45).</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Olaparib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">52 plasma and DBS samples from 16 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Conversion factor met the criteria.</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Rucaparib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">16 plasma and DBS samples from 4 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Conversion factor met the criteria.</td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Zanchetta et al. (<a href="#bmc70056-bib-0079" class="usa-link" aria-describedby="bmc70056-bib-0079">2023</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Lenvatinib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS; Whatman 31ETCHR and Whatman 903</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">10 DBS and plasma samples from 4 patients. DBS made from venous blood using pipette.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Only preliminary data (DBS‐to‐plasma ratio and regression) and no conversion method was evaluated</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">NA</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="6" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Mukai et al. (<a href="#bmc70056-bib-0049" class="usa-link" aria-describedby="bmc70056-bib-0049">2022</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Bosutinib</td>
<td align="center" rowspan="6" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Whatman 903</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS collected out of venous whole blood with pipette; DBS and plasma from 19 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Empirical: conversion factor and Deming‐regression</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Both conversion methods met the criteria.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Dasatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS and plasma from 29 patients (3 excluded due to &lt;LLOQ)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Empirical: correction factor and Deming‐regression</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Both conversion methods did not meet the criteria.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Not suitable for trough levels of dasatinib (related to toxicity), but with DBS conc. ≥ 7.25 ng/mL, (corresponding to 4.33 ng/mL in plasma) the predictive performance improved, meaning DBS is suitable for top levels (related to efficacy)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Ibrutinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS and plasma from 2 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">NA, too few samples</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">NA</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS and plasma from 9 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Empirical: correction factor and Deming‐regression</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Both conversion methods met the criteria.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Also correction found by Antunes, Raymundo, Wagner, et al. (<a href="#bmc70056-bib-0002" class="usa-link" aria-describedby="bmc70056-bib-0002">2015</a>) tested as external validation, did meet the criteria.</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Nilotinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS and plasma from 22 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Empirical: correction factor and Deming‐regression</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Correction factor did not meet the criteria; regression formula met the criteria.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">When only including samples drawn after peak concentrations, both conversion methods fell within acceptable criteria (only 7 samples)</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Ponatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS and plasma from 15 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Empirical: correction factor and Deming‐regression</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Both conversion methods met the criteria</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Zhang et al. (<a href="#bmc70056-bib-0080" class="usa-link" aria-describedby="bmc70056-bib-0080">2022</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Anlotinib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS; Whatman 903</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS and plasma samples from 23 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Empirical: Deming‐regression</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Conversion method met the criteria</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Braal et al. (<a href="#bmc70056-bib-0008" class="usa-link" aria-describedby="bmc70056-bib-0008">2021</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Ribociclib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; Whatman 903</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS and plasma samples from 17 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">No conversion method needed</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1"></td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="3" style="background-color:#FFFFFF" align="left" valign="top" colspan="1">Poetto et al. (<a href="#bmc70056-bib-0054" class="usa-link" aria-describedby="bmc70056-bib-0054">2021</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Palbociclib</td>
<td align="center" rowspan="3" style="background-color:#FFFFFF" valign="top" colspan="1">DBS; Whatman ET31CHR</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS capillary and prepared from venous blood, and plasma samples <em>n</em> = 20, from 13 patients</td>
<td align="center" rowspan="3" style="background-color:#FFFFFF" valign="top" colspan="1">
<p>Individual Hct normalization with plasma fraction</p>
<p>Individual Hct normalization with red blood cell to plasma partitioning coefficient</p>
<p>Empirical: correction factor</p>
</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">All methods met the criteria; but drug distribution model was selected as conversion method.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>No significant difference between venous and capillary DBS</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Ribociclib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS capillary and prepared from venous blood, and plasma samples <em>n</em> = 22 from 5 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">All method met the criteria; correction factor was selected as best method.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">No significant difference between venous and capillary DBS</td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Letrozol</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS capillary and prepared from venous blood, and plasma samples <em>n</em> = 34 from 11 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">All method met the criteria; correction factor was selected as best conversion method.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">No significant difference between venous and capillary DBS.</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Guo et al. (<a href="#bmc70056-bib-0027" class="usa-link" aria-describedby="bmc70056-bib-0027">2021</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Bortezomib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS Whatman 903</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">13 DBS and plasma sample pairs from 4 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">No conversion method needed</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">NA</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="2" align="left" valign="top" colspan="1">Dillenburg Weiss et al. (<a href="#bmc70056-bib-0023" class="usa-link" aria-describedby="bmc70056-bib-0023">2021</a>)</td>
<td align="center" valign="top" rowspan="1" colspan="1">Abiraterone</td>
<td align="center" rowspan="2" valign="top" colspan="1">DBS; Whatman 903</td>
<td align="center" rowspan="2" valign="top" colspan="1">16 DBS (capillary and venous) and plasma sample pairs from 10 patients</td>
<td align="center" valign="top" rowspan="1" colspan="1">Individual Hct normalization with plasma fraction</td>
<td align="center" valign="top" rowspan="1" colspan="1">The conversion method met the criteria.</td>
<td align="center" valign="top" rowspan="1" colspan="1">No significant difference between venous and capillary DBS</td>
</tr>
<tr>
<td align="center" valign="top" rowspan="1" colspan="1">Delta(4)‐abiraterone</td>
<td align="center" valign="top" rowspan="1" colspan="1">Individual Hct normalization with plasma fraction</td>
<td align="center" valign="top" rowspan="1" colspan="1">The conversion method met the criteria.</td>
<td align="center" valign="top" rowspan="1" colspan="1">No significant difference between venous and capillary DBS</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Lee et al. (<a href="#bmc70056-bib-0042" class="usa-link" aria-describedby="bmc70056-bib-0042">2020</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Radotinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; Whatman 903 protein saver</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS and plasma samples from 45 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Empirical: Deming regression formula</p>
<p>Individual Hct normalization (second‐degree polynomial function)</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Both methods met the criteria.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Number of study samples was not sufficient to predict radotinib blood concentrations above 1500 ng/mL.</td>
</tr>
<tr>
<td rowspan="2" style="background-color:#FFFFFF" align="left" valign="top" colspan="1">Iacuzzi et al. (<a href="#bmc70056-bib-0030" class="usa-link" aria-describedby="bmc70056-bib-0030">2019</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" rowspan="2" style="background-color:#FFFFFF" valign="top" colspan="1">DBS; Whatman ET31CHR</td>
<td align="center" rowspan="2" style="background-color:#FFFFFF" valign="top" colspan="1">55 venous and capillary DBS and plasma samples from 26 patients</td>
<td align="center" rowspan="2" style="background-color:#FFFFFF" valign="top" colspan="1">
<p>Individual Hct normalization</p>
<p>Empirical: correction factor</p>
</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Both methods met the criteria. Correction factor showed higher agreement than with Hct normalization. Validation cohort of 12 extra patients with correction factor method met the criteria.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>No significant difference between venous and capillary DBS</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Norimatinib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Both methods met the criteria. Correction factor showed higher agreement than with Hct normalization. Validation cohort of 12 extra patients with correction factor method met the criteria.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">No significant difference between Venous and capillary DBS</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Irie et al. (<a href="#bmc70056-bib-0031" class="usa-link" aria-describedby="bmc70056-bib-0031">2018</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Gefitinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; qualitative filter paper No. 2, 125 g/m<sup>2</sup> (Advantec)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">10 DBS and plasma samples from 10 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>No conversion method necessary</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>NA</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">No influence of Hct tested, as only patients with Hct values within a narrow normal range were included.</td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Willemsen et al. (<a href="#bmc70056-bib-0075" class="usa-link" aria-describedby="bmc70056-bib-0075">2018</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Everolimus</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS; Whatman 903 protein saver</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">20 capillary and venous DBS, and venous whole blood samples from 20 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Empirical: Passing‐Bablok regression, excluding data of the individual patient from whom the WB concentration is to be predicted. Repeated for each individual patient.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">The conversion method met the criteria.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>No significant difference between venous and capillary DBS.</p>
<p>Without conversion method also good agreement between capillary DBS and whole blood concentrations.</p>
</td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Boons et al. (<a href="#bmc70056-bib-0006" class="usa-link" aria-describedby="bmc70056-bib-0006">2017</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Nilotinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; Whatman DMPK‐C</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">40 capillary DBS and venipuncture plasma samples from 20 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">
<p>Hct normalization with red blood cell to plasma partitioning coefficient for both individual and population Hct</p>
<p>Empirical: Deming regression</p>
</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">All conversion methods met the criteria. Individual Hct did not improve predictive performance compared to population Hct</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Nijenhuis et al. (<a href="#bmc70056-bib-0051" class="usa-link" aria-describedby="bmc70056-bib-0051">2016</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Vemurafenib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS; Whatman FTA DMPK‐A</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">41 (duplicate) DBS capillary and plasma samples from 8 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>Individual Hct normalization with red blood cell to plasma partitioning coefficient</p>
<p>Empirical: Deming regression</p>
</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Both methods met the criteria</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">Verheijen et al. (<a href="#bmc70056-bib-0069" class="usa-link" aria-describedby="bmc70056-bib-0069">2016</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Pazopanib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; Whatman 903 protein saver</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">221 paired DBS and plasma samples from 30 patients</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Empirical: Deming regression</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">The conversion method met the criteria.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Hct normalization based conversion did not improve the correlation between calculated and measured plasma (unknown if criteria were met)</td>
</tr>
<tr>
<td rowspan="4" style="background-color:#FFFFFF" align="left" valign="top" colspan="1">Antunes, Raymundo, de Oliveira, et al. (<a href="#bmc70056-bib-0001" class="usa-link" aria-describedby="bmc70056-bib-0001">2015</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Tamoxifen</td>
<td align="center" rowspan="4" style="background-color:#FFFFFF" valign="top" colspan="1">DBS; Whatman 903</td>
<td align="center" rowspan="4" style="background-color:#FFFFFF" valign="top" colspan="1">DBS and plasma samples from 91 patients</td>
<td align="center" rowspan="4" style="background-color:#FFFFFF" valign="top" colspan="1">
<p>Individual Hct normalization with correction factor</p>
</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">The conversion method met the criteria.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">N‐desmethyl tamoxifen</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">The conversion method met the criteria.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">4‐Hydroxy tamoxifen</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">The conversion method met the criteria.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Z‐endoxifen</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">The conversion method met the criteria.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td style="background-color:#E7E6E6" align="left" valign="top" rowspan="1" colspan="1">de Wit et al. (<a href="#bmc70056-bib-0017" class="usa-link" aria-describedby="bmc70056-bib-0017">2015</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Pazopanib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">DBS; Whatman FTA</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">9 paired DBS venous and plasma samples, and 3 DBS capillary for every patient, 12 patients (so 108 DBS venous and plasma pairs, and 36 capillary paired with venous from 12 patients)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Hct normalization for both individual and population Hct (0.40 for women and 0.45 for men)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Both conversion methods met the criteria</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">No significant difference between venous and capillary DBS</td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Antunes, Raymundo, Wagner, et al. (<a href="#bmc70056-bib-0002" class="usa-link" aria-describedby="bmc70056-bib-0002">2015</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS; Whatman 903</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS and plasma samples from 50 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Individual Hct normalization with plasma factionEmpirical: correction factor</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Both conversion methods met the criteria</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS threshold = 765 ng/mL (converted to 1000 ng/mL in plasma)</td>
</tr>
<tr>
<td rowspan="2" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Jager, Rosing, Schellens, Beijnen, and Linn (<a href="#bmc70056-bib-0034" class="usa-link" aria-describedby="bmc70056-bib-0034">2014</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Tamoxifen</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Whatman FTA DMPK‐A</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">44 DBS capillary and plasma samples from 44 patients</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">Population Hct normalization (0.41) and fixed blood cell to plasma partitioning coefficient resulting in empirical correction factor.</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Conversion method met the criteria</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">Empirical formula can be used for Hct between 0.29 and 0.48, Outside these values, an adequate correction can be made by using the equation and computing the patient‐specific Hct.</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Z‐endoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Conversion method met the criteria</td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Xu et al. (<a href="#bmc70056-bib-0077" class="usa-link" aria-describedby="bmc70056-bib-0077">2012</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Adavosertib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">DBS; Whatman DMPK‐A</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">36 plasma and DBS venous from 12 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Only DBS‐to‐plasma ratio and regression were calculated and no conversion method was evaluated</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">NR</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="3" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Kralj et al. (<a href="#bmc70056-bib-0038" class="usa-link" aria-describedby="bmc70056-bib-0038">2012</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Imatinib</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">DBS; Agilent DMS blood spot cards</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">18 plasma and DBS venous samples from 18 patients</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>Individual Hct normalization</p>
</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Conversion method met the criteria</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">
<p>All drugs analyzed together;</p>
<p>No capillary DBS used</p>
</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Nilotinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">2 plasma and DBS venous samples from 2 patients</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Dasatinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">3 plasma and DBS venous samples from 3 patients</td>
</tr>
<tr>
<td rowspan="5" style="background-color:#FFFFFF" align="left" valign="top" colspan="1">Zimmermann et al. (<a href="#bmc70056-bib-0082" class="usa-link" aria-describedby="bmc70056-bib-0082">2023</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Cabozantinib</td>
<td align="center" rowspan="5" style="background-color:#FFFFFF" valign="top" colspan="1">VAMS; Mitra® 20 μL</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">40 serum and VAMS samples from 18 patients</td>
<td align="center" rowspan="5" style="background-color:#FFFFFF" valign="top" colspan="1">
<p>Empirical: Passing‐Bablok regression</p>
<p>Empirical: conversion factor</p>
<p>Both individual and population Hct normalization with blood cell‐to‐plasma partitioning</p>
</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">All three conversion methods met the criteria. Individual Hct did not improve predictive performance</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Dabrafenib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">41 serum and VAMS samples from 18 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">All three conversion methods met the criteria.Individual Hct did not improve predictive performance</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Nilotinib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">41 serum and VAMS samples from 10 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">All three conversion methods met the criteria. Individual Hct did not improve predictive performance</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Ruxolitinib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">45 serum and VAMS samples from 13 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">No conversion method met the criteria</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Trametinib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">63 serum and VAMS samples from 17 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">No conversion method met the criteria</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Correlation between VAMS and plasma: <em>R</em>
<sup>2</sup> = 0.5811; in subanalysis showed differences based on gender and obesity</td>
</tr>
<tr>
<td rowspan="2" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Isberner et al. (<a href="#bmc70056-bib-0032" class="usa-link" aria-describedby="bmc70056-bib-0032">2022</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Dabrafenib</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1">VAMS; Mitra® 20 μL</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">278 serum samples from 27 patients and 169 VAMS samples for dabrafenib from 18 patients, not all paired samples, also VAMS drawn at home</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">popPK model‐informed VAMS‐to‐serum conversion model involving individual Hct normalization</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Conversion factor met the criteria.</td>
<td align="center" rowspan="2" style="background-color:#E7E6E6" valign="top" colspan="1"></td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Trametinib</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">266 serum samples from 27 patients and 158 VAMS samples from 18 patients not all paired samples, also VAMS drawn at home</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">popPK model‐informed VAMS‐to‐serum conversion model involving individual Hct normalization with a population value for the blood cell to plasma partition coefficient</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Conversion factor met the criteria.</td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Verheijen et al. (<a href="#bmc70056-bib-0070" class="usa-link" aria-describedby="bmc70056-bib-0070">2019</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Everolimus</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">VAMS; Mitra®</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">25 venous whole blood and VAMS capillary samples from 10 patients</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Empirical: Deming regression formula</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">The conversion method met the criteria.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">
<p>No advantage of VAMS compared to DBS, due to impact of Hct on assay performance.</p>
<p>Despite the effect of Hct, using an empirically derived formula, the whole blood everolimus concentration could be back calculated with reasonable accuracy.</p>
</td>
</tr>
<tr>
<td rowspan="3" style="background-color:#E7E6E6" align="left" valign="top" colspan="1">Rehnmark et al. (<a href="#bmc70056-bib-0055" class="usa-link" aria-describedby="bmc70056-bib-0055">2022</a>)</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Tamoxifen</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Rhelise™ kit 50 μL</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Plasma, venous blood and capillary blood samples from 16 patients</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">Only preliminary data (DBS to plasma ratio) and no conversion method was evaluated</td>
<td align="center" rowspan="3" style="background-color:#E7E6E6" valign="top" colspan="1">NA</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">No significant difference between venous and capillary samples</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">4‐Hydroxytamoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Capillary conc. was 56% of the venous concentration</td>
</tr>
<tr>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Z‐endoxifen</td>
<td align="center" style="background-color:#E7E6E6" valign="top" rowspan="1" colspan="1">Capillary conc. was 545% of venous concentration due to analytical degradation</td>
</tr>
<tr>
<td style="background-color:#FFFFFF" align="left" valign="top" rowspan="1" colspan="1">Saito et al. (<a href="#bmc70056-bib-0058" class="usa-link" aria-describedby="bmc70056-bib-0058">2022</a>)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Lenvatinib</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">MSW (5.6 μL)</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">35 venous whole blood samples and plasma from 11 patients. MSW was filled from the venous whole blood.</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Empirical: Passing‐Bablok regression: No conversion needed MSW plasma ≈ reference plasma</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">NA</td>
<td align="center" style="background-color:#FFFFFF" valign="top" rowspan="1" colspan="1">Venous blood was used for comparison with plasma, instead of capillary</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/bmc70056-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="bmc70056-note-0003"><p>Abbreviations: DBS, dried blood spots; Hct, hematocrit; NA, not applicable; NR, not reported; VAMS, volumetric absorptive microsampling.</p></div></div></section></section></section><section id="bmc70056-sec-0012"><h3 class="pmc_sec_title">3.2. Analytical Validation Experiments</h3>
<section id="bmc70056-sec-0013"><h4 class="pmc_sec_title">3.2.1. Analytical Validation Criteria</h4>
<p>In order to assess the validity of an analytical method for its purpose, the EMA guidelines or the new ICH M10 guidelines are frequently used as a reference (Capiau et al. <a href="#bmc70056-bib-0012" class="usa-link" aria-describedby="bmc70056-bib-0012">2019</a>; European Medicines Agency <a href="#bmc70056-bib-0025" class="usa-link" aria-describedby="bmc70056-bib-0025"><sup>2022</sup></a>). However, only a brief section on dried matrix methods is herein included. It would be advisable to refer to the IATDMCT guideline instead. The IATDMCT's guideline includes an overview of additional evaluation experiments for DBS‐based methods. It is recommended that, as a minimum, recovery, matrix effect, and process efficiency should be tested as additional experiments. These should be reproducible with a %RSD ≤ 15%. This should be conducted at two quality control levels, using samples from six different donors, with one donor modified to three different Hct levels and, all conditions in triplicate. In addition, the volume effect, Hct, and volcano effect should be included as validation experiments, as discussed in this review. For the volume and Hct effect, two quality control levels at three different Hct values were recommended. Similarly for the volcano effect, but in that case for central and peripheral punches. For all criteria, the deviation should not exceed ±15%. Not all articles evaluated these aspects, nor adhered to these strict criteria, as discussed in previous sections.</p></section><section id="bmc70056-sec-0014"><h4 class="pmc_sec_title">3.2.2. Sample Volume</h4>
<p>The sample volume should be small enough for feasible patient collection while being sufficient to reach clinically relevant lower limit of quantification (LLOQ) values. Reported home‐sampling techniques varied in sample volume (Table <a href="#bmc70056-tbl-0001" class="usa-link">1</a>), with the smallest volume of 2.74 μL analyzed for the DBS Hemapen (Venkatesh et al. <a href="#bmc70056-bib-0068" class="usa-link" aria-describedby="bmc70056-bib-0068">2023</a>). Despite this small volume, no evaporation step was required for concentration, and the clinically relevant LLOQ was still achieved. However, to obtain four 2.74 μL samples, patients still needed to collect 20 μL of blood. Thus, in terms of collection volume, the smallest amount was 10 μL (for DBS and VAMS), which was also the volume used for analysis. For non‐volumetric DBS samples, the smallest punch used was 3 mm, with concomitant aliquots of 10 μL for calibrators and quality control samples. For VAMS, sample volumes of 10 and 20 μL were used with equal frequency. Liquid home‐sampling devices like the Rhelise and MSW collected 50 μL and 23 μL, respectively, with only 5.6 μL analyzed from the MSW (Rehnmark et al. <a href="#bmc70056-bib-0055" class="usa-link" aria-describedby="bmc70056-bib-0055">2022</a>; Saito et al. <a href="#bmc70056-bib-0058" class="usa-link" aria-describedby="bmc70056-bib-0058"><sup>2022</sup></a>). Assuming that for 50 μL still only one drop of blood is needed, this will be a feasible volume for patient self‐collection. This has been shown in different studies where feasibility was proved acceptable for volumes up to 20 μL for VAMS and unknown for DBS. In contrast, the Minicollect® device—which was not included in the studies reviewed—required 250–500 μL and resulted in a high rejection rate of 72%. Despite no explicit feasibility study was found for 50 μL – in the specific study a trained nurse obtained the samples—it is expected that this is a manageable self‐collection volume. Generally, 50 μL is widely accepted as the upper limit for defining “microsampling” (Boffel et al. <a href="#bmc70056-bib-0004" class="usa-link" aria-describedby="bmc70056-bib-0004">2024</a>; C.C.L.M. Boons et al. <a href="#bmc70056-bib-0007" class="usa-link" aria-describedby="bmc70056-bib-0007"><sup>2019</sup></a>; Van Uytfanghe, Heughebaert, and Stove <a href="#bmc70056-bib-0063" class="usa-link" aria-describedby="bmc70056-bib-0063"><sup>2021</sup></a>).</p>
<p>Despite minimizing sample collection volumes to increase likelihood of correct sampling, sensitivity must remain priority. Evaporation steps can be considered to concentrate samples when necessary. Antunes et al. used two DBS disks for sample preparation, meaning at least two spots are needed for one result, with the disadvantage of the lack of back‐up samples (Antunes, Raymundo, de Oliveira, et al. <a href="#bmc70056-bib-0001" class="usa-link" aria-describedby="bmc70056-bib-0001"><sup>2015</sup></a>). For axitinib, the LLOQ was lowered from 0.5 to 0.04 ng/mL by using a more sensitive MS/MS detector instead of a single quadrupole detector with a smaller injection volume needed. For performing TDM the LLOQ of 0.5 ng/mL would suffice (Opitz et al. <a href="#bmc70056-bib-0053" class="usa-link" aria-describedby="bmc70056-bib-0053">2022</a>). Other methods reported to optimize source and gas parameters to achieve optimal sensitivity. Overall, all devices provided manageable collection and sample volumes, with sufficient sensitivity.</p></section><section id="bmc70056-sec-0015"><h4 class="pmc_sec_title">3.2.3. Analytical Range</h4>
<p>Most studies used a wide analytical range between LLOQ and the upper limit of quantification (ULOQ), often 100‐fold or more (Table <a href="#bmc70056-tbl-0001" class="usa-link">1</a>). However, for the home‐sampling approach of TDM, a smaller fit‐for‐purpose range may be sufficient for clinical interpretation, as mainly trough levels will be drawn. The therapeutic target should fall mid‐range, allowing clear differentiation between adequate, toxic, and ineffective concentrations, without requiring an extensive analytical range.</p>
<p>For example, for dasatinib targets for preventing toxicity (trough level ≤2.5 ng/mL and ≤1.5 ng/mL for patients over 50) and to prevent resistance (maximum level &gt;50 ng/mL) suggest that the reported range of 0.5–450 ng/L is more suitable than 2.5–250 or 2–200 ng/mL (Kralj et al. <a href="#bmc70056-bib-0038" class="usa-link" aria-describedby="bmc70056-bib-0038">2012</a>; Mukai et al. <a href="#bmc70056-bib-0049" class="usa-link" aria-describedby="bmc70056-bib-0049"><sup>2022</sup></a>; van der Kleij et al. <a href="#bmc70056-bib-0061" class="usa-link" aria-describedby="bmc70056-bib-0061"><sup>2023</sup></a>; Verougstraete and Stove <a href="#bmc70056-bib-0071" class="usa-link" aria-describedby="bmc70056-bib-0071"><sup>2022</sup></a>). Adjusting the range when transitioning from plasma to whole blood measurements in case of DBS and VAMS may be necessary. Overall, most methods used clinically relevant analytical ranges, with occasionally unnecessarily low LLOQs or high ULOQs.</p></section><section id="bmc70056-sec-0016"><h4 class="pmc_sec_title">3.2.4. Sample Preparation and Recovery</h4>
<p>For home sampling, dried matrices are most frequently used, such as DBS or VAMS. These matrices present challenges mainly related to sample preparation and resulting analytical recovery, while sample turnaround should meet the clinical needs. For the Rhelise and MSW devices, sample preparation consisted of a simple protein precipitation (Rehnmark et al. <a href="#bmc70056-bib-0055" class="usa-link" aria-describedby="bmc70056-bib-0055">2022</a>; Saito et al. <a href="#bmc70056-bib-0058" class="usa-link" aria-describedby="bmc70056-bib-0058"><sup>2022</sup></a>).</p>
<p>Dried sample preparation typically involved extraction and/or protein precipitation using organic solvents (e.g., methanol or acetonitrile), often containing or combined with the internal standard (Table <a href="#bmc70056-tbl-0001" class="usa-link">1</a>). To enhance the extraction, mechanical movement such as vortex mixing and sonication was frequently used, followed by an optional dilution step using a solvent similar to the mobile phase. Organic solvents were preferred for their effectiveness in precipitating proteins and dissolving hydrophobic drugs, but solvent selection is a critical step to ensure robust extraction from DBS or VAMS matrices (Capiau et al. <a href="#bmc70056-bib-0012" class="usa-link" aria-describedby="bmc70056-bib-0012">2019</a>). For instance, the polarity of the analyte may influence affinity for the device compared to the extraction solvent, which was in some cases modified by acid or alkaline additions to the extraction solvent (de Wit et al. <a href="#bmc70056-bib-0017" class="usa-link" aria-describedby="bmc70056-bib-0017"><sup>2015</sup></a>; Iacuzzi et al. <a href="#bmc70056-bib-0030" class="usa-link" aria-describedby="bmc70056-bib-0030"><sup>2019</sup></a>; Kralj et al. <a href="#bmc70056-bib-0038" class="usa-link" aria-describedby="bmc70056-bib-0038"><sup>2012</sup></a>; Krützmann et al. <a href="#bmc70056-bib-0039" class="usa-link" aria-describedby="bmc70056-bib-0039"><sup>2023</sup></a>; Verheijen et al. <a href="#bmc70056-bib-0069" class="usa-link" aria-describedby="bmc70056-bib-0069"><sup>2016</sup></a>; Voggu et al. <a href="#bmc70056-bib-0074" class="usa-link" aria-describedby="bmc70056-bib-0074"><sup>2020</sup></a>; Xu et al. <a href="#bmc70056-bib-0077" class="usa-link" aria-describedby="bmc70056-bib-0077"><sup>2012</sup></a>; Zanchetta et al. <a href="#bmc70056-bib-0079" class="usa-link" aria-describedby="bmc70056-bib-0079"><sup>2023</sup></a>). The choice of the extraction solvent is important to minimize the influence of Hct on recovery. For instance described by Krützmann et al., accuracy and precision were sufficient with VAMS extraction with methanol, but Hct affected the extraction yield ranging from 105% at HCT 0.25 to 62% at Hct 0.55. Switching to extraction with acetonitrile with 0.1% formic acid resolved this (Krützmann et al. <a href="#bmc70056-bib-0039" class="usa-link" aria-describedby="bmc70056-bib-0039">2023</a>). In one third of the methods, an evaporation step was added in order to concentrate the samples and thereby improve the sensitivity.</p>
<p>Extraction recovery was frequently improved with additional steps, such as pre‐wetting, mechanical movement or physical homogenization. Pre‐wetting is performed by adding water to the dried matrices before adding the organic solvent for extraction. This causes dissolution of blood components, and so effective removal of red blood cells of for instance VAMS tips, increasing recovery of analytes, but also potential causing a greater matrix effect (Xie et al. <a href="#bmc70056-bib-0076" class="usa-link" aria-describedby="bmc70056-bib-0076">2018</a>). This was resolved by Verougstraete et al. by including a liquid–liquid extraction step (Verougstraete and Stove <a href="#bmc70056-bib-0071" class="usa-link" aria-describedby="bmc70056-bib-0071">2022</a>; Xie et al. <a href="#bmc70056-bib-0076" class="usa-link" aria-describedby="bmc70056-bib-0076"><sup>2018</sup></a>). Other strategies such as sonication, which was used in one‐third of the DBS and VAMS studies, and physical homogenization with small glass or steel balls were also used in two methods (Meertens et al. <a href="#bmc70056-bib-0048" class="usa-link" aria-describedby="bmc70056-bib-0048">2024</a>; Tré‐Hardy et al. <a href="#bmc70056-bib-0059" class="usa-link" aria-describedby="bmc70056-bib-0059"><sup>2016</sup></a>). Sonication not only improved the extraction yield but also proved better reproducibility of the extraction, which probably also counts for physical homogenization (Jager, Rosing, Schellens, and Beijnen <a href="#bmc70056-bib-0033" class="usa-link" aria-describedby="bmc70056-bib-0033"><sup>2014</sup></a>; Maggadani et al. <a href="#bmc70056-bib-0046" class="usa-link" aria-describedby="bmc70056-bib-0046"><sup>2021</sup></a>; Mano, Kita, and Kusano <a href="#bmc70056-bib-0047" class="usa-link" aria-describedby="bmc70056-bib-0047"><sup>2015</sup></a>; Verougstraete and Stove <a href="#bmc70056-bib-0071" class="usa-link" aria-describedby="bmc70056-bib-0071"><sup>2022</sup></a>). Sonication, mechanical movement, physical homogenization, and evaporation steps typically lasted between 10 and 90 min.</p>
<p>Extraction recovery was assessed for nearly all DBS and VAMS methods. In Table <a href="#bmc70056-tbl-0001" class="usa-link">1</a>, the sample preparation recovery is reported, representing the fraction of analyte that was successfully extracted, independent of matrix effects. While there are no strict criteria for acceptable recovery levels, higher recovery is generally preferable. Multiple papers referred to a study of Xie et al. who recommend a recovery above 80% to achieve reproducible results during VAMS extraction (Xie et al. <a href="#bmc70056-bib-0076" class="usa-link" aria-describedby="bmc70056-bib-0076">2018</a>). However, it is important that it is both reproducible and sufficient for the analytical method's purpose. In some methods, recovery was variable with %CV values above 15% or even 20% observed (Meertens et al. <a href="#bmc70056-bib-0048" class="usa-link" aria-describedby="bmc70056-bib-0048">2024</a>; Verougstraete and Stove <a href="#bmc70056-bib-0071" class="usa-link" aria-describedby="bmc70056-bib-0071"><sup>2022</sup></a>). Interestingly, the lowest recovery found in the literature search was only 20.2% for everolimus in VAMS, but with a %CV of &lt; 10%, indicating that despite the low yield, the recovery is reproducible, which mitigates the issue. Interestingly, everolimus in DBS showed a recovery of 74–81%, while using a similar sample preparation, indicating a clear difference of extractability between devices (Knapen et al. <a href="#bmc70056-bib-0036" class="usa-link" aria-describedby="bmc70056-bib-0036">2018</a>). The clearest differences in recovery between different DBS methods were observed for 4‐hydroxy‐tamoxifen and Z‐endoxifen, where the one method retrieved 40 and 48% from Whatman 903 cards (Antunes, Raymundo, de Oliveira, et al. <a href="#bmc70056-bib-0001" class="usa-link" aria-describedby="bmc70056-bib-0001"><sup>2015</sup></a>). Three other methods used either small glass balls during vortexing, or other kind of DBS paper (DMPK‐A and PerkinElmer 226), found recoveries &gt;75% for both metabolites of tamoxifen, thus physical movement or selection of the devices clearly improved the extraction yield (Jager, Rosing, Schellens, and Beijnen <a href="#bmc70056-bib-0033" class="usa-link" aria-describedby="bmc70056-bib-0033"><sup>2014</sup></a>; Maggadani et al. <a href="#bmc70056-bib-0046" class="usa-link" aria-describedby="bmc70056-bib-0046"><sup>2021</sup></a>; Tré‐Hardy et al. <a href="#bmc70056-bib-0059" class="usa-link" aria-describedby="bmc70056-bib-0059"><sup>2016</sup></a>).</p>
<p>Overall, these sample preparation methods are relatively time‐efficient, with techniques like ultrasonication and physical homogenization significantly improving extraction yields, but also lengthening the process. Despite these additional steps, sample analysis can still be completed within a day, maintaining a fast turnaround time.</p></section><section id="bmc70056-sec-0017"><h4 class="pmc_sec_title">3.2.5. Stability</h4>
<p>Analyte stability from sample collection to analysis is crucial and was primarily assessed at ambient temperature of approximately 20–25 °C. This is based on the assumption that samples are not less stable at lower temperatures. But during transport, especially in situations where samples are exposed to sunlight (e.g., in a mailbox), temperatures can exceed room temperature. Consequently, half of the research groups also tested sample stability at elevated temperatures, ranging from 37 to 60 °C.</p>
<p>In all devices except the MSW, all drugs and metabolites were stable for at least 7 days, and often longer, depending on the maximum period tested. Given the limited stability of abiraterone, bortezomib, ibrutinib, and osimertinib in liquid plasma, the dried forms have improved stability highlighting the practical application of this matrix (Benoist et al. <a href="#bmc70056-bib-0003" class="usa-link" aria-describedby="bmc70056-bib-0003">2017</a>; Guo et al. <a href="#bmc70056-bib-0027" class="usa-link" aria-describedby="bmc70056-bib-0027"><sup>2021</sup></a>; Janssen et al. <a href="#bmc70056-bib-0035" class="usa-link" aria-describedby="bmc70056-bib-0035"><sup>2019</sup></a>; Rood et al. <a href="#bmc70056-bib-0056" class="usa-link" aria-describedby="bmc70056-bib-0056"><sup>2016</sup></a>; van Nuland et al. <a href="#bmc70056-bib-0062" class="usa-link" aria-describedby="bmc70056-bib-0062"><sup>2019</sup></a>; van Veelen et al. <a href="#bmc70056-bib-0064" class="usa-link" aria-describedby="bmc70056-bib-0064"><sup>2020</sup></a>; Veerman et al. <a href="#bmc70056-bib-0065" class="usa-link" aria-describedby="bmc70056-bib-0065"><sup>2019</sup></a>; Verougstraete et al. <a href="#bmc70056-bib-0072" class="usa-link" aria-describedby="bmc70056-bib-0072"><sup>2021</sup></a>). For instance, abiraterone is unstable at room temperature in plasma, where in VAMS, it remained stable for 14 days, even at 40 °C, and in DBS minimal 48 h at 60 °C (Benoist et al. <a href="#bmc70056-bib-0003" class="usa-link" aria-describedby="bmc70056-bib-0003">2017</a>; Dillenburg Weiss et al. <a href="#bmc70056-bib-0023" class="usa-link" aria-describedby="bmc70056-bib-0023"><sup>2021</sup></a>; Meertens et al. <a href="#bmc70056-bib-0048" class="usa-link" aria-describedby="bmc70056-bib-0048"><sup>2024</sup></a>; van Nuland et al. <a href="#bmc70056-bib-0062" class="usa-link" aria-describedby="bmc70056-bib-0062"><sup>2019</sup></a>). The MSW demonstrated stability for 5 days, as difficulties arose in centrifuging whole blood to plasma from the capillary samples (Saito et al. <a href="#bmc70056-bib-0058" class="usa-link" aria-describedby="bmc70056-bib-0058">2022</a>). Some studies extended stability testing up to 14 days or even 36 days, while such long stability at high temperature is not necessarily required. Afatinib and osimertinib were not stable in VAMS at 60 °C after 48 h (Zimmermann et al. <a href="#bmc70056-bib-0081" class="usa-link" aria-describedby="bmc70056-bib-0081">2022</a>). Two metabolites of tamoxifen, 4‐hydroxy tamoxifen and Z‐endoxifen, were unstable at 45 °C, showing a 38% increase in concentration after 2 days, possibly due to the degradation of tamoxifen and N‐desmethyl tamoxifen, which are present in much higher concentrations (Antunes, Raymundo, de Oliveira, et al. <a href="#bmc70056-bib-0001" class="usa-link" aria-describedby="bmc70056-bib-0001"><sup>2015</sup></a>).</p>
<p>There were also conflicting stability results for dasatinib, ibrutinib, and norimatinib at elevated temperatures. Dasatinib was stable for 72 h in DBS at 40 °C and 48 h in VAMS at 60 ° C, but another study found it unstable for 72 h in DBS at 40 °C (Kralj et al. <a href="#bmc70056-bib-0038" class="usa-link" aria-describedby="bmc70056-bib-0038">2012</a>; Mukai et al. <a href="#bmc70056-bib-0049" class="usa-link" aria-describedby="bmc70056-bib-0049"><sup>2022</sup></a>; Verougstraete and Stove <a href="#bmc70056-bib-0071" class="usa-link" aria-describedby="bmc70056-bib-0071"><sup>2022</sup></a>). Ibrutinib remained stable for 72 h in DBS at 40 °C but not for 48 h in VAMS (60 °C). Similarly, norimatinib was stable in VAMS at 45 °C for 14 days, but another VAMS study at 40 °C found stability only for 24 h, while also 14 days was tested, although 24 h at 40 °C will suffice in most cases (Krützmann et al. <a href="#bmc70056-bib-0039" class="usa-link" aria-describedby="bmc70056-bib-0039">2023</a>; Meertens et al. <a href="#bmc70056-bib-0048" class="usa-link" aria-describedby="bmc70056-bib-0048"><sup>2024</sup></a>). So, even between two dried forms of whole blood, discrepancies may exist, making it essential to test stability for each different application and device. It is recommended to test multiple time points, as this allows for stability data to support shorter intervals, such as 8 or 24 h at elevated temperatures, even if a longer time point, like 72 h proved unstable.</p>
<p>Zimmermann et al. proposed that the instability of afatinib and osimertinib in VAMS at high temperatures might be due to their characteristic as irreversible inhibitors, which could form covalent bonds with the VAMS surface, exacerbated by increased molecular kinetics at elevated temperatures (Zimmermann et al. <a href="#bmc70056-bib-0081" class="usa-link" aria-describedby="bmc70056-bib-0081">2022</a>). Consequently, the observed lower concentrations may be attributed to the lowered extraction recovery, which was observed as instability. Interestingly, this hypothesis may also explain the stability issues observed with ibrutinib, another irreversible kinase inhibitor, which was stable in DBS but not in VAMS. If longer periods of stability at higher temperatures are required, DBS might be preferable over VAMS for irreversible kinase inhibitors, which may be more prone to covalent binding. These inhibitors include afatinib, dacometinib, futibatinib, ibrutinib, mobocertinib, neratinib, osimertinib, and zanubrutinib (P. Y. Lee, Yeoh, and Low <a href="#bmc70056-bib-0043" class="usa-link" aria-describedby="bmc70056-bib-0043"><sup>2023</sup></a>; Li et al. <a href="#bmc70056-bib-0045" class="usa-link" aria-describedby="bmc70056-bib-0045"><sup>2024</sup></a>). However, this preference is hypothetical, and further research is needed to confirm these findings, as paper cards contain cellulose and therefore hydroxyl‐groups, making them not fully inert (Jager, Rosing, Schellens, and Beijnen <a href="#bmc70056-bib-0033" class="usa-link" aria-describedby="bmc70056-bib-0033"><sup>2014</sup></a>).</p>
<p>In conclusion, all analytes were stable at room temperature and the majority remain stable even at elevated temperatures. However, caution is advised for certain drugs, as some may exhibit instability under stress conditions as temperatures above 20–25 °C.</p></section><section id="bmc70056-sec-0018"><h4 class="pmc_sec_title">3.2.6. Other Critical Factors Influencing Analytical Performance</h4>
<p>Specifically for microsampling techniques, some important factors may have a strong influence on analytical performance, such as Hct and, specifically for DBS methods also spot volume. Hct affects spot size and homogeneity of DBS. Higher Hct levels are related to increased blood viscosity resulting in smaller DBS obtained with the same volume of blood. When using the same punch size to prepare DBS samples, especially with drugs or metabolites that show affinity for red blood cells, Hct variations can seriously affect accuracy (De Kesel et al. <a href="#bmc70056-bib-0015" class="usa-link" aria-describedby="bmc70056-bib-0015">2013</a>; de Vries et al. <a href="#bmc70056-bib-0016" class="usa-link" aria-describedby="bmc70056-bib-0016"><sup>2013</sup></a>; Denniff and Spooner <a href="#bmc70056-bib-0019" class="usa-link" aria-describedby="bmc70056-bib-0019"><sup>2010</sup></a>).</p>
<p>The VAMS device uses a fixed sample volume, making it potentially unaffected by Hct. However, it was shown that Hct may influence recovery from VAMS and consequently, accuracy and precision (Kok and Fillet <a href="#bmc70056-bib-0037" class="usa-link" aria-describedby="bmc70056-bib-0037">2018</a>). Among the eight VAMS methods reviewed, five studies tested the influence of Hct. For bosutinib and gilteritinib, the variability of the recovery was &gt;15% in case of low concentrations levels in combination with low Hct values of 0.18 (Verougstraete and Stove <a href="#bmc70056-bib-0071" class="usa-link" aria-describedby="bmc70056-bib-0071">2022</a>). Everolimus in VAMS showed a clear Hct‐dependent extraction recovery, with biases from −20% at Hct 0.49 and + 31% at Hct 0.31 (Verheijen et al. <a href="#bmc70056-bib-0070" class="usa-link" aria-describedby="bmc70056-bib-0070">2019</a>). Hypothesis is that the drug or metabolite can bind to proteins, red blood cells, and the polymeric tip, hindering extraction and resulting in lower recovery, with increased effect with higher hydrophobicity of the compound. This is also described as entrapment of the drug or metabolite by red blood cells (De Kesel, Lambert, and Stove <a href="#bmc70056-bib-0014" class="usa-link" aria-describedby="bmc70056-bib-0014"><sup>2015</sup></a>; Ye and Gao <a href="#bmc70056-bib-0078" class="usa-link" aria-describedby="bmc70056-bib-0078"><sup>2017</sup></a>). Besides Hct influencing the recovery, time can also play a role, as recovery may vary if samples are stored for long periods before analysis. However, this is in most cases not relevant in this context, as the samples will be analyzed shortly after collection and will not be stored for long periods.</p>
<p>For the 23 DBS methods included in this review, 21 assessed the effects of different Hct levels. Among these, four studies identified significant bias related to the Hct levels, due to reduced dispersion of blood caused by higher blood viscosity at higher Hct levels, and vice versa for lower Hct levels (Antunes, Raymundo, de Oliveira, et al. <a href="#bmc70056-bib-0001" class="usa-link" aria-describedby="bmc70056-bib-0001"><sup>2015</sup></a>; Dillenburg Weiss et al. <a href="#bmc70056-bib-0023" class="usa-link" aria-describedby="bmc70056-bib-0023"><sup>2021</sup></a>; Knapen et al. <a href="#bmc70056-bib-0036" class="usa-link" aria-describedby="bmc70056-bib-0036"><sup>2018</sup></a>; Tré‐Hardy et al. <a href="#bmc70056-bib-0059" class="usa-link" aria-describedby="bmc70056-bib-0059"><sup>2016</sup></a>). As a consequence, valid calibration was only possible for everolimus in case of Hct ≥0.25, tamoxifen and metabolites with Hct ≤0.40 and for abiraterone and D4A only with Hct ≤0.50, all due to accuracy deviations exceeding ±15%. However, most patients with solid tumors have a less extreme Hct range, reducing the clinical relevance of these findings. Additionally, four other studies observed a positive trend between Hct levels and concentrations, but within ±15% and ≤15% (Guo et al. <a href="#bmc70056-bib-0027" class="usa-link" aria-describedby="bmc70056-bib-0027">2021</a>; Jager, Rosing, Schellens, and Beijnen <a href="#bmc70056-bib-0033" class="usa-link" aria-describedby="bmc70056-bib-0033"><sup>2014</sup></a>; Nijenhuis et al. <a href="#bmc70056-bib-0052" class="usa-link" aria-describedby="bmc70056-bib-0052"><sup>2014</sup></a>). Thus, an opposite effect in DBS was observed compared to VAMS methods.</p>
<p>Homogeneity of the spot is a DBS specific aspect that should be assessed. The “volcano effect,” where after application of whole blood, red blood cells concentrate more at the center of the spot than at the margins, can impact results (Capiau et al. <a href="#bmc70056-bib-0012" class="usa-link" aria-describedby="bmc70056-bib-0012">2019</a>). Therefore, it is important to test if different punch sites, i.e., central or peripheral, influence the accuracy. Large punches tend to be less affected by homogeneity compared to smaller punches. Among seven DBS studies in this review that assessed different punch sites, none found significant differences in accuracy (Iacuzzi et al. <a href="#bmc70056-bib-0030" class="usa-link" aria-describedby="bmc70056-bib-0030">2019</a>; Jager, Rosing, Schellens, and Beijnen <a href="#bmc70056-bib-0033" class="usa-link" aria-describedby="bmc70056-bib-0033"><sup>2014</sup></a>; Nijenhuis et al. <a href="#bmc70056-bib-0052" class="usa-link" aria-describedby="bmc70056-bib-0052"><sup>2014</sup></a>; Poetto et al. <a href="#bmc70056-bib-0054" class="usa-link" aria-describedby="bmc70056-bib-0054"><sup>2021</sup></a>; Verheijen et al. <a href="#bmc70056-bib-0069" class="usa-link" aria-describedby="bmc70056-bib-0069"><sup>2016</sup></a>; Xu et al. <a href="#bmc70056-bib-0077" class="usa-link" aria-describedby="bmc70056-bib-0077"><sup>2012</sup></a>; Zhang et al. <a href="#bmc70056-bib-0080" class="usa-link" aria-describedby="bmc70056-bib-0080"><sup>2022</sup></a>). However, all experiments used a pipette which will be different than capillary blood from the finger. In one study, using 3 mm DBS punches 3 mm led to underestimation; therefore, 8 mm punches were selected, which cover the entire 10 μL aliquot spot (Zanchetta et al. <a href="#bmc70056-bib-0079" class="usa-link" aria-describedby="bmc70056-bib-0079">2023</a>). The punch‐to‐punch carry‐over was rarely tested, and when it was, it did not result in any issues (Nijenhuis et al. <a href="#bmc70056-bib-0052" class="usa-link" aria-describedby="bmc70056-bib-0052">2014</a>; Verheijen et al. <a href="#bmc70056-bib-0069" class="usa-link" aria-describedby="bmc70056-bib-0069"><sup>2016</sup></a>).</p>
<p>Techniques like VAMS, Rhelise, and MSW use a fixed volume of blood unlike DBS cards. Therefore, the influence of the applied volume of blood on DBS cards needs to be evaluated. Despite variability in applied volume (5 to 60 μL), nine DBS studies reported no significant effects on accuracy and precision (Dillenburg Weiss et al. <a href="#bmc70056-bib-0023" class="usa-link" aria-describedby="bmc70056-bib-0023">2021</a>; Iacuzzi et al. <a href="#bmc70056-bib-0030" class="usa-link" aria-describedby="bmc70056-bib-0030"><sup>2019</sup></a>; Jager, Rosing, Schellens, and Beijnen <a href="#bmc70056-bib-0033" class="usa-link" aria-describedby="bmc70056-bib-0033"><sup>2014</sup></a>; Knapen et al. <a href="#bmc70056-bib-0036" class="usa-link" aria-describedby="bmc70056-bib-0036"><sup>2018</sup></a>; Nijenhuis et al. <a href="#bmc70056-bib-0052" class="usa-link" aria-describedby="bmc70056-bib-0052"><sup>2014</sup></a>; Poetto et al. <a href="#bmc70056-bib-0054" class="usa-link" aria-describedby="bmc70056-bib-0054"><sup>2021</sup></a>; Verheijen et al. <a href="#bmc70056-bib-0069" class="usa-link" aria-describedby="bmc70056-bib-0069"><sup>2016</sup></a>; Xu et al. <a href="#bmc70056-bib-0077" class="usa-link" aria-describedby="bmc70056-bib-0077"><sup>2012</sup></a>; Zhang et al. <a href="#bmc70056-bib-0080" class="usa-link" aria-describedby="bmc70056-bib-0080"><sup>2022</sup></a>). However, larger volume differences possibly lead to more pronounced impacts on accuracy.</p>
<p>To address accuracy issues at certain Hct values, alternative approaches include analyzing the entire DBS, or using a full set of calibration standards that match the Hct of the sample. However, this requires knowledge of the Hct, which is likely not the case in home‐sampling. An empirical approach would be to use the patient's last recorded Hct value. Other methods would involve non‐contact methods as near‐infrared or ultra‐violet/visible spectroscopy‐based analyses, which can estimate Hct, including analyses based on measuring endogenous components such as hemoglobin or potassium content (Capiau et al. <a href="#bmc70056-bib-0011" class="usa-link" aria-describedby="bmc70056-bib-0011">2013</a>; Capiau et al. <a href="#bmc70056-bib-0013" class="usa-link" aria-describedby="bmc70056-bib-0013"><sup>2016</sup></a>; Deprez et al. <a href="#bmc70056-bib-0021" class="usa-link" aria-describedby="bmc70056-bib-0021"><sup>2023</sup></a>; Velghe, Delahaye, and Stove <a href="#bmc70056-bib-0066" class="usa-link" aria-describedby="bmc70056-bib-0066"><sup>2019</sup></a>). Incorporation of Hct in the analytical procedure may improve accuracy and could lead to reasonable accuracy in the clinical application study (Verheijen et al. <a href="#bmc70056-bib-0070" class="usa-link" aria-describedby="bmc70056-bib-0070">2019</a>).</p></section></section><section id="bmc70056-sec-0019"><h3 class="pmc_sec_title">3.3. Clinical Validation Experiments</h3>
<p>After the analytical validation, clinical validation experiments are required before implementing home‐sampling for TDM in routine care. Of the oral targeted anticancer drugs included in this review, only everolimus is measured in whole blood for routine TDM; the others are typically measured in plasma, both matrices obtained via venipuncture. In the studies published thus far, home‐sampling was mainly performed using whole blood, except for lenvatinib, where the MSW device was used. Out of the 39 articles reviewed, 26 conducted clinical validation experiments.</p>
<section id="bmc70056-sec-0020"><h4 class="pmc_sec_title">3.3.1. Capillary Versus Venous Blood</h4>
<p>Four studies used venous blood instead of capillary sampling in the clinical validation experiment (Kralj et al. <a href="#bmc70056-bib-0038" class="usa-link" aria-describedby="bmc70056-bib-0038">2012</a>; Mukai et al. <a href="#bmc70056-bib-0049" class="usa-link" aria-describedby="bmc70056-bib-0049"><sup>2022</sup></a>; Saito et al. <a href="#bmc70056-bib-0058" class="usa-link" aria-describedby="bmc70056-bib-0058"><sup>2022</sup></a>; Zanchetta et al. <a href="#bmc70056-bib-0079" class="usa-link" aria-describedby="bmc70056-bib-0079"><sup>2023</sup></a>), an ex vivo setup that can be used if venous and capillary blood concentrations are known to align. Generally, no significant differences are expected between capillary and venous blood for drugs with long half‐lives and if drawn outside the distribution phase (Rowland and Emmons <a href="#bmc70056-bib-0057" class="usa-link" aria-describedby="bmc70056-bib-0057">2010</a>). Two of these studies justified this ex vivo setup with theoretical or literature support, while the others did not. It is recommended to include a comparison of capillary versus venous blood in the clinical validation study design, to ensure that any differences in results are attributed to the microsampling device itself, rather than the sampling site, which is crucial for accurate method validation. Five studies performed this comparison and found no significant differences for pazopanib, everolimus, imatinib and norimatinib, abiraterone and D4A, palbociclib, ribociclib, and letrozole (de Wit et al. <a href="#bmc70056-bib-0017" class="usa-link" aria-describedby="bmc70056-bib-0017"><sup>2015</sup></a>; Dillenburg Weiss et al. <a href="#bmc70056-bib-0023" class="usa-link" aria-describedby="bmc70056-bib-0023"><sup>2021</sup></a>; Iacuzzi et al. <a href="#bmc70056-bib-0030" class="usa-link" aria-describedby="bmc70056-bib-0030"><sup>2019</sup></a>; Poetto et al. <a href="#bmc70056-bib-0054" class="usa-link" aria-describedby="bmc70056-bib-0054"><sup>2021</sup></a>; Willemsen et al. <a href="#bmc70056-bib-0075" class="usa-link" aria-describedby="bmc70056-bib-0075"><sup>2018</sup></a>). However, tamoxifen's metabolites endoxifen and 4‐hydroxy‐tamoxifen showed significant differences between venous and capillary samples, with capillary concentrations at 545% and 56% of venous levels, respectively. This was probably caused by photo degradation of Z‐endoxifen in the internal standard solution used for the capillary blood quantification (Rehnmark et al. <a href="#bmc70056-bib-0055" class="usa-link" aria-describedby="bmc70056-bib-0055">2022</a>). Therefore, the elevated percentages do not accurately represent true ex vivo levels, but rather result from analytical issues. Since endoxifen is the key metabolite for monitoring, this method using the Rhelise kit is not yet suitable for TDM with home‐sampling.</p></section><section id="bmc70056-sec-0021"><h4 class="pmc_sec_title">3.3.2. Conversion Methods</h4>
<p>To establish conversion methods from whole blood to plasma concentrations, patient samples were collected from both reference matrices (e.g., plasma) and home‐sampling methods (e.g., DBS or VAMS) to assess the need for conversion. Weighted Deming or Passing‐Bablok regression were used to compare the reference matrix with the capillary samples.</p>
<p>For lenvatinib in the MSW, venous plasma and MSW plasma showed good agreement (Saito et al. <a href="#bmc70056-bib-0058" class="usa-link" aria-describedby="bmc70056-bib-0058">2022</a>). For everolimus, lower concentrations were observed in liquid whole blood compared to DBS and VAMS, despite all matrices involve whole blood (Verheijen et al. <a href="#bmc70056-bib-0070" class="usa-link" aria-describedby="bmc70056-bib-0070">2019</a>; Willemsen et al. <a href="#bmc70056-bib-0075" class="usa-link" aria-describedby="bmc70056-bib-0075"><sup>2018</sup></a>). For bortezomib, gefitinib, osimertinib, and ribociclib, whole blood and plasma were considered in accordance with each other, indicating similar distribution between blood cells and plasma (Braal et al. <a href="#bmc70056-bib-0008" class="usa-link" aria-describedby="bmc70056-bib-0008">2021</a>; Guo et al. <a href="#bmc70056-bib-0027" class="usa-link" aria-describedby="bmc70056-bib-0027"><sup>2021</sup></a>; Irie et al. <a href="#bmc70056-bib-0031" class="usa-link" aria-describedby="bmc70056-bib-0031"><sup>2018</sup></a>; Venkatesh et al. <a href="#bmc70056-bib-0068" class="usa-link" aria-describedby="bmc70056-bib-0068"><sup>2023</sup></a>). For most other drugs, regression analyses between plasma and whole blood showed strong correlations, though slopes differed from 1, indicating that conversion methods were necessary. For trametinib in VAMS, the correlation was weaker, with an <em>R</em>
<sup>2</sup> of 0.5811 based on 63 serum and VAMS samples from 17 patients. A subanalysis showed differences based on gender and obesity: Males had an <em>R</em>
<sup>2</sup> of 0.6429 (<em>n</em> = 44), females had an <em>R</em>
<sup>2</sup> of 0.5022 (<em>n</em> = 19), and non‐obese males showed the strongest correlation with an <em>R</em>
<sup>2</sup> of 0.7581 (<em>n</em> = 39).</p>
<p>Various conversion methods were tested across the clinical validations to adjust concentrations between matrices. Iacuzzi et al. reviewed different DBS‐to‐plasma conversion for anticancer drugs, identifying three main approaches (Iacuzzi et al. <a href="#bmc70056-bib-0029" class="usa-link" aria-describedby="bmc70056-bib-0029">2021</a>). First, conversions that consider the individual Hct and the influence of blood‐to‐plasma partitioning. Second, simple normalization based on individual Hct for drugs that do not enter blood cells. Third, conversions based on empirical methods, using correction factors or linear regression formulas (Iacuzzi et al. <a href="#bmc70056-bib-0029" class="usa-link" aria-describedby="bmc70056-bib-0029">2021</a>).</p>
<p>Of the 26 articles with clinical validation experiments, 13 tested conversion methods considered a method based on individual Hct, and 7 of these also evaluated a normalization based on empirical data. Interestingly, the empirical method—requiring no Hct value—met the criteria in all methods and was often the method of preference (Antunes, Raymundo, Wagner, et al. <a href="#bmc70056-bib-0002" class="usa-link" aria-describedby="bmc70056-bib-0002"><sup>2015</sup></a>; C. C. L. M. Boons et al. <a href="#bmc70056-bib-0006" class="usa-link" aria-describedby="bmc70056-bib-0006"><sup>2017</sup></a>; de Wit et al. <a href="#bmc70056-bib-0017" class="usa-link" aria-describedby="bmc70056-bib-0017"><sup>2015</sup></a>; Iacuzzi et al. <a href="#bmc70056-bib-0030" class="usa-link" aria-describedby="bmc70056-bib-0030"><sup>2019</sup></a>; Nijenhuis et al. <a href="#bmc70056-bib-0051" class="usa-link" aria-describedby="bmc70056-bib-0051"><sup>2016</sup></a>; Poetto et al. <a href="#bmc70056-bib-0054" class="usa-link" aria-describedby="bmc70056-bib-0054"><sup>2021</sup></a>; Zimmermann et al. <a href="#bmc70056-bib-0082" class="usa-link" aria-describedby="bmc70056-bib-0082"><sup>2023</sup></a>). Only for palbociclib in DBS the drug distribution model was specifically favored as conversion method; however, the simple correction factor also met the criteria (Poetto et al. <a href="#bmc70056-bib-0054" class="usa-link" aria-describedby="bmc70056-bib-0054">2021</a>). For tamoxifen and endoxifen in DBS, a population Hct combined with a fixed partition coefficient effectively resulted in a standardized correction factor (Jager, Rosing, Schellens, Beijnen, and Linn <a href="#bmc70056-bib-0034" class="usa-link" aria-describedby="bmc70056-bib-0034"><sup>2014</sup></a>). However, in cases where a patient's Hct fell outside the studied range, the individual Hct method was recommended instead of the empirical method (Jager, Rosing, Schellens, Beijnen, and Linn <a href="#bmc70056-bib-0034" class="usa-link" aria-describedby="bmc70056-bib-0034"><sup>2014</sup></a>; Nijenhuis et al. <a href="#bmc70056-bib-0051" class="usa-link" aria-describedby="bmc70056-bib-0051"><sup>2016</sup></a>). Also, it was noted that using empirical methods requires limiting the Hct range to the validated values during the analytical validation, which can be a challenge with home‐sampling (Canil et al. <a href="#bmc70056-bib-0010" class="usa-link" aria-describedby="bmc70056-bib-0010">2023</a>). One innovative method involved a popPK model to establish a VAMS‐to‐serum conversion for dabrafenib and trametinib, with also home‐samples informing the model (with lacking of paired plasma samples). Still, Hct values were involved in the obtained formula, complicating its use for home‐sampling (Isberner et al. <a href="#bmc70056-bib-0032" class="usa-link" aria-describedby="bmc70056-bib-0032">2022</a>).</p>
<p>Some conversions did not meet the predefined validation criteria or were only valid under certain conditions. For example, radotinib in DBS did not predict concentrations above 1500 ng/mL due to insufficient sample collection at the higher concentration range, and the predictive performance of dasatinib in DBS was only adequate for plasma concentrations &gt;4.33 ng/mL, i.e., the method can only be applied for the efficacy target of dasatinib (J. Lee et al. <a href="#bmc70056-bib-0042" class="usa-link" aria-describedby="bmc70056-bib-0042"><sup>2020</sup></a>; Mukai et al. <a href="#bmc70056-bib-0049" class="usa-link" aria-describedby="bmc70056-bib-0049"><sup>2022</sup></a>). For nilotinib in DBS, samples collected during the absorption phase (i.e. 4 h after intake) were excluded in order to fulfill the criteria (Mukai et al. <a href="#bmc70056-bib-0049" class="usa-link" aria-describedby="bmc70056-bib-0049">2022</a>). No successful conversion methods were established for ruxolitinib and trametinib in VAMS, despite testing three approaches (individual and population Hct, correction factor, linear regression) with respectively 45 and 63 sample pairs (Zimmermann et al. <a href="#bmc70056-bib-0082" class="usa-link" aria-describedby="bmc70056-bib-0082">2023</a>). Potentially the short half‐life of ruxolitinib (~ 3 h) with slight differences in time between VAMS and plasma collection and inter‐individual variability in covariates (other than Hct) for trametinib, potentially contributed to these issues (Zimmermann et al. <a href="#bmc70056-bib-0082" class="usa-link" aria-describedby="bmc70056-bib-0082">2023</a>).</p>
<p>For certain drugs, conflicting results were obtained for clinical validation. For ribociclib in DBS, Braal et al. concluded that no conversion was needed (based on 17 paired samples and patients), whereas Poetto et al. found that DBS were approximately a factor 1.4 higher than plasma (based on 22 samples from 5 patients) (Braal et al. <a href="#bmc70056-bib-0008" class="usa-link" aria-describedby="bmc70056-bib-0008">2021</a>; Poetto et al. <a href="#bmc70056-bib-0054" class="usa-link" aria-describedby="bmc70056-bib-0054"><sup>2021</sup></a>). Imatinib and tamoxifen were well studied, with at least two articles with sufficient amount of samples and patients researched. Therefore, the conversion methods could be adopted immediately without the need to establish a new conversion method.</p></section><section id="bmc70056-sec-0022"><h4 class="pmc_sec_title">3.3.3. Clinical Evaluation Criteria</h4>
<p>The established conversion methods were evaluated using several different criteria, including the EMA guideline where conversion experiments can be interpreted as a cross‐validation, where at least two‐thirds of the predicted concentrations must fall within ± 20% (or 1.96 standard deviation) of the reference concentrations, analyzed via Bland–Altman analyses (European Medicines Agency <a href="#bmc70056-bib-0024" class="usa-link" aria-describedby="bmc70056-bib-0024"><sup>2011</sup></a>). Also measures such as mean absolute percentage error (MAPE), mean percentage prediction error (MPPE), median prediction error (MPE), and residual mean square error (RMSE) were used, which are particularly convenient for comparing multiple conversion methods. Some methods used a regression between the estimated plasma concentrations and the reference plasma concentrations to check the slope.</p>
<p>A minimum of 40 paired samples has been recommended, covering the full relevant clinical range. A sample size of smaller than 40 is only possible when the %CV of the method is &lt;5% and the range ratio from LLOQ to ULOQ is &lt;25 (Capiau et al. <a href="#bmc70056-bib-0012" class="usa-link" aria-describedby="bmc70056-bib-0012">2019</a>). Ideally, 80 paired samples should be collected—40 to develop the conversion method and 40 to validate the established method. In studies with limited patient numbers available, which will be the case for many oral targeted anticancer drugs, a minimum of 40 samples from 25 unique patients is recommended (Capiau et al. <a href="#bmc70056-bib-0012" class="usa-link" aria-describedby="bmc70056-bib-0012">2019</a>). Six studies met this requirement, all using DBS, for imatinib (2×), pazopanib, radotinib, and tamoxifen (2×). If fewer than 25 patients were available, the jackknife method is recommended, though only one study reported application (Willemsen et al. <a href="#bmc70056-bib-0075" class="usa-link" aria-describedby="bmc70056-bib-0075">2018</a>). Most studies included &gt;20 patients or samples but did not meet the full criteria. However, if the paired samples cover the concentration range and yield a reliable conversion, this can be acceptable. For instance, olaparib in DBS conversion with 52 samples from 16 patients led to 94.2% of the predicted concentrations within 20% of the plasma concentration, while for ribociclib in 17 paired samples no need for conversion was shown.</p></section></section><section id="bmc70056-sec-0023"><h3 class="pmc_sec_title">3.4. Practical Recommendations</h3>
<p>In recent years, advancements in microsampling techniques have been made and volumetric DBS devices have been introduced as an alternative to the traditional “paper + punch” methods. While these newer devices have not replaced conventional approaches on a large scale yet, they offer various advantages by ensuring accurate blood volume collection and reducing Hct‐related variability. This volumetric aspect of the device diminish the need to test and validate the impact of different Hct ranges on spot size and punch site during analytical validation. Examples of these volumetric DBS devices include Hemapen, Hemaxis DB10, and the Capitainer (Canil et al. <a href="#bmc70056-bib-0010" class="usa-link" aria-describedby="bmc70056-bib-0010">2023</a>; Deprez et al. <a href="#bmc70056-bib-0022" class="usa-link" aria-describedby="bmc70056-bib-0022"><sup>2019</sup></a>; Leuthold et al. <a href="#bmc70056-bib-0044" class="usa-link" aria-describedby="bmc70056-bib-0044"><sup>2015</sup></a>; Neto et al. <a href="#bmc70056-bib-0050" class="usa-link" aria-describedby="bmc70056-bib-0050"><sup>2018</sup></a>; Velghe and Stove <a href="#bmc70056-bib-0067" class="usa-link" aria-describedby="bmc70056-bib-0067"><sup>2018</sup></a>; Venkatesh et al. <a href="#bmc70056-bib-0068" class="usa-link" aria-describedby="bmc70056-bib-0068"><sup>2023</sup></a>). When developing and validating a home‐sampling method for oral targeted anti‐cancer drugs, it is recommended to consider volumetric DBS or VAMS, or explore even more innovative microsampling methods.</p>
<p>Additionally, the use of sensitive LC‐MS/MS techniques is recommended to improve detection limits and analytical reliability. The selection of an appropriate analytical range is essential, with calibration curves ideally not exceeding two orders of magnitude of analyte concentration to maintain clinical relevance without unnecessary sensitivity. Besides the standard validation parameters that should be investigated, stability and recovery should be extensively tested under various conditions, including different temperatures, concentrations, and time intervals, with particular attention to handling from collection of the sample to receipt at the laboratory. For drugs with established conversion methods, such as imatinib and endoxifen, the previously described methods can be implemented following external validation, making the clinical validation process more efficient. Furthermore, patients should be well instructed to ensure correct self‐sampling, minimizing pre‐analytical errors and improving sample quality.</p></section></section><section id="bmc70056-sec-0024"><h2 class="pmc_sec_title">4. Conclusions</h2>
<p>Home‐sampling is a promising tool for TDM of oral targeted anticancer drugs, though it presents unique challenges compared to conventional hospital‐based TDM. One of the critical aspects was ensuring robust sample collection and subsequent pretreatment. Stability during transportation, as well as factors like Hct, were carefully studied. For a variety of analytes, the analytical methods reviewed, showed sufficient robustness to support home‐based TDM. Clinical validation studies also reported good results for most analytes, although external validation of established conversion methods would be a crucial future step before widespread clinical implementation. Collaboration across hospitals could facilitate the establishment of home‐sampling infrastructures for TDM, leveraging shared expertise and resources.</p>
<p>After analytical and clinical validation, an essential consideration is the feasibility of self‐sampling by patients. Boffel et al. demonstrated that self‐sampling at home was overall positively received by inexperienced individuals, with success rates for one successful sample ranging from 65 to 89% across different devices such as DBS, VAMS, Tasso‐M20, and Capitainer®. The exception was the Minicollect device, which had a lower success rate of 12%, probably due to large collection volumes. While these results suggest home‐sampling is feasible for many devices, there remains room for improvement (Boffel et al. <a href="#bmc70056-bib-0004" class="usa-link" aria-describedby="bmc70056-bib-0004">2024</a>).</p>
<p>Interestingly, while mainly DBS and VAMS devices were included in this review, plasma separation devices—except for the MSW—were underrepresented in the literature. These devices, such as Telimmune™ separation cards and the Capitainer® SEP10 (currently in development) could offer theoretical advantages allowing direct measurement in (dried) plasma (Bondan and Linden <a href="#bmc70056-bib-0005" class="usa-link" aria-describedby="bmc70056-bib-0005">2023</a>). However, analytical validation experiments should be performed to ensure a robust method, for instance whether Hct influences the separation quality. Also clinical validation experiments must be performed to test if these devices provide consistent results with conventional plasma samples.</p>
<p>In summary, the findings of this review support the implementation of home‐sampling for TDM of oral targeted anticancer drugs. Certain methods, such as those for imatinib and tamoxifen, may be clinically implemented immediately, while others require external validation before or during their implementation. Future research should focus on device‐specific challenges, and ensuring patient feasibility to make home‐sampling a routine clinical practice.</p></section><section id="bmc70056-sec-0025"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>
<strong>Marinda Meertens:</strong> conceptualization, methodology, investigation, writing – original draft, writing – review and editing. <strong>Hilde Rosing:</strong> conceptualization, supervision, writing – review and editing. <strong>Neeltje Steeghs:</strong> conceptualization, supervision, writing – review and editing. <strong>Jos H. Beijnen:</strong> supervision, writing – review and editing. <strong>Alwin D.R. Huitema:</strong> conceptualization, supervision, writing – review and editing.</p></section><section id="bmc70056-sec-0026"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>Neeltje Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Ellipses Pharma, GlaxoSmithKline, Incyte, Luszana. N Steeghs received research grants from Abbvie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol‐Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Cresecendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Lixte, Luszana, Merck, Merck Sharp &amp; DohmeMerck Sharp &amp; Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda. All outside the submitted work, all payment to the Netherlands Cancer Institute. Jos. H. Beijnen is (indirect) shareholder of Modra Pharmaceuticals B.V. He is (partly) patent holder of oral taxane formulations which are clinically developed by Modra Pharmaceuticals B.V. (a spinoff company of the Netherlands Cancer Institute, not related to this work). Marinda Meertens, Hilde Rosing, Neeltje Steeghs, Jos H. Beijnen, and Alwin D.R. Huitema declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></section><section id="sec27"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="bmc70056-supitem-0001"><div class="caption p"><p>
<strong>Data S1.</strong> Supporting Information</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11907759/bin/BMC-39-e70056-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">BMC-39-e70056-s001.pdf</a><sup> (634.1KB, pdf) </sup>
</div></div></section></section><section id="notes1"><section id="bmc70056-ntgp-0001" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="bmc70056-note-0001"><p>
<strong>Funding:</strong> The authors received no specific funding for this work.</p></div></div></section></section><section id="bmc70056-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="bmc70056-bibl-0001_sec2"><ol class="ref-list font-sm">
<li id="bmc70056-bib-0001">
<cite>

Antunes, M. V.
, Raymundo S., de Oliveira V., et al. 2015. “Ultra‐High Performance Liquid Chromatography Tandem Mass Spectrometric Method for the Determination of Tamoxifen, N‐Desmethyltamoxifen, 4‐Hydroxytamoxifen and Endoxifen in Dried Blood Spots‐‐Development, Validation and Clinical Application During Breast Cancer Adjuvant Therapy.” Talanta
132: 775–784.
</cite> [<a href="https://doi.org/10.1016/j.talanta.2014.10.040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25476377/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Talanta&amp;title=Ultra%E2%80%90High%20Performance%20Liquid%20Chromatography%20Tandem%20Mass%20Spectrometric%20Method%20for%20the%20Determination%20of%20Tamoxifen,%20N%E2%80%90Desmethyltamoxifen,%204%E2%80%90Hydroxytamoxifen%20and%20Endoxifen%20in%20Dried%20Blood%20Spots%E2%80%90%E2%80%90Development,%20Validation%20and%20Clinical%20Application%20During%20Breast%20Cancer%20Adjuvant%20Therapy&amp;author=M.%20V.%20Antunes&amp;author=S.%20Raymundo&amp;author=V.%20de%20Oliveira&amp;volume=132&amp;publication_year=2015&amp;pages=775-784&amp;pmid=25476377&amp;doi=10.1016/j.talanta.2014.10.040&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0002">
<cite>

Antunes, M. V.
, Raymundo S., Wagner S. C., et al. 2015. “DBS Sampling in Imatinib Therapeutic Drug Monitoring: From Method Development to Clinical Application.” Bioanalysis
7, no. 16: 2105–2117.
</cite> [<a href="https://doi.org/10.4155/bio.15.101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26327189/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=DBS%20Sampling%20in%20Imatinib%20Therapeutic%20Drug%20Monitoring:%20From%20Method%20Development%20to%20Clinical%20Application&amp;author=M.%20V.%20Antunes&amp;author=S.%20Raymundo&amp;author=S.%20C.%20Wagner&amp;volume=7&amp;issue=16&amp;publication_year=2015&amp;pages=2105-2117&amp;pmid=26327189&amp;doi=10.4155/bio.15.101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0003">
<cite>

Benoist, G. E.
, van der Meulen E., Lubberman F. J. E., et al. 2017. “Analytical Challenges in Quantifying Abiraterone With LC‐MS/MS in Human Plasma.” Biomedical Chromatography
31, no. 11: e3986. 10.1002/bmc.3986.</cite> [<a href="https://doi.org/10.1002/bmc.3986" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6114173/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28370076/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedical%20Chromatography&amp;title=Analytical%20Challenges%20in%20Quantifying%20Abiraterone%20With%20LC%E2%80%90MS/MS%20in%20Human%20Plasma&amp;author=G.%20E.%20Benoist&amp;author=E.%20van%20der%20Meulen&amp;author=F.%20J.%20E.%20Lubberman&amp;volume=31&amp;issue=11&amp;publication_year=2017&amp;pages=e3986&amp;pmid=28370076&amp;doi=10.1002/bmc.3986&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0004">
<cite>

Boffel, L.
, Van Mensel A., Pauwels J., et al. 2024. “Self‐Sampling by Adolescents at Home: Assessment of the Feasibility to Successfully Collect Blood Microsamples by Inexperienced Individuals.” AAPS Journal
26, no. 4: 75.
</cite> [<a href="https://doi.org/10.1208/s12248-024-00947-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38955903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AAPS%20Journal&amp;title=Self%E2%80%90Sampling%20by%20Adolescents%20at%20Home:%20Assessment%20of%20the%20Feasibility%20to%20Successfully%20Collect%20Blood%20Microsamples%20by%20Inexperienced%20Individuals&amp;author=L.%20Boffel&amp;author=A.%20Van%20Mensel&amp;author=J.%20Pauwels&amp;volume=26&amp;issue=4&amp;publication_year=2024&amp;pages=75&amp;pmid=38955903&amp;doi=10.1208/s12248-024-00947-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0005">
<cite>

Bondan, A. P.
, and Linden R.. 2023. “Capillary Plasma Separation Microsampling Devices: A Solution for Dried Blood Spot Limitations in Clinical Testing.” Bioanalysis
15, no. 11: 591–593.
</cite> [<a href="https://doi.org/10.4155/bio-2023-0109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37350402/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=Capillary%20Plasma%20Separation%20Microsampling%20Devices:%20A%20Solution%20for%20Dried%20Blood%20Spot%20Limitations%20in%20Clinical%20Testing&amp;author=A.%20P.%20Bondan&amp;author=R.%20Linden&amp;volume=15&amp;issue=11&amp;publication_year=2023&amp;pages=591-593&amp;pmid=37350402&amp;doi=10.4155/bio-2023-0109&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0006">
<cite>

Boons, C. C. L. M.
, Chahbouni A., Schimmel A. M., et al. 2017. “Dried Blood Spot Sampling of Nilotinib in Patients With Chronic Myeloid Leukaemia: A Comparison With Venous Blood Sampling.” Journal of Pharmacy and Pharmacology
69, no. 10: 1265–1274.
</cite> [<a href="https://doi.org/10.1111/jphp.12757" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28643375/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmacy%20and%20Pharmacology&amp;title=Dried%20Blood%20Spot%20Sampling%20of%20Nilotinib%20in%20Patients%20With%20Chronic%20Myeloid%20Leukaemia:%20A%20Comparison%20With%20Venous%20Blood%20Sampling&amp;author=C.%20C.%20L.%20M.%20Boons&amp;author=A.%20Chahbouni&amp;author=A.%20M.%20Schimmel&amp;volume=69&amp;issue=10&amp;publication_year=2017&amp;pages=1265-1274&amp;pmid=28643375&amp;doi=10.1111/jphp.12757&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0007">
<cite>

Boons, C. C. L. M.
, Timmers L., Janssen J. J. W. M., Swart E. L., Hugtenburg J. G., and Hendrikse N. H.. 2019. “Feasibility of and Patients' Perspective on Nilotinib Dried Blood Spot Self‐Sampling.” European Journal of Clinical Pharmacology
75, no. 6: 825–829.
</cite> [<a href="https://doi.org/10.1007/s00228-019-02640-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30729257/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Clinical%20Pharmacology&amp;title=Feasibility%20of%20and%20Patients'%20Perspective%20on%20Nilotinib%20Dried%20Blood%20Spot%20Self%E2%80%90Sampling&amp;author=C.%20C.%20L.%20M.%20Boons&amp;author=L.%20Timmers&amp;author=J.%20J.%20W.%20M.%20Janssen&amp;author=E.%20L.%20Swart&amp;author=J.%20G.%20Hugtenburg&amp;volume=75&amp;issue=6&amp;publication_year=2019&amp;pages=825-829&amp;pmid=30729257&amp;doi=10.1007/s00228-019-02640-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0008">
<cite>

Braal, C. L.
, Lam M. H., Rienks T., et al. 2021. “Quantification of Ribociclib in Dried Blood Spots by LC–MS/MS: Method Development and Clinical Validation.” Journal of Pharmaceutical and Biomedical Analysis
201: 114118.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2021.114118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34000578/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Quantification%20of%20Ribociclib%20in%20Dried%20Blood%20Spots%20by%20LC%E2%80%93MS/MS:%20Method%20Development%20and%20Clinical%20Validation&amp;author=C.%20L.%20Braal&amp;author=M.%20H.%20Lam&amp;author=T.%20Rienks&amp;volume=201&amp;publication_year=2021&amp;pages=114118&amp;pmid=34000578&amp;doi=10.1016/j.jpba.2021.114118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0009">
<cite>

Brunet, M.
, van Gelder T., Asberg A., et al. 2019. “Therapeutic Drug Monitoring of Tacrolimus‐Personalized Therapy: Second Consensus Report.” Therapeutic Drug Monitoring
41, no. 3: 261–307.
</cite> [<a href="https://doi.org/10.1097/FTD.0000000000000640" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31045868/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapeutic%20Drug%20Monitoring&amp;title=Therapeutic%20Drug%20Monitoring%20of%20Tacrolimus%E2%80%90Personalized%20Therapy:%20Second%20Consensus%20Report&amp;author=M.%20Brunet&amp;author=T.%20van%20Gelder&amp;author=A.%20Asberg&amp;volume=41&amp;issue=3&amp;publication_year=2019&amp;pages=261-307&amp;pmid=31045868&amp;doi=10.1097/FTD.0000000000000640&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0010">
<cite>

Canil, G.
, Orleni M., Posocco B., et al. 2023. “LC‐MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring.” Pharmaceutics
15, no. 5: 1524.
</cite> [<a href="https://doi.org/10.3390/pharmaceutics15051524" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10221204/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37242766/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutics&amp;title=LC%E2%80%90MS/MS%20Method%20for%20the%20Quantification%20of%20PARP%20Inhibitors%20Olaparib,%20Rucaparib%20and%20Niraparib%20in%20Human%20Plasma%20and%20Dried%20Blood%20Spot:%20Development,%20Validation%20and%20Clinical%20Validation%20for%20Therapeutic%20Drug%20Monitoring&amp;author=G.%20Canil&amp;author=M.%20Orleni&amp;author=B.%20Posocco&amp;volume=15&amp;issue=5&amp;publication_year=2023&amp;pages=1524&amp;pmid=37242766&amp;doi=10.3390/pharmaceutics15051524&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0011">
<cite>

Capiau, S.
, Stove V. V., Lambert W. E., and Stove C. P.. 2013. “Prediction of the Hematocrit of Dried Blood Spots via Potassium Measurement on a Routine Clinical Chemistry Analyzer.” Analytical Chemistry
85, no. 1: 404–410.
</cite> [<a href="https://doi.org/10.1021/ac303014b" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23190205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Analytical%20Chemistry&amp;title=Prediction%20of%20the%20Hematocrit%20of%20Dried%20Blood%20Spots%20via%20Potassium%20Measurement%20on%20a%20Routine%20Clinical%20Chemistry%20Analyzer&amp;author=S.%20Capiau&amp;author=V.%20V.%20Stove&amp;author=W.%20E.%20Lambert&amp;author=C.%20P.%20Stove&amp;volume=85&amp;issue=1&amp;publication_year=2013&amp;pages=404-410&amp;pmid=23190205&amp;doi=10.1021/ac303014b&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0012">
<cite>

Capiau, S.
, Veenhof H., Koster R. A., et al. 2019. “Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot‐Based Methods for Therapeutic Drug Monitoring.” Therapeutic Drug Monitoring
41, no. 4: 409–430.
</cite> [<a href="https://doi.org/10.1097/FTD.0000000000000643" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31268966/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapeutic%20Drug%20Monitoring&amp;title=Official%20International%20Association%20for%20Therapeutic%20Drug%20Monitoring%20and%20Clinical%20Toxicology%20Guideline:%20Development%20and%20Validation%20of%20Dried%20Blood%20Spot%E2%80%90Based%20Methods%20for%20Therapeutic%20Drug%20Monitoring&amp;author=S.%20Capiau&amp;author=H.%20Veenhof&amp;author=R.%20A.%20Koster&amp;volume=41&amp;issue=4&amp;publication_year=2019&amp;pages=409-430&amp;pmid=31268966&amp;doi=10.1097/FTD.0000000000000643&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0013">
<cite>

Capiau, S.
, Wilk L. S., Aalders M. C., and Stove C. P.. 2016. “A Novel, Nondestructive, Dried Blood Spot‐Based Hematocrit Prediction Method Using Noncontact Diffuse Reflectance Spectroscopy.” Analytical Chemistry
88, no. 12: 6538–6546.
</cite> [<a href="https://doi.org/10.1021/acs.analchem.6b01321" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27206105/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Analytical%20Chemistry&amp;title=A%20Novel,%20Nondestructive,%20Dried%20Blood%20Spot%E2%80%90Based%20Hematocrit%20Prediction%20Method%20Using%20Noncontact%20Diffuse%20Reflectance%20Spectroscopy&amp;author=S.%20Capiau&amp;author=L.%20S.%20Wilk&amp;author=M.%20C.%20Aalders&amp;author=C.%20P.%20Stove&amp;volume=88&amp;issue=12&amp;publication_year=2016&amp;pages=6538-6546&amp;pmid=27206105&amp;doi=10.1021/acs.analchem.6b01321&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0014">
<cite>

De Kesel, P. M.
, Lambert W. E., and Stove C. P.. 2015. “Does Volumetric Absorptive Microsampling Eliminate the Hematocrit bias for Caffeine and Paraxanthine in Dried Blood Samples? A Comparative Study.” Analytica Chimica Acta
881: 65–73.
</cite> [<a href="https://doi.org/10.1016/j.aca.2015.04.056" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26041521/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Analytica%20Chimica%20Acta&amp;title=Does%20Volumetric%20Absorptive%20Microsampling%20Eliminate%20the%20Hematocrit%20bias%20for%20Caffeine%20and%20Paraxanthine%20in%20Dried%20Blood%20Samples?%20A%20Comparative%20Study&amp;author=P.%20M.%20De%20Kesel&amp;author=W.%20E.%20Lambert&amp;author=C.%20P.%20Stove&amp;volume=881&amp;publication_year=2015&amp;pages=65-73&amp;pmid=26041521&amp;doi=10.1016/j.aca.2015.04.056&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0015">
<cite>

De Kesel, P. M.
, Sadones N., Capiau S., Lambert W. E., and Stove C. P.. 2013. “Hemato‐Critical Issues in Quantitative Analysis of Dried Blood Spots: Challenges and Solutions.” Bioanalysis
5, no. 16: 2023–2041.
</cite> [<a href="https://doi.org/10.4155/bio.13.156" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23937137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=Hemato%E2%80%90Critical%20Issues%20in%20Quantitative%20Analysis%20of%20Dried%20Blood%20Spots:%20Challenges%20and%20Solutions&amp;author=P.%20M.%20De%20Kesel&amp;author=N.%20Sadones&amp;author=S.%20Capiau&amp;author=W.%20E.%20Lambert&amp;author=C.%20P.%20Stove&amp;volume=5&amp;issue=16&amp;publication_year=2013&amp;pages=2023-2041&amp;pmid=23937137&amp;doi=10.4155/bio.13.156&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0016">
<cite>

de Vries, R.
, Barfield M., van de Merbel N., et al. 2013. “The Effect of Hematocrit on Bioanalysis of DBS: Results From the EBF DBS‐Microsampling Consortium.” Bioanalysis
5, no. 17: 2147–2160.
</cite> [<a href="https://doi.org/10.4155/bio.13.170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23829463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=The%20Effect%20of%20Hematocrit%20on%20Bioanalysis%20of%20DBS:%20Results%20From%20the%20EBF%20DBS%E2%80%90Microsampling%20Consortium&amp;author=R.%20de%20Vries&amp;author=M.%20Barfield&amp;author=N.%20van%20de%20Merbel&amp;volume=5&amp;issue=17&amp;publication_year=2013&amp;pages=2147-2160&amp;pmid=23829463&amp;doi=10.4155/bio.13.170&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0017">
<cite>

de Wit, D.
, den Hartigh J., Gelderblom H., et al. 2015. “Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Pazopanib.” Journal of Clinical Pharmacology
55, no. 12: 1344–1350.
</cite> [<a href="https://doi.org/10.1002/jcph.558" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26032288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Pharmacology&amp;title=Dried%20Blood%20Spot%20Analysis%20for%20Therapeutic%20Drug%20Monitoring%20of%20Pazopanib&amp;author=D.%20de%20Wit&amp;author=J.%20den%20Hartigh&amp;author=H.%20Gelderblom&amp;volume=55&amp;issue=12&amp;publication_year=2015&amp;pages=1344-1350&amp;pmid=26032288&amp;doi=10.1002/jcph.558&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0018">
<cite>

Delahaye, L.
, Veenhof H., Koch B. C. P., Alffenaar J. C., Linden R., and Stove C.. 2021. “Alternative Sampling Devices to Collect Dried Blood Microsamples: State‐Of‐The‐Art.” Therapeutic Drug Monitoring
43, no. 3: 310–321.
</cite> [<a href="https://doi.org/10.1097/FTD.0000000000000864" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33470777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapeutic%20Drug%20Monitoring&amp;title=Alternative%20Sampling%20Devices%20to%20Collect%20Dried%20Blood%20Microsamples:%20State%E2%80%90Of%E2%80%90The%E2%80%90Art&amp;author=L.%20Delahaye&amp;author=H.%20Veenhof&amp;author=B.%20C.%20P.%20Koch&amp;author=J.%20C.%20Alffenaar&amp;author=R.%20Linden&amp;volume=43&amp;issue=3&amp;publication_year=2021&amp;pages=310-321&amp;pmid=33470777&amp;doi=10.1097/FTD.0000000000000864&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0019">
<cite>

Denniff, P.
, and Spooner N.. 2010. “The Effect of Hematocrit on Assay bias When Using DBS Samples for the Quantitative Bioanalysis of Drugs.” Bioanalysis
2, no. 8: 1385–1395.
</cite> [<a href="https://doi.org/10.4155/bio.10.103" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21083339/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=The%20Effect%20of%20Hematocrit%20on%20Assay%20bias%20When%20Using%20DBS%20Samples%20for%20the%20Quantitative%20Bioanalysis%20of%20Drugs&amp;author=P.%20Denniff&amp;author=N.%20Spooner&amp;volume=2&amp;issue=8&amp;publication_year=2010&amp;pages=1385-1395&amp;pmid=21083339&amp;doi=10.4155/bio.10.103&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0020">
<cite>

Denniff, P.
, and Spooner N.. 2014. “Volumetric Absorptive Microsampling: A Dried Sample Collection Technique for Quantitative Bioanalysis.” Analytical Chemistry
86, no. 16: 8489–8495.
</cite> [<a href="https://doi.org/10.1021/ac5022562" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25058158/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Analytical%20Chemistry&amp;title=Volumetric%20Absorptive%20Microsampling:%20A%20Dried%20Sample%20Collection%20Technique%20for%20Quantitative%20Bioanalysis&amp;author=P.%20Denniff&amp;author=N.%20Spooner&amp;volume=86&amp;issue=16&amp;publication_year=2014&amp;pages=8489-8495&amp;pmid=25058158&amp;doi=10.1021/ac5022562&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0021">
<cite>

Deprez, S.
, Heughebaert L., Boffel L., and Stove C. P.. 2023. “Application of non‐contact Hematocrit Prediction Technologies to Overcome Hematocrit Effects on Immunosuppressant Quantification From Dried Blood Spots.” Talanta
254: 124111.
</cite> [<a href="https://doi.org/10.1016/j.talanta.2022.124111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36462285/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Talanta&amp;title=Application%20of%20non%E2%80%90contact%20Hematocrit%20Prediction%20Technologies%20to%20Overcome%20Hematocrit%20Effects%20on%20Immunosuppressant%20Quantification%20From%20Dried%20Blood%20Spots&amp;author=S.%20Deprez&amp;author=L.%20Heughebaert&amp;author=L.%20Boffel&amp;author=C.%20P.%20Stove&amp;volume=254&amp;publication_year=2023&amp;pages=124111&amp;pmid=36462285&amp;doi=10.1016/j.talanta.2022.124111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0022">
<cite>

Deprez, S.
, Paniagua‐Gonzalez L., Velghe S., and Stove C. P.. 2019. “Evaluation of the Performance and Hematocrit Independence of the HemaPEN as a Volumetric Dried Blood Spot Collection Device.” Analytical Chemistry
91, no. 22: 14467–14475.
</cite> [<a href="https://doi.org/10.1021/acs.analchem.9b03179" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31638372/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Analytical%20Chemistry&amp;title=Evaluation%20of%20the%20Performance%20and%20Hematocrit%20Independence%20of%20the%20HemaPEN%20as%20a%20Volumetric%20Dried%20Blood%20Spot%20Collection%20Device&amp;author=S.%20Deprez&amp;author=L.%20Paniagua%E2%80%90Gonzalez&amp;author=S.%20Velghe&amp;author=C.%20P.%20Stove&amp;volume=91&amp;issue=22&amp;publication_year=2019&amp;pages=14467-14475&amp;pmid=31638372&amp;doi=10.1021/acs.analchem.9b03179&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0023">
<cite>

Dillenburg Weiss, T. L.
, Gossling G., Venzon Antunes M., Schwartsmann G., Linden R., and Gasparin Verza S.. 2021. “Evaluation of Dried Blood Spots as an Alternative Matrix for Therapeutic Drug Monitoring of Abiraterone and delta(4)‐abiraterone in Prostate cancer Patients.” Journal of Pharmaceutical and Biomedical Analysis
195: 113861.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2020.113861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33373824/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Evaluation%20of%20Dried%20Blood%20Spots%20as%20an%20Alternative%20Matrix%20for%20Therapeutic%20Drug%20Monitoring%20of%20Abiraterone%20and%20delta(4)%E2%80%90abiraterone%20in%20Prostate%20cancer%20Patients&amp;author=T.%20L.%20Dillenburg%20Weiss&amp;author=G.%20Gossling&amp;author=M.%20Venzon%20Antunes&amp;author=G.%20Schwartsmann&amp;author=R.%20Linden&amp;volume=195&amp;publication_year=2021&amp;pages=113861&amp;pmid=33373824&amp;doi=10.1016/j.jpba.2020.113861&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0024"><cite>
European Medicines Agency
. 2011. “Guideline on Bioanalytical Method Validation.” Retrieved from <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐bioanalytical‐method‐validation_en.pdf</a> [Cited 2024 16 september 2024].</cite></li>
<li id="bmc70056-bib-0025"><cite>
European Medicines Agency
. 2022. “ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis.” Retrieved from <a href="https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/en/ich‐m10‐bioanalytical‐method‐validation</a>.</cite></li>
<li id="bmc70056-bib-0026"><cite>
Food and Drug Administration
. 2011. “Center for Drug Evaluation and Research. Vermurafenib. Clinical Pharmacology and Biopharmaceutics Review 2011.”</cite></li>
<li id="bmc70056-bib-0027">
<cite>

Guo, Z. X.
, Yang F., van den Anker J. N., Zheng Y., and Zhao W.. 2021. “A Simplified Method for Bortezomib Determination Using Dried Blood Spots in Combination With Liquid Chromatography/Tandem Mass Spectrometry.” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
1181: 122905. 10.1016/j.jchromb.2021.122905.
</cite> [<a href="https://doi.org/10.1016/j.jchromb.2021.122905" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34438277/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Chromatography%20B:%20Analytical%20Technologies%20in%20the%20Biomedical%20and%20Life%20Sciences&amp;title=A%20Simplified%20Method%20for%20Bortezomib%20Determination%20Using%20Dried%20Blood%20Spots%20in%20Combination%20With%20Liquid%20Chromatography/Tandem%20Mass%20Spectrometry&amp;author=Z.%20X.%20Guo&amp;author=F.%20Yang&amp;author=J.%20N.%20van%20den%20Anker&amp;author=Y.%20Zheng&amp;author=W.%20Zhao&amp;volume=1181&amp;publication_year=2021&amp;pages=122905&amp;pmid=34438277&amp;doi=10.1016/j.jchromb.2021.122905&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0028">
<cite>

Hotta, K.
, Ishida T., Noritake K. I., Kita K., and Mano Y.. 2021. “Quantitative and Qualitative Application of a Novel Capillary Microsampling Device, Microsampling Wing (MSW), using Antiepileptic Drugs in Rats.” Journal of Pharmaceutical and Biomedical Analysis
194: 113788.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2020.113788" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33281005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Quantitative%20and%20Qualitative%20Application%20of%20a%20Novel%20Capillary%20Microsampling%20Device,%20Microsampling%20Wing%20(MSW),%20using%20Antiepileptic%20Drugs%20in%20Rats&amp;author=K.%20Hotta&amp;author=T.%20Ishida&amp;author=K.%20I.%20Noritake&amp;author=K.%20Kita&amp;author=Y.%20Mano&amp;volume=194&amp;publication_year=2021&amp;pages=113788&amp;pmid=33281005&amp;doi=10.1016/j.jpba.2020.113788&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0029">
<cite>

Iacuzzi, V.
, Posocco B., Zanchetta M., et al. 2021. “Dried Blood Spot Technique Applied in Therapeutic Drug Monitoring of Anticancer Drugs: A Review on Conversion Methods to Correlate Plasma and Dried Blood Spot Concentrations.” Pharmaceutical Research
38, no. 5: 759–778.
</cite> [<a href="https://doi.org/10.1007/s11095-021-03036-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33846903/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceutical%20Research&amp;title=Dried%20Blood%20Spot%20Technique%20Applied%20in%20Therapeutic%20Drug%20Monitoring%20of%20Anticancer%20Drugs:%20A%20Review%20on%20Conversion%20Methods%20to%20Correlate%20Plasma%20and%20Dried%20Blood%20Spot%20Concentrations&amp;author=V.%20Iacuzzi&amp;author=B.%20Posocco&amp;author=M.%20Zanchetta&amp;volume=38&amp;issue=5&amp;publication_year=2021&amp;pages=759-778&amp;pmid=33846903&amp;doi=10.1007/s11095-021-03036-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0030">
<cite>

Iacuzzi, V.
, Posocco B., Zanchetta M., et al. 2019. “Development and Validation of LC‐MS/MS Method for Imatinib and Norimatinib Monitoring by Finger‐Prick DBS in Gastrointestinal Stromal Tumor Patients.” PLoS ONE
14, no. 11: e0225225.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0225225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6863526/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31743371/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20ONE&amp;title=Development%20and%20Validation%20of%20LC%E2%80%90MS/MS%20Method%20for%20Imatinib%20and%20Norimatinib%20Monitoring%20by%20Finger%E2%80%90Prick%20DBS%20in%20Gastrointestinal%20Stromal%20Tumor%20Patients&amp;author=V.%20Iacuzzi&amp;author=B.%20Posocco&amp;author=M.%20Zanchetta&amp;volume=14&amp;issue=11&amp;publication_year=2019&amp;pages=e0225225&amp;pmid=31743371&amp;doi=10.1371/journal.pone.0225225&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0031">
<cite>

Irie, K.
, Shobu S., Hiratsuji S., et al. 2018. “Development and Validation of a Method for Gefitinib Quantification in Dried Blood Spots Using Liquid Chromatography‐Tandem Mass Spectrometry: Application to Finger‐Prick Clinical Blood Samples of Patients With Non‐Small Cell Lung cancer.” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
1087–1088: 1–5.</cite> [<a href="https://doi.org/10.1016/j.jchromb.2018.04.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29689441/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Chromatography%20B:%20Analytical%20Technologies%20in%20the%20Biomedical%20and%20Life%20Sciences&amp;title=Development%20and%20Validation%20of%20a%20Method%20for%20Gefitinib%20Quantification%20in%20Dried%20Blood%20Spots%20Using%20Liquid%20Chromatography%E2%80%90Tandem%20Mass%20Spectrometry:%20Application%20to%20Finger%E2%80%90Prick%20Clinical%20Blood%20Samples%20of%20Patients%20With%20Non%E2%80%90Small%20Cell%20Lung%20cancer&amp;author=K.%20Irie&amp;author=S.%20Shobu&amp;author=S.%20Hiratsuji&amp;volume=1087%E2%80%931088&amp;publication_year=2018&amp;pages=1-5&amp;pmid=29689441&amp;doi=10.1016/j.jchromb.2018.04.027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0032">
<cite>

Isberner, N.
, Gesierich A., Balakirouchenane D., et al. 2022. “Monitoring of Dabrafenib and Trametinib in Serum and Self‐Sampled Capillary Blood in Patients With BRAFV600‐Mutant Melanoma.” Cancers
14, no. 19: 4566.
</cite> [<a href="https://doi.org/10.3390/cancers14194566" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9558510/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36230489/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Monitoring%20of%20Dabrafenib%20and%20Trametinib%20in%20Serum%20and%20Self%E2%80%90Sampled%20Capillary%20Blood%20in%20Patients%20With%20BRAFV600%E2%80%90Mutant%20Melanoma&amp;author=N.%20Isberner&amp;author=A.%20Gesierich&amp;author=D.%20Balakirouchenane&amp;volume=14&amp;issue=19&amp;publication_year=2022&amp;pages=4566&amp;pmid=36230489&amp;doi=10.3390/cancers14194566&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0033">
<cite>

Jager, N. G. L.
, Rosing H., Schellens J. H. M., and Beijnen J. H.. 2014. “Determination of Tamoxifen and Endoxifen in Dried Blood Spots Using LC‐MS/MS and the Effect of Coated DBS Cards on Recovery and Matrix Effects.” Bioanalysis
6, no. 22: 2999–3009.
</cite> [<a href="https://doi.org/10.4155/bio.14.157" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25496254/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=Determination%20of%20Tamoxifen%20and%20Endoxifen%20in%20Dried%20Blood%20Spots%20Using%20LC%E2%80%90MS/MS%20and%20the%20Effect%20of%20Coated%20DBS%20Cards%20on%20Recovery%20and%20Matrix%20Effects&amp;author=N.%20G.%20L.%20Jager&amp;author=H.%20Rosing&amp;author=J.%20H.%20M.%20Schellens&amp;author=J.%20H.%20Beijnen&amp;volume=6&amp;issue=22&amp;publication_year=2014&amp;pages=2999-3009&amp;pmid=25496254&amp;doi=10.4155/bio.14.157&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0034">
<cite>

Jager, N. G. L.
, Rosing H., Schellens J. H. M., Beijnen J. H., and Linn S. C.. 2014. “Use of Dried Blood Spots for the Determination of Serum Concentrations of Tamoxifen and Endoxifen.” Breast Cancer Research and Treatment
146, no. 1: 137–144.
</cite> [<a href="https://doi.org/10.1007/s10549-014-2999-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24859000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer%20Research%20and%20Treatment&amp;title=Use%20of%20Dried%20Blood%20Spots%20for%20the%20Determination%20of%20Serum%20Concentrations%20of%20Tamoxifen%20and%20Endoxifen&amp;author=N.%20G.%20L.%20Jager&amp;author=H.%20Rosing&amp;author=J.%20H.%20M.%20Schellens&amp;author=J.%20H.%20Beijnen&amp;author=S.%20C.%20Linn&amp;volume=146&amp;issue=1&amp;publication_year=2014&amp;pages=137-144&amp;pmid=24859000&amp;doi=10.1007/s10549-014-2999-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0035">
<cite>

Janssen, J. M.
, de Vries N., Venekamp N., Rosing H., Huitema A. D. R., and Beijnen J. H.. 2019. “Development and Validation of a Liquid Chromatography‐Tandem Mass Spectrometry Assay for Nine Oral Anticancer Drugs in Human Plasma.” Journal of Pharmaceutical and Biomedical Analysis
174: 561–566.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2019.06.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31255856/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Development%20and%20Validation%20of%20a%20Liquid%20Chromatography%E2%80%90Tandem%20Mass%20Spectrometry%20Assay%20for%20Nine%20Oral%20Anticancer%20Drugs%20in%20Human%20Plasma&amp;author=J.%20M.%20Janssen&amp;author=N.%20de%20Vries&amp;author=N.%20Venekamp&amp;author=H.%20Rosing&amp;author=A.%20D.%20R.%20Huitema&amp;volume=174&amp;publication_year=2019&amp;pages=561-566&amp;pmid=31255856&amp;doi=10.1016/j.jpba.2019.06.034&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0036">
<cite>

Knapen, L. M.
, de Beer Y., Bruggemann R. J. M., et al. 2018. “Development and Validation of an Analytical Method Using UPLC‐MS/MS to Quantify Everolimus in Dried Blood Spots in the Oncology Setting.” Journal of Pharmaceutical and Biomedical Analysis
149: 106–113.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2017.10.039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29112898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Development%20and%20Validation%20of%20an%20Analytical%20Method%20Using%20UPLC%E2%80%90MS/MS%20to%20Quantify%20Everolimus%20in%20Dried%20Blood%20Spots%20in%20the%20Oncology%20Setting&amp;author=L.%20M.%20Knapen&amp;author=Y.%20de%20Beer&amp;author=R.%20J.%20M.%20Bruggemann&amp;volume=149&amp;publication_year=2018&amp;pages=106-113&amp;pmid=29112898&amp;doi=10.1016/j.jpba.2017.10.039&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0037">
<cite>

Kok, M. G. M.
, and Fillet M.. 2018. “Volumetric Absorptive Microsampling: Current Advances and Applications.” Journal of Pharmaceutical and Biomedical Analysis
147: 288–296.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2017.07.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28803682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Volumetric%20Absorptive%20Microsampling:%20Current%20Advances%20and%20Applications&amp;author=M.%20G.%20M.%20Kok&amp;author=M.%20Fillet&amp;volume=147&amp;publication_year=2018&amp;pages=288-296&amp;pmid=28803682&amp;doi=10.1016/j.jpba.2017.07.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0038">
<cite>

Kralj, E.
, Trontelj J., Pajič T., and Kristl A.. 2012. “Simultaneous Measurement of Imatinib, Nilotinib and Dasatinib in Dried Blood Spot by Ultra High Performance Liquid Chromatography Tandem Mass Spectrometry.” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
903: 150–156.
</cite> [<a href="https://doi.org/10.1016/j.jchromb.2012.07.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22857863/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Chromatography%20B:%20Analytical%20Technologies%20in%20the%20Biomedical%20and%20Life%20Sciences&amp;title=Simultaneous%20Measurement%20of%20Imatinib,%20Nilotinib%20and%20Dasatinib%20in%20Dried%20Blood%20Spot%20by%20Ultra%20High%20Performance%20Liquid%20Chromatography%20Tandem%20Mass%20Spectrometry&amp;author=E.%20Kralj&amp;author=J.%20Trontelj&amp;author=T.%20Paji%C4%8D&amp;author=A.%20Kristl&amp;volume=903&amp;publication_year=2012&amp;pages=150-156&amp;pmid=22857863&amp;doi=10.1016/j.jchromb.2012.07.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0039">
<cite>

Krützmann, M. E.
, Martini R. R., de Souza Guterres F., et al. 2023. “Volumetric Dried Blood Microsampling for Monitoring Imatinib Mesylate Therapy: Method Development and Clinical Application in Patients With Chronic Myeloid Leukemia.” Journal of Pharmaceutical and Biomedical Analysis
222: 115108.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2022.115108" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36279845/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Volumetric%20Dried%20Blood%20Microsampling%20for%20Monitoring%20Imatinib%20Mesylate%20Therapy:%20Method%20Development%20and%20Clinical%20Application%20in%20Patients%20With%20Chronic%20Myeloid%20Leukemia&amp;author=M.%20E.%20Kr%C3%BCtzmann&amp;author=R.%20R.%20Martini&amp;author=F.%20de%20Souza%20Guterres&amp;volume=222&amp;publication_year=2023&amp;pages=115108&amp;pmid=36279845&amp;doi=10.1016/j.jpba.2022.115108&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0040">
<cite>

Lau, C.
, Mohmaed Ali M. I., Lin L., et al. 2024. “Impact of Bariatric Surgery on Oral Anticancer Drugs: An Analysis of Real‐World Data.” Cancer Chemotherapy and Pharmacology
94, no. 1: 25–34. 10.1007/s00280-024-04640-0.
</cite> [<a href="https://doi.org/10.1007/s00280-024-04640-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11258081/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38427065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemotherapy%20and%20Pharmacology&amp;title=Impact%20of%20Bariatric%20Surgery%20on%20Oral%20Anticancer%20Drugs:%20An%20Analysis%20of%20Real%E2%80%90World%20Data&amp;author=C.%20Lau&amp;author=M.%20I.%20Mohmaed%20Ali&amp;author=L.%20Lin&amp;volume=94&amp;issue=1&amp;publication_year=2024&amp;pages=25-34&amp;pmid=38427065&amp;doi=10.1007/s00280-024-04640-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0041">
<cite>

Le Louedec, F.
, Puisset F., Chatelut E., and Tod M.. 2023. “Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug‐Drug Interaction and Improving Clinical Practice.” Clinical Pharmacokinetics
62, no. 1: 55–66.
</cite> [<a href="https://doi.org/10.1007/s40262-022-01200-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36631685/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Pharmacokinetics&amp;title=Considering%20the%20Oral%20Bioavailability%20of%20Protein%20Kinase%20Inhibitors:%20Essential%20in%20Assessing%20the%20Extent%20of%20Drug%E2%80%90Drug%20Interaction%20and%20Improving%20Clinical%20Practice&amp;author=F.%20Le%20Louedec&amp;author=F.%20Puisset&amp;author=E.%20Chatelut&amp;author=M.%20Tod&amp;volume=62&amp;issue=1&amp;publication_year=2023&amp;pages=55-66&amp;pmid=36631685&amp;doi=10.1007/s40262-022-01200-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0042">
<cite>

Lee, J.
, Jung S. Y., Choi M.‐Y., et al. 2020. “Development of a Dried Blood Spot Sampling Method Towards Therapeutic Monitoring of Radotinib in the Treatment of Chronic Myeloid Leukaemia.” Journal of Clinical Pharmacy and Therapeutics
45, no. 5: 1006–1013.
</cite> [<a href="https://doi.org/10.1111/jcpt.13124" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32022312/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Pharmacy%20and%20Therapeutics&amp;title=Development%20of%20a%20Dried%20Blood%20Spot%20Sampling%20Method%20Towards%20Therapeutic%20Monitoring%20of%20Radotinib%20in%20the%20Treatment%20of%20Chronic%20Myeloid%20Leukaemia&amp;author=J.%20Lee&amp;author=S.%20Y.%20Jung&amp;author=M.%E2%80%90Y.%20Choi&amp;volume=45&amp;issue=5&amp;publication_year=2020&amp;pages=1006-1013&amp;pmid=32022312&amp;doi=10.1111/jcpt.13124&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0043">
<cite>

Lee, P. Y.
, Yeoh Y., and Low T. Y.. 2023. “A Recent Update on Small‐Molecule Kinase Inhibitors for Targeted cancer Therapy and Their Therapeutic Insights From Mass Spectrometry‐Based Proteomic Analysis.” FEBS Journal
290, no. 11: 2845–2864.
</cite> [<a href="https://doi.org/10.1111/febs.16442" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35313089/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20Journal&amp;title=A%20Recent%20Update%20on%20Small%E2%80%90Molecule%20Kinase%20Inhibitors%20for%20Targeted%20cancer%20Therapy%20and%20Their%20Therapeutic%20Insights%20From%20Mass%20Spectrometry%E2%80%90Based%20Proteomic%20Analysis&amp;author=P.%20Y.%20Lee&amp;author=Y.%20Yeoh&amp;author=T.%20Y.%20Low&amp;volume=290&amp;issue=11&amp;publication_year=2023&amp;pages=2845-2864&amp;pmid=35313089&amp;doi=10.1111/febs.16442&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0044">
<cite>

Leuthold, L. A.
, Heudi O., Deglon J., et al. 2015. “New Microfluidic‐Based Sampling Procedure for Overcoming the Hematocrit Problem Associated With Dried Blood Spot Analysis.” Analytical Chemistry
87, no. 4: 2068–2071.
</cite> [<a href="https://doi.org/10.1021/ac503931g" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25607538/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Analytical%20Chemistry&amp;title=New%20Microfluidic%E2%80%90Based%20Sampling%20Procedure%20for%20Overcoming%20the%20Hematocrit%20Problem%20Associated%20With%20Dried%20Blood%20Spot%20Analysis&amp;author=L.%20A.%20Leuthold&amp;author=O.%20Heudi&amp;author=J.%20Deglon&amp;volume=87&amp;issue=4&amp;publication_year=2015&amp;pages=2068-2071&amp;pmid=25607538&amp;doi=10.1021/ac503931g&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0045">
<cite>

Li, J.
, Gong C., Zhou H., et al. 2024. “Kinase Inhibitors and Kinase‐Targeted Cancer Therapies: Recent Advances and Future Perspectives.” International Journal of Molecular Sciences
25, no. 10: 5489. 10.3390/ijms25105489.
</cite> [<a href="https://doi.org/10.3390/ijms25105489" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11122109/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38791529/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Molecular%20Sciences&amp;title=Kinase%20Inhibitors%20and%20Kinase%E2%80%90Targeted%20Cancer%20Therapies:%20Recent%20Advances%20and%20Future%20Perspectives&amp;author=J.%20Li&amp;author=C.%20Gong&amp;author=H.%20Zhou&amp;volume=25&amp;issue=10&amp;publication_year=2024&amp;pages=5489&amp;pmid=38791529&amp;doi=10.3390/ijms25105489&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0046">
<cite>

Maggadani, B. P.
, Harahap Y., Harmita H., Haryono S. J., and Untu C. W. P.. 2021. “Analysis of Tamoxifen and Its Metabolites in Dried Blood Spot and Volumetric Absorptive Microsampling: Comparison and Clinical Application.” Heliyon
7, no. 6: e07275.
</cite> [<a href="https://doi.org/10.1016/j.heliyon.2021.e07275" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8213905/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34179536/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heliyon&amp;title=Analysis%20of%20Tamoxifen%20and%20Its%20Metabolites%20in%20Dried%20Blood%20Spot%20and%20Volumetric%20Absorptive%20Microsampling:%20Comparison%20and%20Clinical%20Application&amp;author=B.%20P.%20Maggadani&amp;author=Y.%20Harahap&amp;author=H.%20Harmita&amp;author=S.%20J.%20Haryono&amp;author=C.%20W.%20P.%20Untu&amp;volume=7&amp;issue=6&amp;publication_year=2021&amp;pages=e07275&amp;pmid=34179536&amp;doi=10.1016/j.heliyon.2021.e07275&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0047">
<cite>

Mano, Y.
, Kita K., and Kusano K.. 2015. “Hematocrit‐Independent Recovery Is a key for Bioanalysis Using Volumetric Absorptive Microsampling Devices, Mitra.” Bioanalysis
7, no. 15: 1821–1829.
</cite> [<a href="https://doi.org/10.4155/bio.15.111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26295984/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=Hematocrit%E2%80%90Independent%20Recovery%20Is%20a%20key%20for%20Bioanalysis%20Using%20Volumetric%20Absorptive%20Microsampling%20Devices,%20Mitra&amp;author=Y.%20Mano&amp;author=K.%20Kita&amp;author=K.%20Kusano&amp;volume=7&amp;issue=15&amp;publication_year=2015&amp;pages=1821-1829&amp;pmid=26295984&amp;doi=10.4155/bio.15.111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0048">
<cite>

Meertens, M.
, de Vries N., Rosing H., Steeghs N., Beijnen J. H., and Huitema A. D. R.. 2024. “Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites.” Therapeutic Drug Monitoring
46, no. 4: 494–502.
</cite> [<a href="https://doi.org/10.1097/FTD.0000000000001175" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38321598/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapeutic%20Drug%20Monitoring&amp;title=Analytical%20Validation%20of%20a%20Volumetric%20Absorptive%20Microsampling%20Method%20for%20Therapeutic%20Drug%20Monitoring%20of%20the%20Oral%20Targeted%20Anticancer%20Agents,%20Abiraterone,%20Alectinib,%20Cabozantinib,%20Imatinib,%20Olaparib,%20and%20Sunitinib,%20and%20Metabolites&amp;author=M.%20Meertens&amp;author=N.%20de%20Vries&amp;author=H.%20Rosing&amp;author=N.%20Steeghs&amp;author=J.%20H.%20Beijnen&amp;volume=46&amp;issue=4&amp;publication_year=2024&amp;pages=494-502&amp;pmid=38321598&amp;doi=10.1097/FTD.0000000000001175&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0049">
<cite>

Mukai, Y.
, Yoshida T., Kondo T., Miura J., Inotsume N., and Toda T.. 2022. “Development and Validation of a Simple Method for Simultaneously Measuring the Concentrations of BCR‐ABL and Bruton Tyrosine Kinase Inhibitors in Dried Blood Spot (DBS): A Pilot Study to Obtain Candidate Conversion Equations for Predicting Plasma Concentration Based on DBS Concentration.” Therapeutic Drug Monitoring
44, no. 6: 762–770.
</cite> [<a href="https://doi.org/10.1097/FTD.0000000000000997" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36372934/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapeutic%20Drug%20Monitoring&amp;title=Development%20and%20Validation%20of%20a%20Simple%20Method%20for%20Simultaneously%20Measuring%20the%20Concentrations%20of%20BCR%E2%80%90ABL%20and%20Bruton%20Tyrosine%20Kinase%20Inhibitors%20in%20Dried%20Blood%20Spot%20(DBS):%20A%20Pilot%20Study%20to%20Obtain%20Candidate%20Conversion%20Equations%20for%20Predicting%20Plasma%20Concentration%20Based%20on%20DBS%20Concentration&amp;author=Y.%20Mukai&amp;author=T.%20Yoshida&amp;author=T.%20Kondo&amp;author=J.%20Miura&amp;author=N.%20Inotsume&amp;volume=44&amp;issue=6&amp;publication_year=2022&amp;pages=762-770&amp;pmid=36372934&amp;doi=10.1097/FTD.0000000000000997&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0050">
<cite>

Neto, R.
, Gooley A., Breadmore M. C., Hilder E. F., and Lapierre F.. 2018. “Precise, Accurate and User‐Independent Blood Collection System for Dried Blood Spot Sample Preparation.” Analytical and Bioanalytical Chemistry
410, no. 14: 3315–3323.
</cite> [<a href="https://doi.org/10.1007/s00216-018-0993-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29623384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Analytical%20and%20Bioanalytical%20Chemistry&amp;title=Precise,%20Accurate%20and%20User%E2%80%90Independent%20Blood%20Collection%20System%20for%20Dried%20Blood%20Spot%20Sample%20Preparation&amp;author=R.%20Neto&amp;author=A.%20Gooley&amp;author=M.%20C.%20Breadmore&amp;author=E.%20F.%20Hilder&amp;author=F.%20Lapierre&amp;volume=410&amp;issue=14&amp;publication_year=2018&amp;pages=3315-3323&amp;pmid=29623384&amp;doi=10.1007/s00216-018-0993-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0051">
<cite>

Nijenhuis, C. M.
, Huitema A. D., Marchetti S., et al. 2016. “The use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.” Journal of Clinical Pharmacology
56, no. 10: 1307–1312. 10.1002/jcph.728.
</cite> [<a href="https://doi.org/10.1002/jcph.728" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26918324/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Pharmacology&amp;title=The%20use%20of%20Dried%20Blood%20Spots%20for%20Pharmacokinetic%20Monitoring%20of%20Vemurafenib%20Treatment%20in%20Melanoma%20Patients&amp;author=C.%20M.%20Nijenhuis&amp;author=A.%20D.%20Huitema&amp;author=S.%20Marchetti&amp;volume=56&amp;issue=10&amp;publication_year=2016&amp;pages=1307-1312&amp;pmid=26918324&amp;doi=10.1002/jcph.728&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0052">
<cite>

Nijenhuis, C. M.
, Rosing H., Schellens J. H. M., and Beijnen J. H.. 2014. “Quantifying Vemurafenib in Dried Blood Spots Using High‐Performance LC‐MS/MS.” Bioanalysis
6, no. 23: 3215–3224.
</cite> [<a href="https://doi.org/10.4155/bio.14.171" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25529888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=Quantifying%20Vemurafenib%20in%20Dried%20Blood%20Spots%20Using%20High%E2%80%90Performance%20LC%E2%80%90MS/MS&amp;author=C.%20M.%20Nijenhuis&amp;author=H.%20Rosing&amp;author=J.%20H.%20M.%20Schellens&amp;author=J.%20H.%20Beijnen&amp;volume=6&amp;issue=23&amp;publication_year=2014&amp;pages=3215-3224&amp;pmid=25529888&amp;doi=10.4155/bio.14.171&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0053">
<cite>

Opitz, P.
, Zimmermann S., Mc Laughlin A. M., et al. 2022. “Development and Validation of a Bioanalytical Method for the Quantification of Axitinib From Plasma and Capillary Blood Using Volumetric Absorptive Microsampling (VAMS) and On‐Line Solid Phase Extraction (SPE) LC‐MS.” Journal of Pharmaceutical and Biomedical Analysis
221: 115033.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2022.115033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36148722/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Development%20and%20Validation%20of%20a%20Bioanalytical%20Method%20for%20the%20Quantification%20of%20Axitinib%20From%20Plasma%20and%20Capillary%20Blood%20Using%20Volumetric%20Absorptive%20Microsampling%20(VAMS)%20and%20On%E2%80%90Line%20Solid%20Phase%20Extraction%20(SPE)%20LC%E2%80%90MS&amp;author=P.%20Opitz&amp;author=S.%20Zimmermann&amp;author=A.%20M.%20Mc%20Laughlin&amp;volume=221&amp;publication_year=2022&amp;pages=115033&amp;pmid=36148722&amp;doi=10.1016/j.jpba.2022.115033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0054">
<cite>

Poetto, A. S.
, Posocco B., Gagno S., et al. 2021. “A New Dried Blood Spot LC‐MS/MS Method for Therapeutic Drug Monitoring of Palbociclib, Ribociclib, and Letrozole in Patients With cancer.” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
1185: 122985.
</cite> [<a href="https://doi.org/10.1016/j.jchromb.2021.122985" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34700133/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Chromatography%20B:%20Analytical%20Technologies%20in%20the%20Biomedical%20and%20Life%20Sciences&amp;title=A%20New%20Dried%20Blood%20Spot%20LC%E2%80%90MS/MS%20Method%20for%20Therapeutic%20Drug%20Monitoring%20of%20Palbociclib,%20Ribociclib,%20and%20Letrozole%20in%20Patients%20With%20cancer&amp;author=A.%20S.%20Poetto&amp;author=B.%20Posocco&amp;author=S.%20Gagno&amp;volume=1185&amp;publication_year=2021&amp;pages=122985&amp;pmid=34700133&amp;doi=10.1016/j.jchromb.2021.122985&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0055">
<cite>

Rehnmark, S.
, Shabo I., Randahl H., Wengström Y., Rydberg P., and Hedayati E.. 2022. “Preliminary Results Using a kit to Measure Tamoxifen and Metabolites Concentrations in Capillary Blood Samples From Women With Breast cancer.” Scientific Reports
12, no. 1: 1643.
</cite> [<a href="https://doi.org/10.1038/s41598-022-05443-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8803831/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35102224/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=Preliminary%20Results%20Using%20a%20kit%20to%20Measure%20Tamoxifen%20and%20Metabolites%20Concentrations%20in%20Capillary%20Blood%20Samples%20From%20Women%20With%20Breast%20cancer&amp;author=S.%20Rehnmark&amp;author=I.%20Shabo&amp;author=H.%20Randahl&amp;author=Y.%20Wengstr%C3%B6m&amp;author=P.%20Rydberg&amp;volume=12&amp;issue=1&amp;publication_year=2022&amp;pages=1643&amp;pmid=35102224&amp;doi=10.1038/s41598-022-05443-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0056">
<cite>

Rood, J. J. M.
, van Hoppe S., Schinkel A. H., Schellens J. H. M., Beijnen J. H., and Sparidans R. W.. 2016. “Liquid Chromatography‐Tandem Mass Spectrometric Assay for the Simultaneous Determination of the Irreversible BTK Inhibitor Ibrutinib and Its Dihydrodiol‐Metabolite in Plasma and Its Application in Mouse Pharmacokinetic Studies.” Journal of Pharmaceutical and Biomedical Analysis
118: 123–131.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2015.10.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26540627/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Liquid%20Chromatography%E2%80%90Tandem%20Mass%20Spectrometric%20Assay%20for%20the%20Simultaneous%20Determination%20of%20the%20Irreversible%20BTK%20Inhibitor%20Ibrutinib%20and%20Its%20Dihydrodiol%E2%80%90Metabolite%20in%20Plasma%20and%20Its%20Application%20in%20Mouse%20Pharmacokinetic%20Studies&amp;author=J.%20J.%20M.%20Rood&amp;author=S.%20van%20Hoppe&amp;author=A.%20H.%20Schinkel&amp;author=J.%20H.%20M.%20Schellens&amp;author=J.%20H.%20Beijnen&amp;volume=118&amp;publication_year=2016&amp;pages=123-131&amp;pmid=26540627&amp;doi=10.1016/j.jpba.2015.10.033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0057">
<cite>

Rowland, M.
, and Emmons G. T.. 2010. “Use of Dried Blood Spots in Drug Development: Pharmacokinetic Considerations.” AAPS Journal
12, no. 3: 290–293.
</cite> [<a href="https://doi.org/10.1208/s12248-010-9188-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2895450/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20383669/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=AAPS%20Journal&amp;title=Use%20of%20Dried%20Blood%20Spots%20in%20Drug%20Development:%20Pharmacokinetic%20Considerations&amp;author=M.%20Rowland&amp;author=G.%20T.%20Emmons&amp;volume=12&amp;issue=3&amp;publication_year=2010&amp;pages=290-293&amp;pmid=20383669&amp;doi=10.1208/s12248-010-9188-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0058">
<cite>

Saito, A.
, Kikuchi M., Matsumoto Y., et al. 2022. “Evaluation of a Capillary Microsampling Device for Analyzing Plasma Lenvatinib Concentration in Patients With Hepatocellular Carcinoma.” Therapeutic Drug Monitoring
44, no. 6: 771–776.
</cite> [<a href="https://doi.org/10.1097/FTD.0000000000001013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35863065/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapeutic%20Drug%20Monitoring&amp;title=Evaluation%20of%20a%20Capillary%20Microsampling%20Device%20for%20Analyzing%20Plasma%20Lenvatinib%20Concentration%20in%20Patients%20With%20Hepatocellular%20Carcinoma&amp;author=A.%20Saito&amp;author=M.%20Kikuchi&amp;author=Y.%20Matsumoto&amp;volume=44&amp;issue=6&amp;publication_year=2022&amp;pages=771-776&amp;pmid=35863065&amp;doi=10.1097/FTD.0000000000001013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0059">
<cite>

Tré‐Hardy, M.
, Capron A., Antunes M. V., Linden R., and Wallemacq P.. 2016. “Fast Method for Simultaneous Quantification of Tamoxifen and Metabolites in Dried Blood Spots Using an Entry Level LC–MS/MS System.” Clinical Biochemistry
49, no. 16–17: 1295–1298.
</cite> [<a href="https://doi.org/10.1016/j.clinbiochem.2016.07.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27498307/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Biochemistry&amp;title=Fast%20Method%20for%20Simultaneous%20Quantification%20of%20Tamoxifen%20and%20Metabolites%20in%20Dried%20Blood%20Spots%20Using%20an%20Entry%20Level%20LC%E2%80%93MS/MS%20System&amp;author=M.%20Tr%C3%A9%E2%80%90Hardy&amp;author=A.%20Capron&amp;author=M.%20V.%20Antunes&amp;author=R.%20Linden&amp;author=P.%20Wallemacq&amp;volume=49&amp;issue=16%E2%80%9317&amp;publication_year=2016&amp;pages=1295-1298&amp;pmid=27498307&amp;doi=10.1016/j.clinbiochem.2016.07.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0060">
<cite>

van de Schoot, R.
, de Bruin J., Schram R., et al. 2021. “An Open Source Machine Learning Framework for Efficient and Transparent Systematic Reviews.” Nature Machine Intelligence
3: 125–133.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Machine%20Intelligence&amp;title=An%20Open%20Source%20Machine%20Learning%20Framework%20for%20Efficient%20and%20Transparent%20Systematic%20Reviews&amp;author=R.%20van%20de%20Schoot&amp;author=J.%20de%20Bruin&amp;author=R.%20Schram&amp;volume=3&amp;publication_year=2021&amp;pages=125-133&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0061">
<cite>

van der Kleij, M. B. A.
, Guchelaar N. A. D., Mathijssen R. H. J., et al. 2023. “Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.” Clinical Pharmacokinetics
62, no. 10: 1333–1364.
</cite> [<a href="https://doi.org/10.1007/s40262-023-01293-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10519871/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37584840/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Pharmacokinetics&amp;title=Therapeutic%20Drug%20Monitoring%20of%20Kinase%20Inhibitors%20in%20Oncology&amp;author=M.%20B.%20A.%20van%20der%20Kleij&amp;author=N.%20A.%20D.%20Guchelaar&amp;author=R.%20H.%20J.%20Mathijssen&amp;volume=62&amp;issue=10&amp;publication_year=2023&amp;pages=1333-1364&amp;pmid=37584840&amp;doi=10.1007/s40262-023-01293-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0062">
<cite>

van Nuland, M.
, Venekamp N., de Vries N., de Jong K. A. M., Rosing H., and Beijnen J. H.. 2019. “Development and Validation of an UPLC‐MS/MS Method for the Therapeutic Drug Monitoring of Oral Anti‐Hormonal Drugs in Oncology.” Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
1106–1107: 26–34.</cite> [<a href="https://doi.org/10.1016/j.jchromb.2019.01.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30639947/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Chromatography.%20B,%20Analytical%20Technologies%20in%20the%20Biomedical%20and%20Life%20Sciences&amp;title=Development%20and%20Validation%20of%20an%20UPLC%E2%80%90MS/MS%20Method%20for%20the%20Therapeutic%20Drug%20Monitoring%20of%20Oral%20Anti%E2%80%90Hormonal%20Drugs%20in%20Oncology&amp;author=M.%20van%20Nuland&amp;author=N.%20Venekamp&amp;author=N.%20de%20Vries&amp;author=K.%20A.%20M.%20de%20Jong&amp;author=H.%20Rosing&amp;volume=1106%E2%80%931107&amp;publication_year=2019&amp;pages=26-34&amp;pmid=30639947&amp;doi=10.1016/j.jchromb.2019.01.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0063">
<cite>

Van Uytfanghe, K.
, Heughebaert L., and Stove C. P.. 2021. “Self‐Sampling at Home Using Volumetric Absorptive Microsampling: Coupling Analytical Evaluation to Volunteers' Perception in the Context of a Large Scale Study.” Clinical Chemistry and Laboratory Medicine
59, no. 5: e185‐e187.
</cite> [<a href="https://doi.org/10.1515/cclm-2020-1180" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33112777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Chemistry%20and%20Laboratory%20Medicine&amp;title=Self%E2%80%90Sampling%20at%20Home%20Using%20Volumetric%20Absorptive%20Microsampling:%20Coupling%20Analytical%20Evaluation%20to%20Volunteers'%20Perception%20in%20the%20Context%20of%20a%20Large%20Scale%20Study&amp;author=K.%20Van%20Uytfanghe&amp;author=L.%20Heughebaert&amp;author=C.%20P.%20Stove&amp;volume=59&amp;issue=5&amp;publication_year=2021&amp;pages=e185%E2%80%90e187&amp;pmid=33112777&amp;doi=10.1515/cclm-2020-1180&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0064">
<cite>

van Veelen, A.
, van Geel R., de Beer Y., et al. 2020. “Validation of an Analytical Method Using HPLC‐MS/MS to Quantify Osimertinib in Human Plasma and Supplementary Stability Results.” Biomedical Chromatography
34, no. 4: e4771.
</cite> [<a href="https://doi.org/10.1002/bmc.4771" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31808583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedical%20Chromatography&amp;title=Validation%20of%20an%20Analytical%20Method%20Using%20HPLC%E2%80%90MS/MS%20to%20Quantify%20Osimertinib%20in%20Human%20Plasma%20and%20Supplementary%20Stability%20Results&amp;author=A.%20van%20Veelen&amp;author=R.%20van%20Geel&amp;author=Y.%20de%20Beer&amp;volume=34&amp;issue=4&amp;publication_year=2020&amp;pages=e4771&amp;pmid=31808583&amp;doi=10.1002/bmc.4771&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0065">
<cite>

Veerman, G. D. M.
, Lam M. H., Mathijssen R. H. J., Koolen S. L. W., and de Bruijn P.. 2019. “Quantification of Afatinib, Alectinib, Crizotinib and Osimertinib in Human Plasma by Liquid Chromatography/Triple‐Quadrupole Mass Spectrometry; Focusing on the Stability of Osimertinib.” Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
1113: 37–44.
</cite> [<a href="https://doi.org/10.1016/j.jchromb.2019.03.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30889498/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Chromatography.%20B,%20Analytical%20Technologies%20in%20the%20Biomedical%20and%20Life%20Sciences&amp;title=Quantification%20of%20Afatinib,%20Alectinib,%20Crizotinib%20and%20Osimertinib%20in%20Human%20Plasma%20by%20Liquid%20Chromatography/Triple%E2%80%90Quadrupole%20Mass%20Spectrometry;%20Focusing%20on%20the%20Stability%20of%20Osimertinib&amp;author=G.%20D.%20M.%20Veerman&amp;author=M.%20H.%20Lam&amp;author=R.%20H.%20J.%20Mathijssen&amp;author=S.%20L.%20W.%20Koolen&amp;author=P.%20de%20Bruijn&amp;volume=1113&amp;publication_year=2019&amp;pages=37-44&amp;pmid=30889498&amp;doi=10.1016/j.jchromb.2019.03.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0066">
<cite>

Velghe, S.
, Delahaye L., and Stove C. P.. 2019. “Is the Hematocrit Still an Issue in Quantitative Dried Blood Spot Analysis?” Journal of Pharmaceutical and Biomedical Analysis
163: 188–196.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2018.10.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30317075/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Is%20the%20Hematocrit%20Still%20an%20Issue%20in%20Quantitative%20Dried%20Blood%20Spot%20Analysis?&amp;author=S.%20Velghe&amp;author=L.%20Delahaye&amp;author=C.%20P.%20Stove&amp;volume=163&amp;publication_year=2019&amp;pages=188-196&amp;pmid=30317075&amp;doi=10.1016/j.jpba.2018.10.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0067">
<cite>

Velghe, S.
, and Stove C. P.. 2018. “Evaluation of the Capitainer‐B Microfluidic Device as a new Hematocrit‐Independent Alternative for Dried Blood Spot Collection.” Analytical Chemistry
90, no. 21: 12893–12899.
</cite> [<a href="https://doi.org/10.1021/acs.analchem.8b03512" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30256092/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Analytical%20Chemistry&amp;title=Evaluation%20of%20the%20Capitainer%E2%80%90B%20Microfluidic%20Device%20as%20a%20new%20Hematocrit%E2%80%90Independent%20Alternative%20for%20Dried%20Blood%20Spot%20Collection&amp;author=S.%20Velghe&amp;author=C.%20P.%20Stove&amp;volume=90&amp;issue=21&amp;publication_year=2018&amp;pages=12893-12899&amp;pmid=30256092&amp;doi=10.1021/acs.analchem.8b03512&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0068">
<cite>

Venkatesh, B.
, Yuile A., McKay M. J., et al. 2023. “A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, From Microsampled Dried Blood Spots and Plasma.” Therapeutic Drug Monitoring
46: 332–343.</cite> [<a href="https://doi.org/10.1097/FTD.0000000000001157" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11078286/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38263583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapeutic%20Drug%20Monitoring&amp;title=A%20Validated%20Assay%20to%20Quantify%20Osimertinib%20and%20Its%20Metabolites,%20AZ5104%20and%20AZ7550,%20From%20Microsampled%20Dried%20Blood%20Spots%20and%20Plasma&amp;author=B.%20Venkatesh&amp;author=A.%20Yuile&amp;author=M.%20J.%20McKay&amp;volume=46&amp;publication_year=2023&amp;pages=332-343&amp;pmid=38263583&amp;doi=10.1097/FTD.0000000000001157&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0069">
<cite>

Verheijen, R. B.
, Bins S., Thijssen B., et al. 2016. “Development and Clinical Validation of an LC‐MS/MS Method for the Quantification of Pazopanib in DBS.” Bioanalysis
8, no. 2: 123–134.
</cite> [<a href="https://doi.org/10.4155/bio.15.235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26652864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=Development%20and%20Clinical%20Validation%20of%20an%20LC%E2%80%90MS/MS%20Method%20for%20the%20Quantification%20of%20Pazopanib%20in%20DBS&amp;author=R.%20B.%20Verheijen&amp;author=S.%20Bins&amp;author=B.%20Thijssen&amp;volume=8&amp;issue=2&amp;publication_year=2016&amp;pages=123-134&amp;pmid=26652864&amp;doi=10.4155/bio.15.235&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0070">
<cite>

Verheijen, R. B.
, Thijssen B., Atrafi F., et al. 2019. “Validation and Clinical Application of an LC‐MS/MS Method for the Quantification of Everolimus Using Volumetric Absorptive Microsampling.” Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
1104: 234–239.
</cite> [<a href="https://doi.org/10.1016/j.jchromb.2018.11.030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30530116/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Chromatography.%20B,%20Analytical%20Technologies%20in%20the%20Biomedical%20and%20Life%20Sciences&amp;title=Validation%20and%20Clinical%20Application%20of%20an%20LC%E2%80%90MS/MS%20Method%20for%20the%20Quantification%20of%20Everolimus%20Using%20Volumetric%20Absorptive%20Microsampling&amp;author=R.%20B.%20Verheijen&amp;author=B.%20Thijssen&amp;author=F.%20Atrafi&amp;volume=1104&amp;publication_year=2019&amp;pages=234-239&amp;pmid=30530116&amp;doi=10.1016/j.jchromb.2018.11.030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0071">
<cite>

Verougstraete, N.
, and Stove C. P.. 2022. “Volumetric Absorptive Microsampling as a Suitable Tool to Monitor Tyrosine Kinase Inhibitors.” Journal of Pharmaceutical and Biomedical Analysis
207: 114418.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2021.114418" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34655987/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Volumetric%20Absorptive%20Microsampling%20as%20a%20Suitable%20Tool%20to%20Monitor%20Tyrosine%20Kinase%20Inhibitors&amp;author=N.%20Verougstraete&amp;author=C.%20P.%20Stove&amp;volume=207&amp;publication_year=2022&amp;pages=114418&amp;pmid=34655987&amp;doi=10.1016/j.jpba.2021.114418&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0072">
<cite>

Verougstraete, N.
, Stove V., Verstraete A. G., and Stove C.. 2021. “Quantification of Eight Hematological Tyrosine Kinase Inhibitors in Both Plasma and Whole Blood by a Validated LC‐MS/MS Method.” Talanta
226: 122140.
</cite> [<a href="https://doi.org/10.1016/j.talanta.2021.122140" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33676691/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Talanta&amp;title=Quantification%20of%20Eight%20Hematological%20Tyrosine%20Kinase%20Inhibitors%20in%20Both%20Plasma%20and%20Whole%20Blood%20by%20a%20Validated%20LC%E2%80%90MS/MS%20Method&amp;author=N.%20Verougstraete&amp;author=V.%20Stove&amp;author=A.%20G.%20Verstraete&amp;author=C.%20Stove&amp;volume=226&amp;publication_year=2021&amp;pages=122140&amp;pmid=33676691&amp;doi=10.1016/j.talanta.2021.122140&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0073">
<cite>

Verougstraete, N.
, Stove V., Verstraete A. G., and Stove C. P.. 2022. “Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples.” Frontiers in Oncology
12: 821807.
</cite> [<a href="https://doi.org/10.3389/fonc.2022.821807" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8980857/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35392223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=Therapeutic%20Drug%20Monitoring%20of%20Tyrosine%20Kinase%20Inhibitors%20Using%20Dried%20Blood%20Microsamples&amp;author=N.%20Verougstraete&amp;author=V.%20Stove&amp;author=A.%20G.%20Verstraete&amp;author=C.%20P.%20Stove&amp;volume=12&amp;publication_year=2022&amp;pages=821807&amp;pmid=35392223&amp;doi=10.3389/fonc.2022.821807&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0074">
<cite>

Voggu, R. R.
, Brus T. S., Barksdale C. T., et al. 2020. “Novel LC‐MS/MS Method for the Determination of Selumetinib (AZD6244) in Whole Blood Collected With Volumetric Absorptive Microsampling.” Bioanalysis
12, no. 13: 883–892.
</cite> [<a href="https://doi.org/10.4155/bio-2020-0062" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32628506/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=Novel%20LC%E2%80%90MS/MS%20Method%20for%20the%20Determination%20of%20Selumetinib%20(AZD6244)%20in%20Whole%20Blood%20Collected%20With%20Volumetric%20Absorptive%20Microsampling&amp;author=R.%20R.%20Voggu&amp;author=T.%20S.%20Brus&amp;author=C.%20T.%20Barksdale&amp;volume=12&amp;issue=13&amp;publication_year=2020&amp;pages=883-892&amp;pmid=32628506&amp;doi=10.4155/bio-2020-0062&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0075">
<cite>

Willemsen, A. E. C. A. B.
, Knapen L. M., de Beer Y. M., et al. 2018. “Clinical Validation Study of Dried Blood Spot for Determining Everolimus Concentration in Patients With cancer.” European Journal of Clinical Pharmacology
74, no. 4: 465–471.
</cite> [<a href="https://doi.org/10.1007/s00228-017-2394-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5849667/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29222715/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Clinical%20Pharmacology&amp;title=Clinical%20Validation%20Study%20of%20Dried%20Blood%20Spot%20for%20Determining%20Everolimus%20Concentration%20in%20Patients%20With%20cancer&amp;author=A.%20E.%20C.%20A.%20B.%20Willemsen&amp;author=L.%20M.%20Knapen&amp;author=Y.%20M.%20de%20Beer&amp;volume=74&amp;issue=4&amp;publication_year=2018&amp;pages=465-471&amp;pmid=29222715&amp;doi=10.1007/s00228-017-2394-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0076">
<cite>

Xie, I.
, Xu Y., Anderson M., et al. 2018. “Extractability‐Mediated Stability bias and Hematocrit Impact: High Extraction Recovery Is Critical to Feasibility of Volumetric Adsorptive Microsampling (VAMS) in Regulated Bioanalysis.” Journal of Pharmaceutical and Biomedical Analysis
156: 58–66.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2018.04.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29689469/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Extractability%E2%80%90Mediated%20Stability%20bias%20and%20Hematocrit%20Impact:%20High%20Extraction%20Recovery%20Is%20Critical%20to%20Feasibility%20of%20Volumetric%20Adsorptive%20Microsampling%20(VAMS)%20in%20Regulated%20Bioanalysis&amp;author=I.%20Xie&amp;author=Y.%20Xu&amp;author=M.%20Anderson&amp;volume=156&amp;publication_year=2018&amp;pages=58-66&amp;pmid=29689469&amp;doi=10.1016/j.jpba.2018.04.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0077">
<cite>

Xu, Y.
, Fang W., Zeng W., Leijen S., and Woolf E. J.. 2012. “Evaluation of Dried Blood Spot (DBS) Technology Versus Plasma Analysis for the Determination of MK‐1775 by HILIC‐MS/MS in Support of Clinical Studies.” Analytical and Bioanalytical Chemistry
404, no. 10: 3037–3048.
</cite> [<a href="https://doi.org/10.1007/s00216-012-6440-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23099526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Analytical%20and%20Bioanalytical%20Chemistry&amp;title=Evaluation%20of%20Dried%20Blood%20Spot%20(DBS)%20Technology%20Versus%20Plasma%20Analysis%20for%20the%20Determination%20of%20MK%E2%80%901775%20by%20HILIC%E2%80%90MS/MS%20in%20Support%20of%20Clinical%20Studies&amp;author=Y.%20Xu&amp;author=W.%20Fang&amp;author=W.%20Zeng&amp;author=S.%20Leijen&amp;author=E.%20J.%20Woolf&amp;volume=404&amp;issue=10&amp;publication_year=2012&amp;pages=3037-3048&amp;pmid=23099526&amp;doi=10.1007/s00216-012-6440-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0078">
<cite>

Ye, Z.
, and Gao H.. 2017. “Evaluation of Sample Extraction Methods for Minimizing Hematocrit Effect on Whole Blood Analysis With Volumetric Absorptive Microsampling.” Bioanalysis
9, no. 4: 349–357.
</cite> [<a href="https://doi.org/10.4155/bio-2015-0028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28102694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioanalysis&amp;title=Evaluation%20of%20Sample%20Extraction%20Methods%20for%20Minimizing%20Hematocrit%20Effect%20on%20Whole%20Blood%20Analysis%20With%20Volumetric%20Absorptive%20Microsampling&amp;author=Z.%20Ye&amp;author=H.%20Gao&amp;volume=9&amp;issue=4&amp;publication_year=2017&amp;pages=349-357&amp;pmid=28102694&amp;doi=10.4155/bio-2015-0028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0079">
<cite>

Zanchetta, M.
, Posocco B., Gagno S., et al. 2023. “A Fast and Validated LC‐MS/MS Method to Quantify Lenvatinib in Dried Blood Spot.” Journal of Pharmaceutical and Biomedical Analysis
226: 115255.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2023.115255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36682207/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=A%20Fast%20and%20Validated%20LC%E2%80%90MS/MS%20Method%20to%20Quantify%20Lenvatinib%20in%20Dried%20Blood%20Spot&amp;author=M.%20Zanchetta&amp;author=B.%20Posocco&amp;author=S.%20Gagno&amp;volume=226&amp;publication_year=2023&amp;pages=115255&amp;pmid=36682207&amp;doi=10.1016/j.jpba.2023.115255&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0080">
<cite>

Zhang, J.
, Wang W., Du J., et al. 2022. “A Rapid and Sensitive Ultra‐Performance Liquid Chromatography Tandem Mass Spectrometry Method for Determination of Anlotinib in Plasma and Dried Blood Spots: Method Development, Validation, and Clinical Application.” Rapid Communications in Mass Spectrometry: RCM
36, no. 21: e9372.
</cite> [<a href="https://doi.org/10.1002/rcm.9372" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35918299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Rapid%20Communications%20in%20Mass%20Spectrometry:%20RCM&amp;title=A%20Rapid%20and%20Sensitive%20Ultra%E2%80%90Performance%20Liquid%20Chromatography%20Tandem%20Mass%20Spectrometry%20Method%20for%20Determination%20of%20Anlotinib%20in%20Plasma%20and%20Dried%20Blood%20Spots:%20Method%20Development,%20Validation,%20and%20Clinical%20Application&amp;author=J.%20Zhang&amp;author=W.%20Wang&amp;author=J.%20Du&amp;volume=36&amp;issue=21&amp;publication_year=2022&amp;pages=e9372&amp;pmid=35918299&amp;doi=10.1002/rcm.9372&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0081">
<cite>

Zimmermann, S.
, Aghai F., Schilling B., et al. 2022. “Volumetric Absorptive Microsampling (VAMS) for the Quantification of ten Kinase Inhibitors and Determination of Their in Vitro VAMS‐To‐Plasma Ratio.” Journal of Pharmaceutical and Biomedical Analysis
211: 114623.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2022.114623" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35121279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Volumetric%20Absorptive%20Microsampling%20(VAMS)%20for%20the%20Quantification%20of%20ten%20Kinase%20Inhibitors%20and%20Determination%20of%20Their%20in%20Vitro%20VAMS%E2%80%90To%E2%80%90Plasma%20Ratio&amp;author=S.%20Zimmermann&amp;author=F.%20Aghai&amp;author=B.%20Schilling&amp;volume=211&amp;publication_year=2022&amp;pages=114623&amp;pmid=35121279&amp;doi=10.1016/j.jpba.2022.114623&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="bmc70056-bib-0082">
<cite>

Zimmermann, S.
, Aghai‐Trommeschlaeger F., Kraus S., et al. 2023. “Clinical Validation and Assessment of Feasibility of Volumetric Absorptive Microsampling (VAMS) for Monitoring of Nilotinib, Cabozantinib, Dabrafenib, Trametinib, and Ruxolitinib.” Journal of Pharmaceutical and Biomedical Analysis
228: 115311.
</cite> [<a href="https://doi.org/10.1016/j.jpba.2023.115311" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36841066/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pharmaceutical%20and%20Biomedical%20Analysis&amp;title=Clinical%20Validation%20and%20Assessment%20of%20Feasibility%20of%20Volumetric%20Absorptive%20Microsampling%20(VAMS)%20for%20Monitoring%20of%20Nilotinib,%20Cabozantinib,%20Dabrafenib,%20Trametinib,%20and%20Ruxolitinib&amp;author=S.%20Zimmermann&amp;author=F.%20Aghai%E2%80%90Trommeschlaeger&amp;author=S.%20Kraus&amp;volume=228&amp;publication_year=2023&amp;pages=115311&amp;pmid=36841066&amp;doi=10.1016/j.jpba.2023.115311&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ol></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>
<strong>Data S1.</strong> Supporting Information</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/11907759/bin/BMC-39-e70056-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">BMC-39-e70056-s001.pdf</a><sup> (634.1KB, pdf) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Biomedical Chromatography are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/bmc.70056"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/BMC-39-e70056.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (648.7 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11907759/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11907759/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11907759%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11907759/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11907759/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11907759/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40084678/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11907759/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40084678/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11907759/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11907759/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="QT0YL6M7nuJ3b53vuSVV75AK6hZS7opuRCKjxvnpTG8LLslLrldVs2JCL0GMQIF6">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
